MitraClip® EXPAND Study  
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY   Page 1 of 68 
Do not distribute or reproduce with the prior written permission of Abbott  
17-518 : The MitraClip ® EXPAND Study  
A Contemporary, Prospective Stud y Evaluating R eal-world Experience of 
Performance and S afety for the Next Generation of MitraClip ® Devices  
Version Number  2.0 
Date  26 June 2018  
Primary 
Investigator s:  OUS:  
[CONTACT_400177] sity Hospi[INVESTIGATOR_400050]: 
[CONTACT_400178] , CA 
Planned Number of 
Sites and Region(s)  Up to [ADDRESS_504153] Market 
Observational Study  
Sponsor  / Study 
Monitor  Abbott   
[ADDRESS_504154], Santa Clara, CA [ZIP_CODE]  
Electronic Data 
Capture  ORACLE CLINICAL  
Core Laborat ories  A core laboratory (core -lab) will be utilized to make echocardiographic 
assessments on a subset of patients enrolled into this study. The core-
lab will be identified at a later stage of the study . 
Clinical Events Committee  An independent clinical ev ents committee (CEC) will be established to 
adjudicate major adverse events in this study. The CEC will be 
established at a later stage of the study.  
Steering Committee  [CONTACT_400179] Estévez -Loureiro  
Hospi[INVESTIGATOR_400051] -Majadahonda 
Madr id, Spain  [CONTACT_400180] Schäfer  
University Hospi[INVESTIGATOR_400052] -
Eppendorf   
Hamburg, [LOCATION_013]  
[CONTACT_400181] of Catania    
Catania, Italy       [CONTACT_400182] at Abbott Northwestern Hospi[INVESTIGATOR_400053], MN  
Prof. Jörg Hausleiter  
Medizinische Klinik und Poliklinik I der Ludwig 
München, [LOCATION_013]  [CONTACT_400183] von Bardeleben  
Universitätsmedizin der Johannes Gutenberg  
Mainz, [LOCATION_013]  
[CONTACT_400184] of Virginia  
Charlottesville, Virginia  [CONTACT_400185], Switzerland  
Protocol Author Erin Tims , MS, CCRP ,  
Clinical Advisor  - Abbott Structural Heart  
Redacted Version  A 
Nov 15, 2021
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 2 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
Table of Contents  
TABLE OF CONTENTS  .................................................................................................................. 2  
COMPLIANCE STATEMENT:  ......................................................................................................... 5  
PROTOCOL  SUMMARY  ................................................................................................................. 6  
1.0 INTRODUCTION  .................................................................................................................. 8  
1.1 Study Design  .................................................................................................................... 8  
1.2 Study Objective  ................................................................................................................ 9  
2.0 BACKGROUND AND RATIONALE  ...................................................................................... 9  
2.1 Background  ...................................................................................................................... 9  
2.1.1  MitraClip® Clinical Trials Conducted for Approval  ......................................................... 9  
2.1.2  MitraClip® Post -Market Clinical Studies  ...................................................................... 11 
2.1.3  Mitral Valve Anatomies: Impact on MitraClip Use and Outcomes  ................................ 12 
2.2 Study Rationale  .............................................................................................................. 13 
2.3 Summary of Device  ........................................................................................................ 14 
2.3.1  Name [CONTACT_17008] D evice .................................................................................................... 14 
2.3.2  Indication for Use  ........................................................................................................ 14 
2.3.3  Description of the Device  ............................................................................................  14 
3.0 STUDY FLOW AND FOLLOW -UP SCHEDULE  ................................................................. 15 
3.1 Number of Subjects  ........................................................................................................ 15 
3.2 Overall Flow of the Study and Follow -up Schedule ......................................................... 16 
3.3 Measures Taken to Avoid and Minimize Bias .................................................................. 16 
3.3.1  Study Flow  .................................................................................................................. 16 
3.3.2  Clinical Events Committee  ..........................................................................................  17 
3.3.3  Steering Committee  .................................................................................................... 17 
3.4 Early Termination of the Clinical Study  ........................................................................... 17 
4.0 STUDY ENDPOINTS  ......................................................................................................... 17 
4.1 Safety and Performance Measures  ................................................................................. 17 
4.2 Acute Measures  .............................................................................................................. 17 
4.3 Clinical Measures  ........................................................................................................... 18 
4.4 Func t
ional Improvement Measures  ................................................................................. 18 
4.5 Site Reported Echocardiographic Measures  ................................................................... 18 
4.6 Core Lab Subgroup:  ....................................................................................................... [ADDRESS_504155]’s Participation ......................................................... [ADDRESS_504156] this Number  ............................................................... 22 
5.10  Study Completion ........................................................................................................... 22 
6.0 TREATMENT AND FOLLOW -UP ASSESSMENTS ............................................................ 23 
6.1 Pre-Treatment  ................................................................................................................ 23 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504157]-Procedure  ............................................................................................................... 24 
6.3.1  Final (Post -procedure) Imaging ................................................................................... [ADDRESS_504158] Follow -up ........................................................................................................... 24 
6.4.1  Follow -Up Imaging  ...................................................................................................... 24 
7.0 ADVERSE EVENTS  ........................................................................................................... 25 
7.1 Definitions  .......................................................................................................................  25 
7.1.1  Adverse Event  ............................................................................................................ 25 
7.1.2  Serious Adverse Event  ............................................................................................... 25 
7.1.3  Device Deficiency/Device Malfunction  ........................................................................ 26 
7.2 Device Relationship ........................................................................................................ 26 
7.3 Adverse Event/Device Deficiency/Product Experience Reporting ................................... 26 
7.3.1  Adverse Event Reporting  ............................................................................................ 26 
7.3.2  Device Deficiency/Device Malfunction Reporting  ........................................................ 27 
7.3.3  Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_1034]  .............. 27 
8.0 ADJUDICATION OF EVENTS  ............................................................................................ 27 
8.1 The Clinical Events Committee (CEC) ............................................................................ [ADDRESS_504159] ACCESS TO SOURCE DATA/DOCUMENTS  ...................................................... 29 
11.0  QUALITY CONTROL AND QUALITY ASSURANCE  .......................................................... 29 
11.1  Selection of Clinical Sites and Investigator s .................................................................... 29 
11.2  Protocol Amendments  .................................................................................................... 30 
11.3  Training .......................................................................................................................... 30 
11.3.1  Site Training  ............................................................................................................ 30 
11.3.2  Training of Sponsor’s Monitors  ................................................................................ 30 
11.4  Monitoring  ....................................................................................................................... 30 
11.5  Deviations from Protocol  ................................................................................................. 31 
11.6  Quality Assurance Audit  ................................................................................................. 31 
11.7  Sponsor Auditing  ............................................................................................................ 31 
11.8  Committees  .................................................................................................................... 32 
11.8.1  Steering Committee  ................................................................................................ 32 
11.8.2  Clinical Events Committee (CEC) ........................................................................... [ADDRESS_504160] KEEPI[INVESTIGATOR_1645]  ..................................................................... 32 
12.1  Source Documentation ................................................................................................... 33 
12.2  Electroni c Case Report Form Completion  ....................................................................... 33 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504161]/Medical Ethics Committee Review  ........................................ 33 
14.0  PUBLICATION POLICY  ..................................................................................................... 34 
15.0  RISK ANALYSIS ................................................................................................................ 34 
15.1  Antic ipated Clinical Benefits  ............................................................................................  34 
15.2  Foreseeable Adverse Events and Anticipated Adverse Device Effects  ........................... 35 
15.3  Residual Risks Associated with the Investigational Device ............................................. 35 
15.4  Risks  Associated with Participation in Clinical Study ....................................................... 36 
15.5  Possible Interactions with Protocol- Required Concomitant Medications  ......................... 36 
15.6  Steps that will b e Taken to Control or Mitigate the Risks  ................................................ 36 
15.7  Risk to Benefit Rationale  ................................................................................................ 36 
APPENDIX I:   MITRACLIP XTR PMCF CLINICAL STUDY PROTOCOL  .................................. 37 
APPENDIX II:  ABBREVIATIONS AND ACRONYM ...................................................................  38 
APPENDIX III:   DEFINITIONS  .................................................................................................... 40 
APPENDIX IV:      LITERATURE REVIEW AND SUMMARY OF PRECLINICAL TRIALS  .............. 47 
APPENDIX V:   MONITORING PLAN ......................................................................................... 63 
APPENDIX VI:      CONTACT [CONTACT_7533]  ................................................................................ 64 
APPENDIX VII:     FORESEEABLE ADVERSE EVENTS  ............................................................... 65 
APPENDIX VIII:   SUMMARY OF CHANGES  ................................................................................ 66 
 
  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 5 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
 
COMPLIANCE STATEMENT:  
 
This Study  will be conducted in accordance with this Protocol, the Declaration of Helsinki, applicable 
Good Clinical P ractices and applicable regulations (e.g., US 21 CFR Part 50, 21 CFR Part 56, and 
OUS ISO14155) and the appropriate local legislation(s). The most stringent requirements, guidelines 
or regulations must always be followed. The conduct of the study  will be a pproved by [CONTACT_81921] (IRB)/Ethics Committee (EC) of the respective site and by [CONTACT_111723] . 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 6 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
PROTOCOL SUMMARY  
 
Protocol Name 
[CONTACT_98567]  17-518:  The MitraClip ® EXPAND Study  
Title A contemporary, prospective study evaluating real -world e xperience 
of performance and safety for the next generation of MitraClip® 
devices (EXPAND)  
Objectiv es To confirm the safety and performance  of the next generation 
MitraClip® NTR System and MitraClip® XTR System  in a 
contemporary, real -world setting.  
Device s MitraClip ® NTR and MitraClip® XTR Systems  
Targeted number 
of subjects   Up to 1,[ADDRESS_504162] Market , 
Observational Study  
Endpoints   Safety  
• Major Adverse Events ( MAE) at 30 days  
 
Performance  
• Mitral Regurgitation ( MR) Reduction to <2+ at 30 days  
 
Acute  Measures : 
• Acute Procedural Success (APS)  
• Acute Device Success  
• Procedure Time  
• Device T ime 
• Number of Clips Implanted 
• Number of Attempted Grasps  
• Use of MitraClip NTR or MitraClip XTR  
• Device -Related Complications  
• User Feedback  
• In-hospi[INVESTIGATOR_400054]  
• MR Reduction to ≤ 1+ at 30 days  
 
 
Clinical Measures (Discharge, 1, 6 and 12 months):  
• All-cause Mortality  
• Heart Failure Hospi[INVESTIGATOR_059] 
• MAE 
• Device -Related Complications  
 
 
Functional improvement Measures (Baseline, Discharge & 12 months):  
• [LOCATION_001] Heart Assoc iation  (NYHA)  class improvement  
• Quality of Life ( QOL ) improvement conducted by [CONTACT_400121] (KCCQ)  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 7 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
 
 
  Echo Measures (Baseline, Post Procedure, 1, & 12 months):  
Based on Site Reported Echocardiogram data for all subjects  
• MR Severit y Grade  
• Effective Regurgitant Orifice Area  (EROA)  
• Coaptation Measures (length and depth ) 
• Flail Measures (gap and width)  
• Graspi[INVESTIGATOR_400055]  
• Chordal Support  
• Regurgitant Jet(s) Position and Quantity  
• Tricuspid Regurgitant (TR) Severity  
 
Core Lab Subgroup:  
Echocardiograms from a minimum of [ADDRESS_504163] Follow -up Echocardiogram:  Discharge, 30 days and 12 Months   
Clinical Visit:  30 days and 12 Months  
Phone Call:   6 Months  
Inclusion Criteria  1. Subjects who giv e consent for study  participation  
2. Subjects scheduled to receive the MitraClip per the current approved 
indications for use  
3. Subjects with Symptomatic MR (≥3+)  
Exclusion Criteria  1. Subjects participating in another clinical study that may impact the 
follow -up or results  of this study.   
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 8 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
1.0 INTRODUCTION  
The MitraClip® System received Conformité Européene approval ( CE Mark ) in 2008 and US Food 
and Drug ad ministration ( FDA) Approval in 2013  for percutaneous treatment of patients with mitral 
regurgitation (MR).   MR stem s from two  main etiologies: degenerative MR (DMR), characterized by 
a prolapse or flail of one or more segments of the mitral leaflets  and functional MR (FMR), which 
manifests as a malcoaptation of leaflets caused by [CONTACT_400122] / scarring of 
the left ventricle.   The MitraClip is implanted during a procedure with echocardiographic and 
fluoroscopic guidance while the patient is under general anesthesia. A trans -septal catheterization is 
performed to access the left heart  and the guide catheter is then percutaneously  inserted into the 
femoral vein.  The MitraClip device is positioned and then used to grasp and join the mitral valve 
leaflets at the maximum coaptation location resulting in fixed approximation of the mitral leaflets.1,[ADDRESS_504164] not yet been evaluated in a clinical study .   
 
The MitraClip EXPAND Study (A Contemporary, Prospective, Multi -center  Study Evaluating Real-
world Experience of Performance and Safety for the Next Generation of MitraCli p Devices ) is 
designed to confirm  the safety and performance of the MitraClip NTR System and M itraClip XTR  
System .  The data collected in this study will be used to evaluate  device outcomes and characterize 
trends in patient selection for MitraClip therapy  in contemporary real -world use .  Specifically, the 
analysis will separate patients  into cohorts based on anatomical characteristics to compare modern 
day use to use in early clinical studies.  Moreover, the data will be assessed to identify patient or 
mitral valve anatomi cal characteristics that may be most appropriate for these next generation 
devices.   Clinical outcomes and Echocardiographic measures will be assessed in the context of 
historical data.   
 
A subset of subjects  in the MitraClip EXPAND S tudy will be come part of the MitraClip XTR Post 
Market Clinical F ollow- up (PMCF)  Study (Appendix I). Data from the MitraClip XTR PMCF  Study will 
be used to fulfill the regulatory requirement for PMCF associated with the CE mark approval of the 
MitraClip  XTR S ystem .  
 The MitraClip EXPAND Study  will be conducted on commercial MitraClip NTR System and MitraClip 
XTR System that have received CE Mark and/or FDA approval as required.   
 
1.[ADDRESS_504165] real -world data on the use of the next generation MitraClip  NTR and MitraClip 
XTR Systems.  Up to 1,000 commercial patients from the EU or  US will be included in the analysis 
 
 
1 Kar, Saibal, The Percutaneous Valve Repair: Adding life to years, J Am Coll Cardiol . 2013 Sep 
17;62(12):1062- 1064  
2 Maisano, [LOCATION_009]sco, Buzzatti, Nicola, Taramasso, Maurizio, and Alfieri, Ottavio,  Mitral Transcatheter 
Technologies.  Rambam Maimonides Medical Journal.   July 2013, Volume 4, Issue 3, e0015  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504166] -market studies differ in 
patient selection from the cases included in early clinical studies (ie. EVEREST, EVEREST II)3,4,5,6.  
The analysis  of these cohorts will allow for the evaluation of outcomes and identification of  trends in 
patient selection and outcomes  in contemporary real- world use in the context o f historical MitraClip 
data.  
 
1.2 Study Objective  
The primary objective is to confirm  the safety and performance of the next generation MitraClip® NTR 
and MitraClip® XTR Systems within a contemporary real -world setting.   
 2.0 BACKGROUND AND RATIONALE  
2.1 Background 
2.1.1  MitraClip ® Clinical Trials Conducted for Approval  
The MitraClip ® System was studied in the [LOCATION_002] as an  investigational device beginning with 
the EVEREST I  trial in July 2003 (IDE G030064) .  A total of [ADDRESS_504167] prospective, multi- center trial to evaluate the safety and effectiveness of 
the Mit raClip  System in patients with 3+ or 4+ MR in surgical candidates .  The trial demonstrat ed 
mechanistic feasibility of implant and safety of the MitraClip System and procedure. Acute procedural 
success was achieved in 70.9% of patients  with a majority of patients ( 83.3%) experiencing a 
reduction in MR severity to 2+ or less at discharge.   At 5 years, freedom from death was 86.4% and 
freedo m from mitral valve surgery was 55.1%
7.  
 
 
3 A Study of the Evalve® Cardiovascular Valve Repair (MitraClip®) System Endovascular Valve Edge- to-
Edge REpair Study  
4 Boerlage- van Dijk K, et al,Mitral valve anatomy predicts outcome of MitraClip implantation, Int J Cardiol  
(2014)  
5Ambrožič J,, Bervar M,  Bunc  M., Wien Klin Wochenschr.  Initial Slovenian experience with  MitraClip therapy: 
Careful selection of patients is crucial for optimal outcome.   2017 Dec 4. doi: 10.1007/s00508- 017-1295- 7. 
[Epub ahead of print]  
[ADDRESS_504168] Inclusion Criteria.  Am J Cardiol .  2017; 119:1255- 1261  
7 IDE G030064/ P100009/A017 EVEREST I Final Clinical Report Version 1.0 - 17/Nov/2011  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504169] II  
Randomized Controlled Trial ( RCT)8,9,10 was a prospective, multi -center, randomized controlled trial 
where patients with severe MR (3+ or 4+)  were randomized in a 2:1 ratio to either receive the MitraClip  
device or undergo  mitral valve surger y. The trial enrolled 279 patients: 184 treated with MitraClip and 
95 with surgery. The trial met both primary safety and effectiveness endpoints. MR reduction to 2+ or 
less at 5 years was in 82.1% of MitraClip patients and 97.6% of surgery patients.  Impr ovement in 
NYHA Functional Class was demonstrated in both groups, with 91.5% of MitraClip patients and 97.6% of surgery patients free from [LOCATION_001] Heart Association (NYHA ) Functional Class III or IV symptoms 
at [ADDRESS_504170] II  trial included a separate study  to evaluate the safety and effectiveness of the 
MitraClip System in patients with 3+ or 4 + MR considered to be at high risk of surgical mortality.  The 
EVEREST I I High Risk Registry (HRR) study enrolled [ADDRESS_504171] II HRR was high with 96.2% of patients implanted with one (59.0%) or two (37.2%) 
MitraClip devices .  At 5 years , MR reduction was sustained to ≤2+ in 73.9% of  surviving patients  with 
paired data and to ≤1+ in 47.8% of  surviving patients  with paired data .  Through 5 years, a total of 42 
(53.8%) deaths occurred in the EVEREST II HRR
12.  This mortality rate is as expected due to the 
high risk nature of the patient population.   
 A continued access study, EVEREST II REALISM , sustained data collection on the use of the 
MitraClip System in “real world” conditions.  There were  two arms (Hig h Risk and Non -High Risk) in 
the REALISM study.  A total of 271 patients were enrolled in the non- high risk arm of REALISM.  
Reduction to MR ≤2+ was achieved in 89% of patients at 30 days and in 84% of patients at 12 months.  
A similar trend was observed a t subsequent follow- ups with a majority (>75%)  of patients with MR 
severity  remaining consistently mild to moderate
13.  A tota l of 628 patients were  enrolled in the high 
risk arm of REALISM.  A majority of patients had multiple pre -existing co-morbidities at baseline and 
were considered high risk for mitral valve surgery.  Reduction of  MR ≤2+ was achieved in 90% of 
patients at discharge/30 days and in 85% of patients at 12 months.   A similar trend was observed  at 
subsequent follow- ups with a majority (>80%)  of patients with MR severity  remaining consistently 
mild to moderate14.  
 
 
[ADDRESS_504172] II Trial: Design and Rationale for a Randomized Study of the Evalve MitraClip 
System Compared with Mitral Valve Surgery for Mitral Regurgitation.  Am Heart J .  2010; 160:23- 29. 
9 Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, 
Loghin  C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, Investigators EI.  Percutaneous 
Repair or Surgery for Mitral Regurgitation.  N Engl J Med.  2011; 364:1395- 1406.  
10 Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling 
RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wa ng A, Glower DD, Mauri L, Investigators EI.  Randomized Comparison of 
Percutaneous Repair and Surgery for Mitral Regurgitation: 5- Year Results of EVEREST II.  J Am Coll Cardiol.  
2015; 66:2844- 2854.  
[ADDRESS_504173] II Randomized Controlled Trial (RCT) -0401– Five Year F inal Report, Report Version 1.0 - 
03/Nov/[ADDRESS_504174] II High Risk Registry (HRR) – 0401 - Five Year Final Report, Report Version 1.0 – 
03/Nov/[ADDRESS_504175] II REALISM – Non- High Risk   2017  Annual Report , Protocol #0401- Clinical Investigation Report  
Ver 1.0  - 24/APR/[ADDRESS_504176] II REALISM– High Risk 2017 Annual Report , Protocol #0401- Clinical Investigation Report Ver 
1.0   24/Apr/2017  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 11 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
2.1.2  MitraClip ® Post -Market  Clinical Studies  
In 2008, based upon data from the EVEREST I study, the MitraClip® received CE mark approval  for 
commercial use in Europe and was indicated for the reconstruction of the insufficient mitral valve for 
tissue approximation.  Clinical evidence generated from EVEREST I, EVER EST II, EVEREST II HRR, 
and EVEREST II REALISM led to FDA approval in 2013 of the MitraClip ® system for the treatm ent 
of patients with severe MR who are at prohibitive risk for surgery .   
 
In the time since these approvals , a number of post-market  clinical studies have been conducted  on 
the MitraClip .  All of these studies have provided continued evidence of the safet y and performance 
of the MitraClip  System.  The studies for Europe and the US are summarized in the Table [ADDRESS_504177] -Market  MitraClip ® Studies  
 
Study Reference  Study Design  Study Population  Study Outcome  
Franzen et al.[ADDRESS_504178] criteria  51 subjects  
35 (69%) would have 
been excluded from 
EVEREST I & II  MitraClip successful in 
treatment of patients outside of 
EVEREST criteria  
ACCESS- EU16 
(EU study 
sponsored by 
[CONTACT_69735])  Two-phase prospective, 
single- arm looking at health 
economics and clinical  567 subjects  
77.1% FMR  
84.9% NYHA III or IV  
High surgical risk  MitraClip implant success 
99.6%  
78.9 %MR reduction <2+ at 1yr 
Improved 6MWT, NYHA and 
QOL17 
Getting Reduction 
of Mitral 
Insufficiency by 
[CONTACT_400123]18 Prospective  Single -center  
study at Ferrarotto Hospi[INVESTIGATOR_400056], Italy.  Site heart team 
led enrollment criteria  117 high surgical risk  
76% FMR  
98% MR3+/4+  
63% met EVEREST 
criteria  100% Acute procedural success 
Post Procedure MR Reduction 
1+ (63%)  2+ (37%)  
KM Freedom from MAE 96.4% 
at 30 days and 75.8% at 1 yr  
German 
TRanscatheter 
Mitral Valve 
Interventions 
(TRAMI) Registry  Had both prospective and 
retrospective enrollment.  828 prospective 
patients at 21 sites 97% implant success  
1.4±0.6 clips/case  
85.2% MR reduced to none/ mild  
Mortality 4.5% 1 m /20.3% [ADDRESS_504179]-
Jackle A, Schluter M, Reichenspurner H, Meinertz T.  Acute Outcomes of MitraClip Therapy for Mitral  
Regurgitation in High- Surgical -Risk Patients: Emphasis on Adverse Valve Morphology and Severe Left 
Ventricular Dysfunction.  Eur Heart J .  2010; 31:1373- 1381.  
16 Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder 
JD, Moccetti T, Schillinger W.  Percutaneous Mitral Valve Interventions in the Real World: Early and 1- Year 
Results from the ACCESS -EU, a Prospective, Multicenter, Nonrandomized Post -Approval Study of the 
MitraClip Therapy in Europe.  J Am Coll Cardiol .  2013; 62:1052- 1061.  
17 ACCESS- EU Phase I Study Final Clinical Report, Version 1.0, 20/Aug/2012  
18 Grasso C, Capodanno D, Scandura S, Cannata S, Imme S, Mangiafico S, Pi[INVESTIGATOR_400057] A, Ministeri M, Barbanti 
M, Caggegi A, Chiaranda M, Dipasqua F, Giaquinta S, Occhipi[INVESTIGATOR_88757] M, Ussia G, Tamburino C.  One- and Twelve -
Month Safety and Efficacy Outcomes of Patients Undergoing Edge- to-Edge Percutaneous Mitral Valve Re pair 
(from the GRASP  Registry).  Am J Cardiol .  2013; 111:1482- 1487.  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504180] 
been published 19,20 (from th e largest 
publication21) 
70%FMR  
94% Severe MR  
The Transcatheter 
Valve Treatment 
Sentinel Pi[INVESTIGATOR_400058]22 European Society of 
Cardiology Euro Observational Research Programme conducted at 25 centers in 8 
European countries  628 patients  
72% FMR  
EuroSCORE 
20.4± 16.7% 
(indicates high risk)  95.4% Acute procedural success  
98.2% MR Reduction ≤2+ post -
procedure  
94% MR Reduction ≤2+ at 1 yr  
15.3% Mortality at 1 yr  
TVT Registry  
(Transcatheter 
Valve Treatment)  
A Joint Initiative 
Society of Thoracic Surgeons (STS) & American College 
of Cardiology 
(ACC)  A platform for: 1) device and 
procedural s urveillance; 2) 
quality  assurance and 
improvement initiatives; and 3) 
efficient conduct of studies that will speed US access to new devices and support the 
expansion of device labeling (Sorajja et al.
[ADDRESS_504181] 
recent publication)   
2,952 patients at 145 
sites  
85.9% DMR  
17.5% (FMR only 
8.6%; mixed 8.9%). 93% MR 3+/ 4+ MR  93% MR reduction ≤2+ 
61.8% MR grade ≤1+ 
5.2% 30- day Mortality  
37.9% 1 yr death and HF re-
hospi[INVESTIGATOR_059] (24.7% DMR)  
 
2.1.3  Mitra l Valve Anatomies : Impact on  MitraClip Use and Outcomes  
As the MitraClip therapy matures , there has been an increasing interest in exploring the potential for 
use in broader  mitral valve anatomies.  The recommended criteria were established early in MitraClip 
use during the EVEREST II Study.  Some recent data have examined the true impact of these criteria 
on patient selection and MR outcomes; a few st udies  are described below.   
 Attizzani et al.
[ADDRESS_504182] criteria (EVEREST on) 
 
 
19 Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Mollmann H, 
Hehrlein C, Ouarrak T, Senges J, Meinertz T, investigators GTMVI.  MitraClip Therapy in Daily Clinical Practice: 
Initial Results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry.  Eur J Heart Fail .  
2012; 14:1050- 1055.  
20 Schillinger W, Hunlich M, Baldus S, Ouarrak T, Boekstegers P, Hink U, Butter C, Bekeredjian R, Plicht B, 
Sievert H, Schofer J, Senges J, Meinertz T, Hasenfuss G.  Acute Outcomes after MitraClip Therapy in Highly 
Aged Patients: Results from German Transcatheter Mitral Valve Interventions (TRAMI) Reg istry. 
EuroIntervention. 2013; 9:84- 90. 
21 Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert 
H, Nickenig G, Eggebrecht H, Senges J, Schillinger W.  One-Year Outcomes and Predictors of Mortality after 
MitraClip Therapy in Contemporary Clinical Practice: Results from the German Transcatheter Mitral Valve 
Interventions Registry.  Eur Heart J .  2016; 37:703- 712. 
22 Therapy in Contemporary Clinical Practice: Results from the German Transcatheter Mitral Valve Interventions 
Registry.  Eur Heart J .  2016; 37:703- 712. 
[ADDRESS_504183] Jr, Stebbins A, Kar S, Thourani  V, Ailawadi G.  
Outcomes With Transcatheter Mitral Valve Repair in the [LOCATION_002]: An STS/ACC TVT Registry Report.  J Am Coll Cardiol. 2017;70(19):2315- 2327.  
[ADDRESS_504184] (Endovascular Valve Edge- to-Edge Repair) Criteria: 30- Day and 12- Month Clinical and 
Echocardiographic Outcomes from the G RASP  (Getting Reduction of Mitral Insufficiency by [CONTACT_400124]) Registry.  JACC Cardiovasc Interv .  2015; 8:74- 82. 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504185] Criteria ( EVEREST OFF)) which included 35 
patients with LVEF ≤25%, 28 patients with LV end systolic diameter >55 mm, 34 patients with 
coaptation depth ≥11 mm, and 10 patients with a flail width ≥15 mm.  High rates of acute procedural 
success were achieved in both groups (97.8% and 100% for EVEREST OFF and E VEREST ON, 
respectively). At 30 -days, the rate of MAEs (i.e. primary safety endpoint) was comparable between 
groups (2.6% vs. 6.5%, respectively, p=0.204).  Reduction in MR severity, s ymptomatic 
improvements, and re -hospi[INVESTIGATOR_400059].  At 
1 year, Kaplan- Meier freedom from the freedom from death, surgery for mitral  valve dysfunction, or 
grade ≥3+ MR at 12 months  was demonstrated in 71.4% and 76.2%, respectively, in the EVEREST OFF 
and EVEREST ON groups.  Approximately 90% of surviving patients in both groups had sustained MR 
reduction to ≤ 2+.   
 
In more  recent 2016 publication, Lesevic et al.25 retrospectively analyzed patients treated with the 
MitraClip ® device and compared the procedural success, long- term outcomes, repair durability, and 
prognostic factors.  Patients were grouped int o the EVEREST group (N=59) or non- EVEREST  group 
(N=75)  according to the presence or absence of EVEREST inclusion criteria.  Acute proc edural 
success was achieved in 95.5% of patients with no difference between EVEREST (97%) and non-EVEREST (95%) patients.  There was no statistically significant difference in the number of device 
implanted between the two groups.  A similar mean acute MR reduction was achieved in both groups 
(-2.3±0.9 vs -2.2±1, respectively; p=0.497).  At a mean follow -up of 3.5 years, recurring MR ≥3+ was 
more frequent in non- EVEREST patients than in EVEREST patients (28% vs 45%; p=0.066).  Re-
interventions for recurring MR were more frequently required in non- EVEREST patients than in 
EVEREST patients, including second MitraClip device interventions (2% vs 13%; p=0.085) and mitral 
valve surgeries (9% vs 28%; p=0.047).  Flail width was found to be an independent predictor for re -
intervention, whereas flail gap ≥10 mm displayed a strong trend (flail width: adjusted HR 11.2, 95% 
CI 2.6 to 48.3; p=0.001; flail gap: adjusted HR 3.1, 95% CI 0.9 to 11.5; p=0.077).   
These data suggest that a closer look at the impact of mitral valve anatomy for MitraClip patient selec tion and outcomes is warranted to understand the appropriate real -world applications of the 
therapy.  In the context of the introduction of the next generation MitraClip System, this analysis can 
be used to identify t he mitral valve anatomical characterist ics that may benefit most from the attributes 
of this device iteration (i.e. improved delivery and longer arms on the implant).  This is the basis for 
the MitraClip EXPAND Study .  
 A full review of MitraClip studies a nd commercial literature was conducted and is shown in Appendix 
III. 
 
2.2 Study Rationale  
The primary objective of the MitraClip EXPAND study is t o confirm the safety and performance of the 
MitraClip ® NTR and MitraClip ® XTR Systems in a contemporary real- world setting.  The rationale for 
conducting this study is as follows:  
• This study will provide first -hand clinical evidence of safety and performance of these next 
generation MitraClip Systems .     
• This study will satisfy p ost-mark et clinical follow- up (PMCF) required as a condition of CE 
Mark approval  for the MitraClip NTR and MitraClip XTR Systems .  A subset of pat ients will be 
analyzed as  part of the Mitra Clip XTR PMCF S tudy ( Appendix 1)  to fulfill this requirement.   
 
 
[ADDRESS_504186] Inclusion Criteria.  Am J  Cardiol .  2017; 119:1255- 1261.  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 14 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
• The device it erations on the MitraClip NTR (improved delivery) and MitraClip XTR  (improved 
delivery and longer clip arms on implant) may offer an advantage in some mitral valve 
anatomies; this study will begin to identify populations that can benefit most from these  next 
generation MitraClip Systems.    
• Recent literature has indicated an evolution in patient selection in MitraClip therapy; this study 
will e valuate outc omes and characterize trends for MitraClip therapy in contemporary real -
world use in the context of  historical MitraClip data.  
 
2.3 Summary of Device  
2.3.1  Name [CONTACT_400174], who will undergo commercial procedures with the MitraClip ® NTR 
System and/or MitraClip ® XTR System  after required approval of the device is obtained.   
 
2.3.2  Indication  for Use  
MitraClip ® procedures for this study will be conducted in accordance with the Instructions for Use 
(IFU) that is approved for the region where the implant is taking place. 
 
2.3.3  D escription of the Device 
The MitraClip System is comprised  of the Clip Delivery System (CDS) and Steerable Guide Catheter 
(SGC). The CDS  is introduced into the body through the SGC . The Clip Delivery System is used to 
advance and manipulate the implantable clip for proper positioning and placement on the mitral  valve 
leaflets. The Clip Delivery System is designed to deploy the implant in a way that requires multiple 
steps to ensure safe delivery of the device. The Steerable Guide Catheter provides a  conduit to 
access the mitral  valve and with the addition of Steerable Sleeve to position the Clip relative to the 
valve. The Delivery Catheter is designed to deliver and deploy the Clip. The Steerable Guide and Clip 
Delivery System are steered and actuated by [CONTACT_400125], levers and fasteners (Figure 
1). 
 
 
 The new MitraClip NTR System and MitraClip XTR System have  a modification to the Delivery 
Catheter (DC) of the current MitraClip NT System intended to make the procedure easier, more 
precise, more predictable, and to optimize manufacturability of the product.  
 
The implantable Clip is fabricated with metal alloys and polyester fabric that are commonly used in 
cardiovascular implants. The Clip can be repeatedly opened, closed and inverted by [CONTACT_400126] 1.  Proximal End of MitraClip NTR and MitraClip XTR Systems  

 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504187] with leaflet 
graspi[INVESTIGATOR_007] ( Figure 2 ). 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
3.0 STUDY FLOW AND FOLLOW -UP SCHEDULE  
3.1 Number of Subjects  
Eligible consecutive patients that present for a MitraClip procedure should be consented.  Once a 
patient has provided written informed consent, the patient is considered enrolled.  Upon 
echocardiographic verification that there is no evidence of intracardiac, inferior vena cava (IVC) or 
femoral venous thrombus  per IFU  requirements;  the MitraClip procedure should be attempted for all 
enrolled patients .  A procedure is considered attempted when the MitraClip delivery system is 
introduced  into the femoral vein .  Only enrolled patients with an attempted MitraClip procedure will 
be included in the analysis popul ation.  Patients that have an attempted procedure, but no MitraClip 
implant will be followed for [ADDRESS_504188] a MitraClip procedure 
attempted will be included for analysis in the MitraClip EXPAND Study .  The Study will be conducted 
at a maximum of  60 centers in the EU and the US.  A site maximum of 1 00 subjects  will be enforced 
so that no site will be permitted to submit data for  more than 10% of the study population.  
 
Figure 1.  MitraClip NTR & MitraClip XTR Clip Implant  

 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504189] of c are.  
Follow- up data on clinical assessment should be submitted for a 30-day visit, 6 -month visit or phone 
call and 12 -month visit.  Echocardiograms are required to be submitted for the baseline, discharge, 
30-day and 12- month  time points .  All Echocardiograms  conducted during the study period (required 
by [CONTACT_400127]) will be collected by [CONTACT_1034]  (see Table 2 for the Clinical Assessment  
Schedule).   Patients that have an attempted procedure, but no MitraClip implant will  be followed for 
[ADDRESS_504190] 220 European patients treated with the MitraClip XTR in the MitraClip EXPAND Study  with 
evaluable APS data will be included in the XTR PMCF Study as described in Appendix 1.  
 
Subjects  with evaluable echocardiograms may be selected for a more detailed assessment  by [CONTACT_400128]. Pre-defined criteria will be used to identify eligible subjects for this assessment. 
A minimum of 100 subjects will be randomly selected f rom this eligible population.  
 
Figure 3 outlines the flow of the Study . 
 
Figure 3: Study Flow  
 
 
3.3 Measures Taken to Avoid and Minimize Bias  
3.3.1  Study Flow  
Study sites are instructed to consent consecutive subjects prior to MitraClip procedure.  All patients eligible to receive a MitraClip (i.e. no evidence of thrombus) will included in the study analysis. 

 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504191] oversight on the study.  
 3.4 Early Termination of the Clinica l Study  
No formal statistical rule for early termination of this study  is defined.  
 
The Sponsor reserves the right to discontinue the study  at any stage or reduce the follow up period 
with suitable writ ten notice to the investigator. Possible reason(s) may  include, but are not limited to:  
• Unanticipated adverse device effect (UADE) occurs and it presents an unreasonable risk to 
the participating subjects.  
• The Steering Committee makes a recommendation to stop or terminate the study   
Should the study be discontinued by [CONTACT_1034], patients will be followed up as per routine hospi[INVESTIGATOR_400060] ( AEs) being reported to the Sponsor as per 
vigilance/commercial reporting requirem ents.  
 
In the event of study termination,  the investigator shall return all clinical study  materials to the Sponsor, 
and provide a written statement as to why the premature termination has taken place to the IRB/EC 
(if applicable). All applicable Clinical Investigation documents shall be subject to the same r etention 
policy as detailed in section 12 of the Protocol entitled, ‘Data Handling and Record Keepi[INVESTIGATOR_007]’.
  
 
4.0 STUDY ENDPOINTS  
4.1 Safety and Performance Measures  
 
• Safety  
The assessment of safety will include all occurrences through [ADDRESS_504192] procedure.  
Occurrence of Major Adverse Events ( MAE) at 30 days  
MAE is defined as a composite of all -cause Death, M yocardial Infarction, Stroke, or non-
elective Cardiovascular ( CV) surgery for device related complications  (CEC adjudicated).   
 
• Performance  
The assessment of performance measures will include all data reported at 30- day visits for 
this study.   
MR Reduction to ≤2+ at 30 days    
 
4.2 Acute Measures  
• Acute Procedural Success (APS) defined as successful implantation of the MitraClip ® device 
with result ing MR severity of 2+ or less on discharge Echocardiogram (30- day 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 18 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
echocardiogram will be used if discharge is unavailable or uninterpretable). Subjects who die 
or undergo mitral valve surgery before discharge are consi dered to be an APS failure 
• Acute Devic e Success defined as successful implant of the MitraClip device without the 
occurrence of a Device- Related Complication ( including mitral valve stenosis, device 
embolization, Single Leaflet Device Attachment (SLDA),  Iatrogenic  atrial septal defect, or 
myocardial perforation) through discharge.   
• Use of MitraClip NTR or MitraClip XTR:  to include the percentage of cases with each device  
and an assessment of reason for device selection  
• Procedure Time: defined as the time elapsed from the first intravascular catheter placement 
or trans -esophageal echocardiogram (TEE) to the removal of the last catheter and TEE  
• Number of Clips Implanted 
• Number of Attempted Grasps defined as the number of attempts to stabilize leaflets by t he 
open Cl ip 
• User feedback  
• Device -Related Complications  defined as the occurrence of one the following adverse events 
that is determined by [CONTACT_400129], possibly or definitely related to 
the MitraClip device.    
‒ Mitral valve stenosis  
‒ SLDA  
‒ Device Embolization 
‒ Iatrogenic atrial septal defect  
‒ Myocardial perforation  
‒ Need for mitral valve replacement instead of repair due at least in part to the MitraClip 
procedure or the presence of the MitraClip device 
• In-hospi[INVESTIGATOR_400061]  
• MR Reduction to ≤1+ at 30 days  
 
4.3 Clinical M easures  
(Discharge, 1, 6 and 12 months):  
• All-cause Mortality  
• Heart Failure Hospi[INVESTIGATOR_059] 
• MAE as defined above  
• Device -Related Complications as defined above  
 4.4 Functional  Improvement M easures  
(Baseline, Discharge & 12 months)  
• [LOCATION_001] Heart Association (NYHA) functional  class improvement  
• Quality of Life (Q OL) assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ)  
 
4.5 Site Reported Echocardiographic  Measures  
(Baseline, Post Procedure, 1, & 12 months):   
• MR Severity Grade  
• Effective Regurgitant Orifice Area (EROA)  as measured by [CONTACT_400130][INVESTIGATOR_400062]  
• Coaptation Measures ( depth/length)  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 19 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
‒ Coaptation depth : Coaptation depth is defined as the distance from the plane of the  
mitral valve annulus to the first point of leaflet coaptation in the atrial -to-ventricular  
direction in the four-chamber view.  
‒ Coaptation length: Coaptation length is defined as the vertical length of leaflets that  is 
in contact, or is available for contact, during systole in the atrial -to-ventricular  direction 
in the four -chamber view.  
• Flail Measures (gap/width) 
‒ Flail Gap: Measured as the greatest distance between the ventricular side of the flail  
segment to the atrial side of the opposing leaflet. This distance is measured 
perpendicular to the plane of the annulus in two views and the largest measurement 
is used. The two views for measurement are the four -chamber long axis (LAX) view  
and the left ventricular outflow tract (LVOT) view.  
‒ Flail Width: Measured as the width of the leaflet segment that moves in and out of  
plane during systole in the short axis (SAX) view.  
• Graspi[INVESTIGATOR_400055] (measure cleft or scallop if significant ) 
• Assess chordal support  
• Regurgitant Jet(s) Position and Quantity  
• TR Severity: None,  Mild, Moderate or Severe  
 
4.6 Core Lab Subgroup : 
Subjects with evaluable echocardiograms m ay be selected for a more detailed assessment by [CONTACT_400128]. Pre- defined criteria will be used to identify eligible subjects for this assessment. 
A minimum of [ADDRESS_504193] Population  
This MitraClip ® EXPAND Study  will enroll male and female subjects with symptomatic mitral 
regurgitation who satisfy the inclusion and exclusion criteria and who are treated with the next 
generation MitraClip  NTR System and/or MitraClip  XTR System . The study  will conduct analysis on  
approximately 1,[ADDRESS_504194] provide written informed consent prior to their data being 
submitted to the Study . 
 5.1.1  Anatomy Complexity  
For analysis, subjects will be sorted  into two groups based on valve anatomies  identified to be 
important for MitraClip placement  
26, 27, 28 
 
 
 
26 Boerlage- van Dijk K, et al,Mitral valve anatomy predicts outcome ofMitraClip implantation, Int J Cardiol 
(2014)  
27 Ambrožič J, Cvijič M , Bervar M ,  Bunc M ., Wien Klin Wochenschr. Initial Slovenian experience 
with MitraClip  therapy : Careful selection of patients is crucial for optimal outcome.  2017 Dec 4. doi: 
10.1007/s00508 -017-1295- 7. [Epub ahead of print]  
[ADDRESS_504195] Inclusion Criteria.  Am J Cardiol .  2017; 119:1255- 1261.  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 20 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
Group 1 (Complex Subjects) : 
 
If one or more of the following characteristics are present:  
• Primary Jet outside of A2P2 
• Presence of more than one significant jet  
• Wide Jet  
• Small Valve  
• Calcified landing zone 
• Minimal leaflet tissue for attachment (due to small coaptation length or too much coaptation 
depth)  
• Presence of severely degenerative leaflets or wide flail gaps or widths  
 
Group 2 (Non-C omplex Subjects) : 
 All subjects who do not qualify as a complex subject will be classified as Non- Complex subjects 
whose characteristics are similar to subjects enrolled in the EVEREST II trial.  
 
5.[ADDRESS_504196] of care procedures for determining if a patient is eligible for 
treatment with  a MitraClip ® System.  Consecutive MitraClip patients should be asked to provide 
consent for participation in the study if they are eligible per the inclusion/exclusion criteria (see section 
5.2.3).  Upon echocardiographic verification that there is no evid ence of intracardiac, inferior vena 
cava (IVC) or femoral venous thrombus  per IFU requirements; the MitraClip procedure should be 
attempted.  The procedure is considered attempted when the MitraClip delivery system is introduced.  All consented patients with an attempted MitraClip procedure will be included in the study analysis.  
 
5.2.[ADDRESS_504197] receive approval of Sponsor and EC/IRB prior to beginning 
enrollment  into the MitraClip ® EXPAND Study . 
 
The Investigator or designee, who has been trained on the Protocol, will explain the nature and scope of the study , potential risks and benefits of participation, and answer questions for the subjects.   For 
this study  the subject  will be treated per standard of car e and must consent only to data collection 
(including echoc ardiogram ) and follow -up visit  schedule.   All subjects (or legally authorized subjects’ 
representatives if applicable) must sign, date and time (if required)  the Institutional Review Board 
(IRB)/Ethics Committee  (EC) approved informed consent prior to any clinical study -specific 
procedures. Obtaining the consent and provisioning of a copy to the subject, along with the date and 
time must be documented in the subject’s medical records. In addition, the signed informed consent 
must be kept in the subject’s medical records.  
 
At sites in the [LOCATION_002], an authorization for use and disclosure of the subject’s protected health information, in accordance with the Health Insurance Portability and Accountability Act (H IPAA), must 
be obtained from the subject or their legally authorized representative. Per site requirements/preference HIPAA elements may be incorporated into the Informed Consent Form ( ICF) 
or it may e xist as a standalone document.  
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 21 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
If approved by [CONTACT_1744]/ EC , subjects from vulnerable populations may be enrolled in the study .  ISO14155 
definition of vulnerable population:  Defined as subject whose willingness to volunteer in a clinical 
investigation could be unduly influenced by [CONTACT_162161], whether justified or not, of benefits 
associated with participation or of retaliatory response from senior members of a hierarchy in case of 
refusal to participate.   Examples of populations which may contain vulnerable subjects include: 
Individuals with lack of or loss of  autonomy due to immaturity or through mental disability, persons in 
nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority 
groups, homeless persons, nomads, refugees, and those incapable of giving informed consent . Other 
vulnerable subjects include, for example, members of a group with a hierarchical structure such as 
university students, subordinate hospi[INVESTIGATOR_248925], employees of the sponsor , 
members of the armed forces, and persons kept in detent ion. 
 
5.[ADDRESS_504198] is excluded from the clinical study.   Consecutive patients 
meeting these criteria should be asked to provide consent for participation in the EXPAND Study.  
 
5.3.1  Inclusion Criteria  
1. Subjects who give conse nt for study  partic ipation  
2. Subjects scheduled  to receive the MitraClip per the current approved indications for use  
3. Subjects with Symptomatic MR ( ≥3+) 
 
5.3.[ADDRESS_504199] s shall remain in the study  until completion of the required follow -up period; however, a 
subject’s  participation in any c linical study is voluntary and the subject has the right to withdraw at 
any time without penalty or loss of benefit.  Conceivable reasons for discontinuation may include, but 
not be limited to, the following:  
• Subject death  
• Subject voluntary withdrawal  
• Subject withdrawal by [CONTACT_26139] -indicated  
• Subject lost -to follow- up as described below  
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504200] be notified of the reason(s) for subject discontinuation. The site will provide this 
information to the Sponsor . Inve stigators must also report this to their respective IRB/EC as defined 
by [CONTACT_1385]’s procedure(s) .  
 
No additional follow–up will be required or data recorded from subjects once withdrawn, except for 
the status (deceased/ alive).  
 
Lost-to-Follow -up: 
 If the subject misses two consecutive scheduled follow up time points and the attempts at contact[CONTACT_400131], then the subject is considered lost to follow -up. Site 
personnel shall make all reasonable efforts to locate  and communicate with the subject (and 
document these efforts in the source documents), including the following, at  each contact [CONTACT_7206]:  
• A minimum of [ADDRESS_504201]. 
• If these attempts are unsuccessful, a letter (certified if applicable)  should be sent to the subject. 
• If a subject misses one or more non- consecutive foll ow-up contact [CONTACT_196565] a missed visit. The subject may then return for subsequent visits. If the subject 
misses two consecutive time points and the above -mentioned attempts at communicating with 
the subject are unsuccessful, the subject will be considered lost -to-follow- up.  
 
Note : Telephone contact [CONTACT_150747], non -study cardiologist or relative without 
presence of subject or indirect documentation obtained via discharge letters will not be considered 
as subject contact. 
 
5.[ADDRESS_504202]’s Participation  
The expected duration of participation for subjects is approximately [ADDRESS_504203] be completed when:  
• the subject is considered lost to follow -up per the above definition or  
• the subject withdraws from the Study or 
• the investigator withdraws the subject from the Study  or 
• the subject has died or  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 23 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
• upon Study completion ( e.g., 1 year follow -up time point has been reached)  or 
• sponsor termination of Study  
 
Sponsor must be notified of the reason for subject discontinuation. The site will provide this 
information on the electronic case report form ( eCRF ). Investi gators must also report this to their  
EC/IRB as defined by [CONTACT_1385]’s procedure. Subjects will not be replaced. 
 
6.0 TREATMENT  AND FOLLOW -UP ASSESSMENTS  
6.1 Pre-Treatment  
Patients presenting with MR appropriate for treatment with the MitraClip® will under go screening per 
standard hospi[INVESTIGATOR_400063].  If a MitraClip  procedure is 
considered appropriate ( with agreement from local a heart team when required)  and the patient meets 
the screening criteria for the study (i.e. Symptomatic MR≥3+ and not participating in another study) 
the site shall obtain consent from the patient.  All efforts should be made by [CONTACT_400132].  Echocardiographic verification that there is  no e vidence of 
intracardiac, IVC  or femoral venous thrombus  is required prior to MitraClip procedure per the MitraClip 
IFU.   The MitraClip procedure should be attempted for all consented patients with no evidence of 
thrombus.  
 
6.1.[ADDRESS_504204] of care procedures for patients that undergo a 
MitraClip ® procedure.   
 6.1.[ADDRESS_504205] of care.  Baseline information to be reported 
into the study include at minimum:  medical history, age, weight, heart rate, blood pressure, history 
of heart failure hospi[INVESTIGATOR_602], MR severity , and [LOCATION_001] Heart Association (NYHA) Functional 
Class.  A baseline QOL  conducted by [CONTACT_400133].   If a [ADDRESS_504206] of care at baseline, these results will be 
collected in the EXPA ND Study.   
 
6.1.3  Pre-treatment Imaging  
Pre-Treatment Transthoracic Echocardiogram (TTE) and Transesophageal Echocardiogram ( TEE) 
should be conducted per standard of care for a MitraClip® Procedure.  Copi[INVESTIGATOR_400064] -up 
echocardiograms .  
 6.2 Index Procedure  
Please refer to IFU for instructions on handling and preparation of the MitraClip ® System.  All 
Investigators must read and understand the IFU that accompanies the Device.   
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 24 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
6.2.1  Treatment   
The MitraClip ® procedure should be conducted in accordance with standard of care practice and 
approved labelling.  All consecutive consented patients with an attempted MitraClip procedure will be 
entered into the study .  A procedure is considered attempted when the Mitr aClip delivery system is 
introduced.   
 
NOTE FOR U. S. Sites Only:   In order to permit device reimburs ement, please enter required data 
into the TVT Registry per your standard processes for all EXPAND Study cases.  The data collected 
in this registry does not replace the data collected by [CONTACT_400134] .    
 
6.[ADDRESS_504207] Clinical Assessments and Laboratory / Clinical Tests should be conducted per standard of care.  
Post-procedure  information to be reported for this study include at minimum:  advers e events , device 
performance, concurrent  procedures, MR severity and NYHA Functional Class.    
 
6.3.1  Final ( Post -procedure) Imaging  
Prior to discharge a TTE should be conducted per standard of care.  The discharge TTE will be 
collected by [CONTACT_400135]/or follow -up 
TTEs.   
 6.[ADDRESS_504208] of and was conducted at baseline; results for 6-minute walk test at 30day and 
12-months visits will be collected  in the EXPAND Study.   
 
Visits at: 
• 30 days  (30 days - 14 days  / +60 days )  
• 12 months (365 days - 30 days  / +90 days )   
 Phone call  or visit at: 
• 6 months (180 days - 30 days  / +90 days ) 
 
6.4.[ADDRESS_504209] of care.  TTEs 
will be collected by [CONTACT_400135]/or follow -
up TTEs.  
 During the follow- up period for this study (12 months) any unscheduled echocardiograms, either TEE 
or TTE, should be submitted to the Sponsor.  
 Table 2 outlines the assessment  schedule for this study.  
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 25 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
Table 2.  Clinical Assessment  Schedule  
Required Assessments to be Collected  Pre-
Treatment  Treatment  DIS 30-D 6-M 1-Y 
-14/+60 
days -30/+90 
days -30/+[ADDRESS_504210]  
(Only if standard of care)  X   X  X 
Adverse E vents1  X X X X X 
Transthoracic Echocardiography (TTE) X X2 X X  X 
Transesophageal Echocardiography (TEE)  X X2     
Unscheduled Echocardiogram (TTE or TEE)    X X X X 
1. Adverse Events to be collected in this study include : cardiovascular events, device -related c omplications (as 
defined in section 4.2), and events classified as MAEs (as defined in section 4.1)   
2.  TTE and TEE during treatment should be submitted  for the study only  if capturing TTE and TTE echoes is part 
of standard of care.  
 
 
7.[ADDRESS_504211] definitions and reporting timelines to be 
used and adhered to by [CONTACT_473].  
 
7.1 Definitions 
7.1.1  Adverse  Event 
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, 
whether or not related to the medical devic e. 
 
Note 1: This  definition includes events related to the device  
Note 2 : This definition includes events related to the procedures involved.  
Note 3 : For users or other persons, this definition is restricted to events related to the MitraClip ® 
device.  
 
An AE can therefor e be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of a medicinal product, whether or 
not related to the medicinal product. 
 
7.1.2  Serious Adverse Event  
If the AE meets any of the criteria below, it is regarded as  a serious adverse event (SAE).  
a) Led to a death,  
b) Led to a serious deterioration in health that either : 
1) Resulted in a life -threatening illness or injury, or  
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 26 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
2) Resulted in a permanent impairment of a body  structure or a body function, or  
3) Required in- patient hospi[INVESTIGATOR_1081], or  
4) Resulted in medical or surgical intervention to prevent life threatening illness or injury or 
permanent impairment to a body structure or a body function. 
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect. 
A planned hospi[INVESTIGATOR_5912] -existing condition, or a procedure required by [CONTACT_400136] , 
without a serious deterioration in health, is not considered to be a se rious adverse event.  
 
7.1.3  Device Deficiency/Device Malfunction  
Device deficiency (DD) is defined as an inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate 
labeling. This includes the failure of the device to meet its performance specifications or otherwise perform as intended.  
 Note : Performance specifications include all claims made in the labeling of the device . 
 A device malfunction (DM) is the failure of a device to meet its performance specifications or otherwise perform as intended, when used in accordance with the IFU or protocol . 
 
7.[ADDRESS_504212] igator  and recorded on the appropriate eCRF 
form. Determination should be based on assessment of temporal relationships, evidence of alternative etiology, medical/biologic plausibility, and patient  condition (pre -existing condition).  
 
7.3 Adverse Event/Device Deficiency /Product Experience Reporting  
7.3.[ADDRESS_504213] during the course of the clinical 
study and report as required by [CONTACT_400137] . AEs need to be collected on the appropriate AE eCRF 
form.  Additional information with regards to an adverse event should be updated within th e 
appropriate case report form.  
Adverse Events to be reported during this study include: all cardiovascular events, device- related 
complications (as defined in section 4.2), and events classified as MAEs (as defined in section 4.1).  These AEs should be reported starting from the time that the MitraClip delivery system is 
introduced to the femoral vein through the [ADDRESS_504214] attempted procedure.   
 The investigator should report all required SAEs to the Sponsor as soon as possible but no later than 
3 calendar days from the day the study personnel became aware of the event or as per the investigative site’s local requirements, if the requirement is more stringent than those outlined. The 
date the si te staff became aware that the event met the criteria of a serious adverse event must be 
recorded in the source document.  
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504215] Experience Report Form . 
 The Investigator will further report the SAE to the local IRB/EC according to reporting requirements.  
 
7.3.2  Device Deficiency /Device Malfunction Reporting 
All device deficiencies/malfunctions should be reported within the Electronic Data Capture ( EDC) 
System on the appropriate eCRF form no later than 3 calendar days from the day the study personnel 
became aware of the event or as per the investigative site’s  local requirements, if the requirement is 
more  stringent than those outlined.  
 
A fax form will be made available to allow the investigator to report device deficiencies/malfunctions 
in the event that  the entry cannot be made in the EDC.  This does not replace the EDC reporting 
system. All information must still be entered in the EDC system as soon as feasible.  
 In case a device deficiency/malfunction occurred before the patient ID has been assigned, the device 
deficiency should be reported to the Sponsor v ia the Product Experience Report Fo rm .   
 The device, if not implanted or not remaining in the subject,  should be returned to Abbott.  
 Device deficiencies/malfunctions should be reported to the IRB/EC per the investigative site’s local 
requirements.  
 
7.3.3  Adverse  Event Reporting to Country Regulatory Authorities by [CONTACT_400138], per local and regional 
requirements.  
 
 
8.0 ADJUDICATION OF EVENTS  
8.1 The Clinical Events Committee (CEC)  
A Clinical Events Committee is comprised of qualified physicians who are not investigators in the 
study . The CEC will review and adjudicate pre -specified events reported by [CONTACT_400139] & Surveillance personnel/designate for the study as documented in a CEC Manual of 
Oper ations (MOP). 
 
 
 
 
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 28 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
9.0 STATISTICAL  ANALYSIS  
The following section describes the statistical methods for the clinical study. Details on 
statistica l analyses  are maintained in a separate Statistical Analysis Plan (SAP).  
 
9.[ADDRESS_504216] an attempted 
treatment  with the MitraClip ® NTR System and/or Mitr aClip® XTR S ystem at participating centers. 
The study will include up to 1,[ADDRESS_504217] -market assessment of device safety and performance.  Descriptive analysis 
will be performed on the study data.  Depending on the type of data (e.g., continuous or ca tegorical), 
statistical methods described in this section below will be used.  
 
For continuous variables, such as age, means, standard deviations, and 95% confidence intervals 
for the mean will be calculated.  
 
For binary variables such as APS, counts, percentages, and 95% confidence intervals based on Exact 
Clopper -Pearson method will be calculated.    
 For time to event data such as all -cause mortality, Kaplan- Meier analyses will be performed .  
 
For recurrent event data such as recurrent heart failure hos pi[INVESTIGATOR_400065]- and post -procedure, 
data will be analyzed using a generalized linear model, such as Poisson regression model.   
 

 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 29 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
Results from this study will be presented within the context of the literature on the MitraClip.  
 
9.4.2  Subgroup Analysis  
 
  
 9.4.3  Handling of Multiplicity  Issues  
Details will be defined in the Statistical A nalysis Plan (SAP).   
 
9.4.[ADDRESS_504218] ACCESS TO SOURCE DATA/DOCUMENTS  
The investigator/institution will permit direct access to source data/documents in order for clinical 
study -related monitoring, audits, IRB/EC review and regulatory inspections to be performed. 
Subjects providing informed consent are agreeing to allow Sponsor  and/or its designee access and 
copying rights to pertinent information in their medical records concerning their participation in this clinical study . The investigator will obtain, as part of the informed consent, permission for clinical 
study monitors or regulatory authorities to review, in confidence, any records identifying the subjects 
in this clinical study . This information may be shared with regulatory agencies; however, Sponsor 
undertakes not to otherwise release the subject's personal and private information.  
  
11.[ADDRESS_504219] Market study . Sites will be selected based upon review of a recent site assessment , if app licable, 
and the qualifications of the Principal Investigator  [INVESTIGATOR_400066].  

 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 30 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
11.2 Protocol  Amendments  
Approved Protocol  amendments will be provided to the Investigators by [CONTACT_150753]. The Principal  Investigator [INVESTIGATOR_179168] /EC or 
equivalent committee of the Protocol amendment (administrative changes) or obtaining IRB’s /EC’s  
approval of the Protocol  amendment (changes in subject care or safety), according to the instructions 
provided by [CONTACT_400140].  
 
Acknowledgement/approval by [CONTACT_1201] /EC of the Protocol  amendment must be documented in 
writing prior to implementation of the Protocol  amendment. Copi[INVESTIGATOR_400067].  
 
11.3 Training  
11.3.1  Site Training  
All Investigators/ study  personnel are required to attend Sponsor training sessions, which may be 
conducted at an Investigator's meeting, a site initiation visit or other appropriate training sessions. 
Over -the-phone  or self-training may take place as required. Training of Investigators/ study personnel 
will include, but is not limited to, the Protocol  requirements, device usage, electronic case report form 
completion and study  personnel responsibilities. All Investigators/ study  personnel that are trained 
must sign a training log (or an equivalent) upon completion of the training. Prior to signing the training 
log, Investigator/ study  personnel must not perform any study -related activities that are not considered 
standard of care at the site.   
 
11.3.2  Training of Sponsor’s Monitors  
Sponsor and/or designated monitors will be trained to the Protocol , case report forms and device 
usage (as appropriate). Documentation of this training will be according to written procedures.  
 11.4 Monitoring  
Per t he Monitoring Plan, centralized monitoring will occur through routine internal data review. This 
monitoring is designed to identify missing and inconsistent data, data outliers, and potential CIP 
deviations that may be indicative of site non- compliance. On -site monitoring may occur at the 
discretion of the Sponsor.  
 Prior to initiating any procedure, the Sponsor monitor (or delegate) will ensure that the following 
criteria are met:  
 
The investigator understands and accepts the obligation to conduct the research study according to 
the Protocol and applicable regulations, and has signed the Investigator Agreement or the Clinical 
Study Agreement . 
 The Investigator and his /her staff have sufficient time and facilities to conduct the study and that they 
have access to an adequate number of appropriate subjects to conduct the study.  
 
Source documentation  (including original medical records) must be available to substantiate proper 
informed consent procedures, adherence to Protocol  procedures, adequate reporting and follow- up 
of adverse events, accuracy of data collected on case report forms, and device information.  
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 31 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
If monitoring visit s are scheduled, t he Investigator/site will permit access to such records. A 
monitoring visit sign -in log will be maintained at the site. The Investigator will agree to dedicate an 
adequate amount of time to the monitoring process. The Investigator and/or resea rch coordinator will 
be available for monitoring visits. It is expected that the Investigator will provide the study monitor 
with a suitable working environment for review of study -related documents.  
 
11.[ADDRESS_504220] -specific deviations from the Protocol , a Protocol  deviation 
case report form will be completed. The occurrence of Protocol  deviations will be monitored by [CONTACT_400141]. Investigators will inform their IRB/EC or equivalent 
committee of all Protocol  deviations in accordance with their specific IRB/EC or equivalent committee 
reporting policies and procedures.  
 In the event of repeated non- compliance, as determined by [CONTACT_1034], a Sponsor’s monitor or 
company representative will attempt to secure compliance by [CONTACT_10980] (and not limited to):  
• Visiting the investigator and/or delegate  
• Telephoning the investigator and/or delegate  
• Corresponding with the investigator and/or delegate  
 
Repeated non- compliance with the signed agreement, the Protocol  or any other conditions of the 
study may result in further escalation in accordance with the Sponsor’s written procedures including 
securing compliance or, at its sole discretion; Sponsor may terminate the investigator's participation 
in the study.  
 
11.[ADDRESS_504221] the rev iew of the 
current clinica l study (e.g., Form FDA 483, Inspectional Observations, Warning Letters , Inspection 
Reports, etc.). Sponsor may provide any needed assistance in responding to regulatory audits.  
 
11.7 Sponsor  Auditing  
In the event that an Investigator is contact[CONTACT_426] a Regulatory Agency in relation to this clinical study, 
the Investigator will notify the Sponsor immediately and IRB/EC as appropriate. The Investigator and 
Research Coordinator must be available to respond to reasonable requests and inspection queries 
made during the inspection process. The Investigator must provide the Sponsor with copi[INVESTIGATOR_400068]  (e.g., Form FDA 483, 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 32 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
Inspectional Observ ations, and Warning Letters ). The Sponsor may provide any needed assistance 
in responding to regulatory inspections.  
 
11.8 Committees   
11.8.1  Steering Committee  
The Steering Committee  will be led by  [CONTACT_400142]-Primary Investigators  (Co-PIs) whose names 
are specified on the cover page of this Protoco l. In addition to the 2 Co- PIs, 8 key opi[INVESTIGATOR_46830]  
(whose names are also specified on the cover page of the protocol) will form the study Steering 
Committee . The Sponsor will be represented by [CONTACT_196584]. The Chairman of the core laboratories and other 
sponsor’s personnel may also participate in the Committee meetings if appropriate. Meeting minutes 
from this committee will be filed with the s ponsor.  
 The Steering Committee is responsible for overseeing the scientific and operational aspects of the 
study. This committee will meet regularly to monitor study progress, general data collection and non-
compliance with the study protocol  at individual centers, to review operational issues that may arise 
and warrant a Protocol  amendment or other corrective action and to determine policy regarding any 
publications arising from data generated from the performance of the study.  
 
11.8.2  Clinical Events Committee (CEC)  
The Clinical Events Committee (CEC) is an independent adjudication body comprised of qualified 
physicians who are not participants in the study . The CEC will review and adjudicate events as 
defined in the CEC charter and according to definitions provided in this Protocol.   
  
12.[ADDRESS_504222] KEEPI[INVESTIGATOR_400069].  
 All CRF data collection will be performed through a secure web portal and all authorized personnel 
with access to the Electronic Data Capture (EDC) system must use an electronic signature [CONTACT_400175], review or correct data. Passwords and electronic signatures will be strictly confidential.  
 All CRF data will be downloaded from the EDC system and reformatted into a data structure 
acceptable to Abbott. The data will be subjected to consistency and validation checks within the EDC 
system and will be subject to supplemental validation following download.  
 
At the conclusion of the study,  completed Case Report Form ( CRF) images with the date- and-time 
stamped electronic audit trail indicating the user, the data entered, and any reason for change (if applicable) will be archived for each site and a backup copy archived with Abbott.  
 For the clinical study duration, the Investigator will maintain complete and accurate documentation 
including, but not limited to , medical records, clinical study  progress records, laboratory reports, 
electronic case report forms, signed ICFs, device accountability records, c orrespondence with the 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 33 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
IRB/EC and clinical study  monitor/Sponsor, adverse event reports, and information regarding subject 
discontinuation or completion of the clinical study . 
 
12.1 Source Documentation  
Regulations and Good Clinical Practice ( GCP ) require that the Investigator maintain information in 
the subject’s original medical records that corroborates data collected on the case report forms. In 
order to comply with these regulatory requirements/GCP , the following information should be included 
in the subject record at a minimum and if applicable to the study : 
• Medical history/physical condition of the subject before involvement in the study  suffic ient to 
verify Protocol  entry criteria  
• Dated and signed notes on the day of entry into the study  referencing the Sponsor , Protocol  
number, subject ID number and a statement that informed consent was obtained 
• Dated and signed notes from each subject visit (for specific results of procedures and exams)  
• Adverse events reported and their resolution including supporting documents such as 
discharge summaries, catheterization laboratory reports, Electrocardiograms ( ECGs ), and lab 
results including documentation of  site awareness of SAEs and of investigator device 
relationship assessment of SAEs.  
• Study required laboratory reports and 12- lead ECGs, review ed and annotated for clinical 
significance of out of range results.  Note : With electronic medical records some clinical sites 
may be able to annotate that labs or ECG have been reviewed in the system. For those sites 
that do not  have such capability the labs or ECG may be able to be printed or signed. Each 
study team should include protocol language regarding these  processes  that is most suitable 
for the specific study .  
• Notes regarding Protocol -required and prescription medications taken during the  study  
(including start and stop dates)  
• Subject’s condition upon completion of or withdrawal from the study  
• Any other data required to substantiate data entered into the CRF  
 
12.2 Electronic Case Report Form Completion  
Primary data collection based on source- documented hospi[INVESTIGATOR_3491]/or clinic chart reviews will be 
performed clearly and accurately by [CONTACT_400143]. 
eCRF data will be collected for all patients in the study.   
 
12.[ADDRESS_504223]/Medical Ethics Committee Review  
Institutional Review Board (IRB)/ Ethics Committee (EC) approval for the Protocol , ICF and other 
written information provided to the patient will be obtained by [CONTACT_079] [INVESTIGATOR_400070] . The approval letter must be received prior to the start of this 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504224] be provided to the Sponsor. No changes will be made to the Protocol  
or ICF or other written information provided to the patient without appropriate approvals, including 
IRB/E C, the Sponsor, and/or the regulatory agencies.  
 
Until the clinical study  is completed, the Investigator will advise his/her IRB/EC of the progress of this 
clinical study , per IRB/EC requirements. Ongoing written approval will be obtained from the IRB/EC 
according to each institution’s IRB/EC requirements. Further, any amendments to the Protocol  as 
well as associated ICF changes will be submitted to the IRB/EC and written approval obtained prior 
to implementation, according to each institution’s IRB/EC requirements.  
 
 
14.[ADDRESS_504225] the 
right to access and use all data and results generated during the clinical study . The Investigators will 
not use the Clinic al study -related data without the written consent of the Sponsor for any other 
purpose than for Clinical study completion or for generation of publication materi al, as referenced in 
the Clinical Study  Site Agreement. The publication and/or presentation of results from a single clinical 
study  site are not allowed until publication and/or presentation of the multi -center results. The Sponsor 
acknowledges that the study’s Principal Investigator [INVESTIGATOR_196540] a multi -center publication 
regarding the clinical study  results. The Sponsor must receive any proposed publication and/or 
presentation materials at least 60 days prior to the proposed date of the presentation  or the initial 
submission of the proposed publication in order for the materials to be reviewed by [CONTACT_400144]’s publication policy set forth in the Clinical Study  Site Agreement.  
 The Sponsor will be responsible for determi ning whether to register the Clinical study  on 
www.clinicaltrials.gov
 or any other clinical study registration sites, in accordance with the International 
Committee of Medical Journal Editors guidelines, or any  other applicable guidelines. In the event 
Sponsor determines that the Study  should be registered, Sponsor shall be responsible for any such 
registration and results posting as required by [CONTACT_103927].gov. Institution and/or Principal 
Investigator(s) shall not take any action to register the study . 
  
15.[ADDRESS_504226].   The MitraClip  XTR System, which includes the same modified DC and longer clip arms 
on the implant, was designed for graspi[INVESTIGATOR_400071].  Based on testing, graspi[INVESTIGATOR_400072].   In design validation testing, differentiation of ease of 
graspi[INVESTIGATOR_400073] a model which simulated a 
mixed functional/degenerative etiology procedure with a tethered posterior leaflet and a flailing anterior leaflet. The end result of both graspi[INVESTIGATOR_400074]. In other development tests 
prior to the design validation, both the MitraClip NT and MitraClip XTR devices were able to grasp 
leaflets equivalently. Subjects with such anatomies may therefore benefit from treat ment with the 
MitraClip XTR.   Moreover, the improved DC may simplify the MitraClip procedure compared to the 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.[ADDRESS_504227] been identified as possible.  
 
Table 3.  Potential Complications and Adverse Events (from MitraClip® IFU)  
Allergic reaction (anesthetic, contrast, Heparin, nickel alloy, latex)  
Aneurysm or pseudo- aneurysm 
Arrhythmias  
Atrial fibrillation  
Atrial septal defect requiring intervention 
Arterio -venous fistula 
Bleeding Cardiac arrest  
Cardiac perforation Cardiac tamponade / Pericardial Effusion Chordal entanglement/rupture Coagulopathy  
Conversion to standard valve surgery  
Death  
Deep venous thrombus (DVT)  
Dislodgement of previously implanted devices  
Dizziness  
Drug reaction to anti -platelet / anticoagulation agents / contrast 
media  
Dyskinesia  
Dyspnea  
Edema  
Emboli (air, thrombus, MitraClip Implant)  
Emergency cardiac surgery  
Endocarditis  
Esophageal irritation  
Esophageal perforation or stricture Failure to deliver MitraClip to the intended site  
Failure to retrieve MitraClip System components  
Fever or hyperthermia  
Gastrointestinal bleeding or infarct  
Hematoma  
Hemolysis  Hemorrhage requiring transfusion  
Hypotension / hypertension Infection  
Lymphatic complications  
Mesenteric ischemia Mitral  stenosis  
Mitral valve injury  
MitraClip Implant erosion, migration or malposition MitraClip Implant thrombosis  
MitraClip System component(s) embolization Multi -system o rgan failure  
Myocardial infarction  
Nausea/vomiting  
Pain Peripheral ischemia  
Prolonged angina  
Prolonged ventilation Pulmonary congestion  
Pulmonary thrombo- embolism 
Renal insufficiency or failure  
Respi[INVESTIGATOR_1399] / atelectasis / pneumonia  
Septicemia Shock, Anaphylactic or Cardiogenic  
Single leaflet device attachment (SLDA)  
Skin injury or tissue changes due to exposure to ionizing radiation Stroke or transient ischemic attack (TIA)  
Urinary tract infection  
Vascular trauma, dissection or occlusion  
Vessel spasm Vessel perforation or laceration  
Worsening heart failure Worsening mitral regurgitation Wound dehiscence 
 
15.[ADDRESS_504228] -market study on an approved commercial device.  There is no investigational device 
being used as part of this study.   
 
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 36 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
15.4 Risks Associated with Participation in Cli nical Study  
Treatment with the MitraClip ® device as part of this study is ident ical to treatment with the MitraClip ® 
device outside of this study.  Participation in the study will not impact the MitraClip procedure or use 
of the MitraClip  in any way.  Participation in the study requires submission of data that may or may 
not be protected heath information.  This information should be kept confidential, but there is a risk that some of the information could be unintentionally made non- confidential.  The risk  of the this 
happening for this study is no greater than the risk of loss of confidentiality in any study.   
 
15.[ADDRESS_504229] of care medications.  There are no 
protocol -required medications being used as part of this study.   
 15.6 Steps that will be Taken to Control or Mitigate the Risks  
Per the device IFU , “Use of the MitraClip Delivery System should be restricted to those physicians 
trained to per form invasive endovascular and transseptal procedures and to those physicians trained 
in the proper use of the system ”.   
 
Risks associated with the use of the device during this clinical study are minimized through device 
design, investigator selection and training, pre- specified patient eligibility requirements, study 
monitoring to ensure adherence to the protocol . All adverse events and device deficiencies will be 
reported to Abbott and will be monitored internally for safety surveillance purposes.  
 
The contraindications, warnings and precautions are listed in the IFU that will b e provided with all 
devices to be used during this study.  
 
15.[ADDRESS_504230] a small risk of loss of confidentiality as part of the data 
collection process.  This risk is mitigated to as low as possible with the use of data collection systems, 
methods and procedures that are used commonly in clinical research.  This includes the use of only 
validated electronic systems, the training of study personnel and the use of de -identified data for all 
data entry.  Based upon the established safety profile of the MitraClip device; t he low risk of loss of 
confidenti ality is adequately mitigated to justify use of the next generation MitraClip to treat patients 
for this study.  
   
 
 MitraClip® EXPAND Study  
  
 
Protocol 17-518: Version 2.0 26 June 2018  
CONFIDENTIAL  and PROPRIETARY       Page 37 of 68 
Do not distribute or reproduce with the prior written permission of Abbott   
 
APPENDIX I:   MITRACLIP XTR PMCF CLINICAL STUDY PROTOCOL
 
 
 
 
 
 
Defines a statistical analysis to be conducted for the first 220 European Patients in the EXPAND Study treated with the MitraClip XTR System  
  
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
   
  
 
  
 
 
 
 
 
 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 1 of 36 
  
 
 
 
 
 
 
 
17-518-1: MitraClip XTR PMCF Study  
 
A Post -Market Clinical Follow -up Assessment of the Safety and 
Performance the MitraClip XTR System  
 
 
Version Number  2.0 
Date  26 June 2018  
Planned Number of Sites and 
Region(s)  Up to [ADDRESS_504231]  
Abbott Structural Heart  
  
 
  
 
 
 
  
 
 
 
 
  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504232]’s Participation ............................................................... [ADDRESS_504233] Follow -up ................................................................................................................. 13 
7.0 ADVERSE EVENTS  ................................................................................................................. 14 
7.1 Definitions ............................................................................................................................. 14 
7.1.1  Advers e Event  ............................................................................................................ 14 
7.1.2  Serious Adverse Event  ............................................................................................... 14 
7.1.3  Device Deficiency/Device Malfunction  ........................................................................ 14 
7.2 Device Relationship .............................................................................................................. 14 
7.3 Adverse Event/Device Deficiency/Product Experience Reporting ......................................... 15 
7.3.1  Adverse Event Reporting  ............................................................................................  15 
7.3.2  Device Deficiency/Device Malfunction Reporting  ........................................................ 15 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 3 of 36 
  
 
 
7.3.3  Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_1034]  .............. 15 
8.0 ADJUDICATION OF EVENTS  ................................................................. ................................. 16 
8.1 The Clinical Events Committee (CEC) ................................................................. ................. [ADDRESS_504234] ACCESS TO SOURCE DATA/DOCUMENTS  ............................................................ 18 
11.0  QUALITY CONTROL AND QUALITY ASSURANCE  ................................................................ 18 
11.1  Selection of Clinical Sites and Investigators  .......................................................................... 18 
11.2  Protocol Amendments  .......................................................................................................... 19 
11.3  Training ................................................................................................................................ 19 
11.3.1  Site Training ........................................................................................................... 19 
11.3.2  Training of Sponsor’s Monitors  ............................................................................... [ADDRESS_504235] KEEPI[INVESTIGATOR_1645]  ........................................................................... 20 
12.1  Data Management/Data Analysis  ......................................................................................... 20 
12.2  Source Documentation ......................................................................................................... 21 
12.3  Electronic Case Report Form Completion  ............................................................................. 21 
12.4  Recor
d Retention .................................................................................................................. 21 
13.0  ETHICAL CONSIDERATION  .................................................................................................... 21 
13.1  Medical Ethics Committee Review  ........................................................................................ 21 
14.0  RISK ANALYSIS ...................................................................................................................... 22 
14.1  Anticipated Clinical Benefits  ................................................................................................. 22 
14.2  Foreseeable Adverse Events and Anticipated Adverse Device  Effects  ................................. 22 
14.3  Residual Risks Associated with the Investigat ional Device  ................................................... 23 
14.4  Risks Associated with Participation in Clinical Study  ............................................................ 23 
14.5  Possible Interactions with Protocol- Required Concomitant Medications  ............................... 23 
14.6  Steps that will be Taken to Control or  Mitigate the Risks  ...................................................... 23 
14.7  Risk to Benefit Rationale ...................................................................................................... 24 
APPENDIX I - ABBREVIATIONS AND ACRONYMS ........................................................................... 25 
APPENDIX II - DEFINITIONS  .............................................................................................................. 26 
APPENDIX III - CASE REPORT FORMS ............................................................................................. 33 
APPENDIX IV - SUMMARY OF CHANGES  ......................................................................................... 34 
 
  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 4 of 36 
  
 
 
COMPLIANCE STATEMENT:  
 
This study will be conducted in accordance with this Plan, the Declaration of Helsinki, applicable Good 
Clinical Practices and applicable regulations including ISO14155 and the appropriate local legislation(s). The most stringent requirements, guidelines or regulations must always be followed. The conduct of the 
study will be approved by [CONTACT_400145] (EC) of the respect ive study site 
and by [CONTACT_179190].  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 5 of 36 
  
 
 
PROTOCOL SUMMARY  
 
 
  Protocol Name 
[CONTACT_98567]  17-518-1: MitraClip XTR PMCF Study  
 
Title Post-Market Clinical Follow -up Assessment of the Safety and 
Performance the MitraClip XTR System  
Objectives  The primary objective of this study to eva luate the safety and 
performance of the MitraClip XTR System in a post -market setting.  
Device  MitraClip XTR System  
Targeted number 
of subjects  A minimum of [ADDRESS_504236] Follow -up Clinical Visit:  30 days and 12 Months  
Phone Call:   6 Months  
Primary Endpoint  Safety and Effectiveness  
Acute Procedural Success (APS) defined as successful implantation of 
the MitraClip XTR device with resulting MR severity of 2+ or less on 
discharge Echocardiogram (30- day echocardiogram will be used if 
discharge is unavailable or uninterpretable). Subjects who die or undergo mitral valve surgery before discharge are considered to be an 
APS failure  
Clinical Endpoints  • Major Adverse Event (MAE).  MAE defined as a composite of all-
cause Death, M yocardial Infarction, St roke, or non-elective CV 
surgery  for device related  complications (CEC adjudicated)  
•  MR Severity  
• Device Related Adverse Events  (including Mitral v alve stenosis, 
device embolization, Single Leaflet Device Attachment (SLDA), 
Iatrogenic atrial septal defect, Myocardial perforation, or the need 
for mitral valve replacement instead of repair due at least in part to 
the MitraClip procedure or the presence of the MitraClip device )) 
• All-cause mortality  
• Recurrent heart failure hospi[INVESTIGATOR_059] 
• [LOCATION_001] Heart Associa tion (NYHA) functional class improvement  
Inclusion Criteria  1. Subjects scheduled to receive the MitraClip per the current approved 
indications for use  
2. Subjects who give consent for their participation  
3. Subjects with Symptomatic MR (≥3+)  
Exclusion Criteria  1. Subjects participating in another clinical study that could impact the 
follow -up or results of this study.   

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504237] clinicians with leaflet graspi[INVESTIGATOR_007].  
Although there is extensive published clinical evidence on the safety and performance of the MitraClip system (see section 2.1), the safety and performance of the MitraClip XTR system has not yet been 
evaluated in a clini cal study.   
 
This PMCF study will be conducted on commercial MitraClip XTR devices that have received CE Mark 
and will be used to fulfill the regulatory requirement for post -market clinical follow- up (PMCF).  
 
1.[ADDRESS_504238] to health economics and clinical care, and to provide further evidence of safety and effectiveness. 
Five hundred sixty -seven (567) patients were treated with the MitraClip.  One- year clinical follow- up was 
available in 487 patients.  Considering the high MitraClip device implant rate (99.6%, 565/567 ), the high 
rate of meaningful MR reduction (78.9%, 258/327 MR<2+), and the resulting improvements in 6- minute 
 
 
29 Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder JD,  
Moccetti T, Schillinger W.  Percutaneous Mitral Valve Interventions in the Real World: Early and 1- Year Results 
from the ACCESS -EU, a Prospective, Multicenter, Nonrandomized Post -Approval Study of the MitraClip Therapy 
in Europe.  J Am Coll Cardiol.  2013; 62:1052- 1061.  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 7 of 36 
  
 
 
walk (59.5 m difference, p<0.0001), Minnesota Living with Heart Failure Questionnaire quality of life score 
(13.5 point improvement, p<0.0001) and NYHA Functional Class (71.5% NYHA Class I or II, p<0.0001), 
at 1 year, the study is concluded that the MitraClip device provides an important therapeutic option for 
patients with significant mitral regurgitation, and is an especially important option for  patients who may 
be considered high surgical risk.  
 The GRASP registry was a single- center, prospective, observational study of consecutive high surgical 
risk patients with moderate- to-severe or severe MR undergoing percutaneous mitral valve repair with t he 
MitraClip System at Ferrarotto Hospi[INVESTIGATOR_307] (Catania, Italy).  The study does not have specific exclusion criteria; and the indication for MitraClip therapy was established by a multidisciplinary Heart Team.  The 
degree of preprocedural MR was quantified according to current guidelines by [CONTACT_400146].  A total of [ADDRESS_504239] 2008 and October 2012 as part of the GRASP registry
30.  MR grade 3+ or 4+ was present in 98% 
of patients, and NYHA functional class symptoms in 80% of patients.  Acute procedural success was achieved in all patients.  MR was reduced to 1+ and 2+ post -procedure in 63% and 37% of patients, 
respectively.  MAEs occurred in 4 patients (4.3%) at 30 days.  One patient died from gastrointestinal 
bleeding within 30 days. Results from the GRASP registry further support the safety and efficacy of the MitraClip device in a real -world setting.  
 The German transcatheter mitral valve interventions (TRAMI) registry was initiate d in August [ADDRESS_504240] prospective cohort was described by [CONTACT_400147].33.  A total of 828 patients were prospectively enrolled at 21 German sites between 2010 and 2013.  
One- year follow- up was available in 749 patients.  The MitraClip implant rate in this cohort was 97%, with 
an average of 1.4 ±0.6 clips implanted per procedure.    Mitral regurgitation was reduced from severe 
(94%) at baseline to none or  mild in 85.2% of patients post procedure.  One patient died intra- operatively 
and in- hospi[INVESTIGATOR_400075] 2.4% (n=18).  No emergent cardiac surgery was required.  The rate of in-
hospi[INVESTIGATOR_400076] (MACCE) was 3.1%.  These results 
demonstrate that treatment of significant MR with the MitraClip device is efficacious and results in 
 
 
30 Grasso C, Capodanno D, Scandura S, Cannata S, Imme S, Mangiafico S, Pi[INVESTIGATOR_400057] A, Ministeri M, Barbanti M, 
Caggegi A, Chiaranda M, Dipasqua F, Giaquinta S, Occhipi[INVESTIGATOR_88757] M, Ussia G, Tamburino C.  One- and Twelve- Month 
Safety and Efficacy Outcomes of Patients Undergoing Edge- to-Edge Percutaneous Mitral Valve Repair (from the 
GRASP Registry).  Am J Cardiol .  2013; 111:1482- 1487.  
31 Baldu s S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Mollmann H, 
Hehrlein C,  Ouarrak T, Senges J, Meinertz T, investigators GTMVI.  MitraClip Therapy in Daily Clinical Practice: 
Initial Results from the German Transcathet er Mitral Valve Interventions (TRAMI) Registry.  Eur J Heart Fail .  2012; 
14:1050- 1055.  
32 Schillinger W, Hunlich M, Baldus S, Ouarrak T, Boekstegers P, Hink U, Butter C, Bekeredjian R, Plicht B, Sievert 
H, Schofer J, Senges J, Meinertz T, Hasenfuss G.  Acute Outcomes after MitraClip Therapy in Highly Aged Patients: 
Results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry.  EuroIntervention .  2013; 9:84-
90. 
33 Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert H, 
Nickenig G, Eggebrecht H, Senges J, Schillinger W.  One-Y ear Outcomes and Predictors of Mortality after MitraClip 
Therapy in Contemporary Clinical Practice: Results from the German Transcatheter Mitral Valve Interventions 
Registry.  Eur Heart J .  2016; 37:703- 712. 
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504241] ratio for predicting 1 -year mortality.  
 The Transcatheter Valve Treatment Sentinel Pi[INVESTIGATOR_400077] 12 -month follow -up result s of 628 
consecutive patients treated between January 2011 and December 2012 in 25 centers in 8 European countries. Acute procedural success was high (95.4%) with no difference between FMR and DMR 
patients.  Overall, in- hospi[INVESTIGATOR_400075] 2.9%.  MR reduction to ≤2+ was achieved in 98.2% of patients 
post-procedure with no difference between MR etiologies.  At 1- year, MR was reduced to ≤2+ in 94.0% 
of patients and 58.6% had mild or no MR, with comparable results obtained for FMR and DMR.  The results of t he pi[INVESTIGATOR_400078] a high -risk cohort, without differences between FMR and DMR.  These 
results confirm long- term benefits previously reported in other real-world registries.  
 The totality of post -market clinical evidence supports the use of the MitraClip System for the treatment of 
MR.  The MitraClip XT R PMCF Study will assess the safety and performance of the next generation 
MitraClip XTR system to conf irm that the new design also performs safely and with acceptable outcomes.   
 
2.2 Rationale for Conducting this Study  
This Study will meet PMCF requirements to confirm safety and performance of the next generation 
MitraClip XTR System.  The primary analysis will be conducted using the endpoint of Acute Procedural 
Success (APS). APS is evaluated by [CONTACT_400148] (re- intervention or death) and performance by [CONTACT_400149] 
(reduced MR to MR2+ or less). APS will be evaluated upon discharge from the hospi[INVESTIGATOR_400079].  
A comparison to the APS rate established by [CONTACT_400150].  
 
2.3 Summary of Device  
2.3.1  Name [CONTACT_400176].   
 
2.3.2  Indication for Use  
MitraClip XTR procedures for this study will be conducted in accordance with the Instructions for Use 
(IFU) that is approved for the region, where the implant is taking place.  
 
2.3.[ADDRESS_504242].  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504243] will be included in this PMCF analysis.  A minimum of 220 commerc ial MitraClip 
XTR patients will be analyzed at a maximum of 50 centers in the EU as part of this PMCF study.  
 
3.2 Overall Flow of the Study and Follow -up Schedule  
Consecutive eligible patients that present for MitraClip procedure should be consented for the Mi traClip 
XTR PMCF Study.  Patients are included in the analysis upon completion of MitraClip XTR procedure.  
A schematic of the study flow for the study is shown in Figure 1.   
  
Figure 1: Schematic for Study Inclusion  
 
 
 
3.3 Early Termination of the Clinical Study  
No formal statistical rule for early termination of the MitraClip XTR PMCF Study is defined.  
The Sponsor reserves the right to discontinue the study at any stage or reduce the follow up period with suitable written notice to the investigator. Possible reason(s) may include, but are not limited to:  
• Unanticipated adverse device effect (UADE) occurs and it presents an unreasonable risk to the participating subjects.  
• Further product development is cancelled.  
 
Should the study be discontinued by [CONTACT_1034], patients will be followed up as per routine hospi[INVESTIGATOR_400080]/commercial reporting requirements.  Should this occur, the investigator shall return all clinical study materials to the Sponsor, 
and provide a written statement as to why the premature termination has taken place to the EC.  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 10 of 36 
  
 
 
4.0 ENDPOINTS  
4.1 Primary Endpoint  
The primary endpoint is Acute Procedural Success (APS).  This is defined as successful implantation of 
the MitraClip devic e with resulting MR severity of 2+ or less upon discharge Echocardiogram (30 -day 
echocardiogram will be used if discharge is unavailable or uninterpretable). Subjects who die or undergo mitral valve surgery before discharge are an APS failure  
 
4.2  Clinic al En dpoints  
Clinical Endpoints will be assessed at each study time point, all data reported at the 
corresponding study visit will be included for the study time point.      
• Major Adverse Events (MAE): defined as a composite of CEC adjudicated all-cause Death,  
Myocardial Infarction, Stroke, or  non-elective CV surgery  for device related complications  
• MR Severity  
• Device Related Adverse Events (including mitral valve  stenosis, device embolization, single 
leaflet device a ttachment (SLDA), Iatrogenic atrial septal defect, myocardial perforation, or the 
need for mitral valve replacement instead of repair due at least in part to the MitraClip procedure 
or the presence of the MitraClip device)  
• All-cause mortality  
• Recurrent heart failure hospit alization  
• [LOCATION_001] Heart Association (NYHA) functional class improvement  
 
4.3 Success Criteria  
The MitraClip XTR PMCF Study will be successful if the lower one -sided 95% confidence interval (CI) of 
the observed APS rate for the study is greater than the Performance Goal (PG) of 80.7%.     
 
 
5.[ADDRESS_504244] of care procedures for determining if a patient is eligible for 
treatment with a MitraClip System.  Consecutive patients who present for their procedure should be 
asked to provide consent for participation in the MitraClip XTR PMCF Study if they are eligible per t he 
inclusion/exclusion criteria.  Only patients that have a MitraClip XTR implanted will  be included in the 
analysis.  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504245] receive approval of Sponsor and EC/IRB prior to beginning enrollment into the MitraClip XTR PMCF Study  
 
The Investigator or designee, who has been trained on the Study, will explain the nature and scope, 
potential risks and benefits of participation, and answer questions for the subjects.  The subject will be 
treated with the MitraC lip System per standard of care and must consent only to data collection and 
follow- up visit schedule. All subjects (or legally authorized subjects’ representatives if applicable) must 
sign, date and time (if required) the Ethics Committee (EC) approved informed consent prior to any data is reported into the PMCF study.  Obtaining the consent  and provisioning of a copy to the subject, must 
be documented in the subject’s medical records. In addition, the signed informed consent must be kept in the subject’s medical records.  
 If approved by [CONTACT_1383], subjects from vulnerable populations may be enrolled in the study.  ISO14155 
definition of vulnerable population:  Defined as subject whose willingness to volunteer in a clinical 
investigation could be unduly influenced by [CONTACT_162161], whether justified or not, of benefits 
associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate.   Examples of populations which may contain vulnerable subjects incl ude: 
Individuals with lack of or loss of autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, 
homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects include, for example, members of a group with a hierarchical structure such as university 
students, subordinate hospi[INVESTIGATOR_248925], employees of the sponsor , members of the 
armed forces, and persons kept in detention.    
 
5.[ADDRESS_504246] meet the criteria below before being included in the MitraClip XTR Study.  
 
5.3.1  Inclusion Criteria  
1. Subjects scheduled  to receive the MitraClip per the current approved indications for use  
2. Subjects who give consent for their participation  
3. Subjects with Symptomatic MR (≥3+)  
5.3.[ADDRESS_504247] an MitraClip XTR implant will be included in the analysis.  
 
5.5 Total Expected Duration of the Study  
The time to complete the MitraClip XTR PMCF Study is estimated to be approximately 18 months.  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504248]’s Participation  
The final required visit for subjects in the MitraClip XTR PMCF Study is at [ADDRESS_504249] Discontinuation 
Subjects that  are consented and receive a MitraClip XTR implant shall remain in the study until 
completion of the required follow -up period; however, a subject’s participation in any clinical study is 
voluntary and the subject has the right to withdraw at any time without penalty or loss of benefit.  
Conceivable reasons for discontinuation may include, but not be limited to, the following:  
• Subject death  
• Subject voluntary withdrawal  
• Subject withdrawal by [CONTACT_26139] -indicated  
• Subject lost -to follow- up as desc ribed below  
 
The Sponsor must be notified of the reason(s) for subject discontinuation. The site will provide this 
information to the Sponsor. Investigators must also report this to their respective EC as defined by [CONTACT_1385]’s procedure(s). No additional follow –up will be required or data recorded from subjects once 
withdrawn, except for the status (deceased/alive).  However, if a subject withdraws due to problems related to the device safety or performance, the investigator shall ask for the subj ect's permission to 
follow his/her status/condition outside of the clinical study.  
Lost -to-Follow -up:  
If the subject misses two consecutive scheduled follow up time points and the attempts at contact[CONTACT_400151], then the subject is considered lost to follow- up. Site personnel shall make all 
reasonable efforts to locate and communicate with the subject.    
 
6.[ADDRESS_504250] hospi[INVESTIGATOR_8829].  If a MitraClip procedure is considered appropriate and the patient meets 
the screening criteria for the study (i.e. MR>3+, compliance with MitraClip approved labelling, and not 
participating in another study) the site shall obtain consent from the patient.  The consent will permit 
information about the patient to be submitted to the study after successful implantation of MitraClip XTR 
device.  No data may be enter ed into the study unless the informed consent is completed.  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504251] of care.  Baseline information to be reported into the study include at minimum:  medical history, weight, heart 
rate, blood pressure, MR severity and [LOCATION_001] Heart Association (NYHA) Functional Class.   
 
6.1.[ADDRESS_504252] of care for a MitraClip Procedure.   
 
6.2 Index Procedure  
Please refer to Instructions for  Use (IFU) for instructions on handling and preparation of the XTR MitraClip 
System. All Investigators must read and understand the Instructions for Use (IFU) that accompanies the 
Device.  
 
6.2.[ADDRESS_504253] treatment TTEs/TEES, Clinical Assessments and Laboratory / Clinical Tests should be conducted 
per standard of care.  Post -procedure  information to be reported for this study include at minimum:  
adverse events, MR severity and [LOCATION_001] Heart Association (NYHA) Functional Class.  
 
6.[ADDRESS_504254] -procedure.  A 6- month phone 
call is requested for patients in the study to assess for new adverse event.  Table 1  below outlines the 
follow- up schedule for this study.   
 
 
Table 1.  Clinical Fo llow- Up Schedule  
 Required Assessments Pre-Treatment  DIS 30-D 6-M 1-Y 
-14/+60 
days -30/+9 
days -30/+9 
days 
Informed Consent  X     
Medical history  X     
Medical Exam and Reporting of Vitals  X X X  X 
NYHA Classification  X X X  X 
Adverse events and h ospi[INVESTIGATOR_602]1 X X X X X 
1. Adverse Events to collected in this study include: all cardiovascular events, device- related complications (as 
defined in section 4.2), and events classified as MAEs (as defined in section 4. 2) 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 14 of 36 
  
 
 
7.0 Adverse Events  
7.1 Definitions  
7.1.1  Adverse Event  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not 
related to the medical device. 
 Note 1: This definition includes events related to the device  
Note 2: This definition includes events related to the procedures involved.  
Note 3: For users or ot her persons, this definition is restricted to events related to the MitraClip device.  
 An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related 
to the medicinal product.  
 
7.1.2  Serious Adverse Event  
If the AE meets any of the criteria below, it is regarded as a serious adverse event (SAE).  
a) Led to a death,  
b) Led to a serious deterioration in health that either:  
1) Resulted in a life -threatening illness or injury, or  
2) Resulted in a permanent impairment of a body structure or a body function, or  
3) Required in- patient hospi[INVESTIGATOR_1081], or  
4) Resulted in medical or surgical intervention to prevent life threatening illness or injury or 
permanent impairment to a body structure or a body functi on. 
c) Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
 A planned hospi[INVESTIGATOR_5912] -existing condition, or a procedure required by [CONTACT_400152], 
without a serious deterioration in health, is not considered to be a serious adverse event.  
 
7.1.3  Device Deficiency/Device Malfunction  
Device deficiency (DD) is defined as an inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety or performance, such as malfunction, misuse or use error and inadequate 
labeling. This includes the failure of the device to meet its performance specifications or otherwise 
perform as intended.  
 
A device malfunction (DM) is the failure of a device to meet its performance specifications or otherwise 
perform as intended, when used in accordance with the instructions for use or CIP. 
 
7.[ADDRESS_504255] or device caused or contributed 
to an AE is to be determined by [CONTACT_80373] r ecorded on the appropriate eCRF form. 
Determination should be based on assessment of temporal relationships, evidence of alternative etiology, medic al/biologic plausibility, and patient condition (pre- existing condition).  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 15 of 36 
  
 
 
7.3 Adverse Event/Device Deficiency/P roduct Experience Reporting  
7.3.[ADDRESS_504256] during the course of the c linical study 
and report as required by [CONTACT_400153] 7 per AE and SAE definitions.  Adverse Event s to 
reported during this study include: all cardiovascular events, device-related complications (as defined in 
section 4.2), and events classified as MAEs (as defined in section 4.2 ).  These AEs should be reported  
starting from the time that the MitraClip  delivery system is introduced to the femoral vein through the 12-
month  follow up  visit. 
 
The investigator should report all required SAEs to the Sponsor as soon as possible but no later than 3 
calendar days from the day the study personnel became aware of  the event or as per the investigative 
site’s local requirements, if the requirement is more stringent than those outlined. The date the site staff 
became aware that the event met the criteria of a serious adverse event must be recorded in the source document.  
 A fax form will be made available to allow the investigator to report required SAEs in the event the entry 
cannot be made in the EDC. This does not replace the EDC reporting system. All information must still be entered in the EDC system as soon as f easible.  
 
Serious adverse events that occurred in the user or persons other than the study subject should not be 
entered in the EDC system, however need to be reported via the SAE Notification Form.  
The Investigator will further report the SAE to the local IRB/EC according to the institution’s EC reporting 
requirements.  
 
7.3.2  Device Deficiency/Device Malfunction Reporting 
All device deficiencies/malfunctions should be reported within the EDC System on the appropriate eCRF 
form no later than 3 calendar days from  the day the study personnel became aware of the event or as 
per the investigative site’s local requirements, if the requirement is more stringent than those outlined. The device, if not implanted or not remaining in the subject, should be returned to Abbo tt.   
 Device deficiencies/malfunctions should be reported to the EC per the investigative  site’s local 
requirements.  A fax form will be made available to allow the investigator to report device 
deficiencies/malfunctions in the event that the entry cannot be made in t he EDC. This does not replace 
the EDC reporting system. All information must still be entered in the EDC system as soon as feasible.  
 
7.3.3  Adverse Event Reporting to Country Regulatory Authorities by [CONTACT_400154], per local 
and regional requirements.  
 
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 16 of 36 
  
 
 
8.0 ADJUDICATION OF EVENTS  
8.1 The Clinical Events Committee (CEC)  
The Clinical Events Committee is comprised of qualified physicians who are not investigators in the study. 
The CEC will review and adjudicate pre -specified events reported by [CONTACT_400155] & Surveillance for the study as documented in CEC Manual of Operations (MOPs).  
  
9.[ADDRESS_504257] clinical evidence 
for the Mitr aClip XTR system to characterize the  use and outcomes associated with the device. The 
primary endpoint is Acute Procedural Success (APS). APS is defined as successful implantation of the 
MitraClip Implant with resulting MR severity of 2+ or less on discharge Echocardiogram (30 -day 
echocardiogram will be used if discharge information is unavailable or uninterpretable). Subjects who die or undergo mitral valve surgery before discharge are considered as an APS failure.  
 
9.2 Analysis Populations  
 
 9.3 Sample Size Calculations and Assumptions  
The sample size of a minimum 220 subjects is determined based on the endpoint of APS.  APS is defined 
as successful implantation of  the MitraClip Implant with resulting MR severity of 2+ or less on discharge 
Echocardiogram.  
 
   
 
 
 
 
  
 
   
   
   
   
 
The powered endpoint of APS will be evaluated against a pre- specified clinical performance goal (PG). 
The power calculation is based on the following statistical hypotheses and assumptions: 
 H 0: APS rate ≤ PG  
 H A: APS rate > PG  
 
 
34 Sorajja et al. J Am Coll Cardiol 2017;70:2315– 27 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 17 of 36 
  
 
 
 
•  
  
• One- sided type I error rate = 0.05  
 
 
 
   
 The sam
ple size calculation was performed using PASS 15 (Hintze J, 2017, NCSS, LLC. Kaysville, Utah).  
 
9.4 Statistical Analyses  
Descriptive analysis will be performed on baseline, APS, clinical and safety event data.  Depending on 
the type of data (e.g., continuous or categorical), statistical methods described in this section below will 
be used.  
 For continuous  variables, such as age, means, standard deviations, and 95% confidence intervals for 
the mean will be calculated.  
 For binary variables such as APS, counts, percentages, and 95% confidence intervals based on Exact 
Clopper -Pearson method will be calculated, and p- values may be presented for  hypothesis generating 
purposes.  
 
For time to event data such as all -cause mortali ty, Kaplan- Meier analyses will be performed .  
 For recurrent event data such as recurrent heart failure hospi[INVESTIGATOR_400065]- and post -procedure, data 
will be analyzed using a generalized linear model, such as Poisson regression model. A p- value to 
measure the strength of evidence may be provided for descriptive purposes.  
 
9.4.[ADDRESS_504258] PG will be performed for the primary endpoint in the analysis population. The null 
and alternative hypotheses will be of the following form:  
H
0: APS rate ≤ PG  
HA: APS rate > PG  
 APS is the Acute Procedural Success . 
 
 
  
 
  
 
 
    

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504259] ACCESS TO SOURCE  DATA/DOCUMENTS  
The investigator/institution will permit direct access to source data/documents in order for clinical study -
related monitoring, audits, EC review and regulatory inspections to be performed.  
 
Subjects providing informed consent are agreeing to allow Sponsor and/or its designee access and 
copying rights to pertinent information in their medical records concerning their participation in this clinical 
study. The investigator will obtain, as part of the informed consent, permission for clinical s tudy monitors 
or regulatory authorities to review, in confidence, any records identifying the subjects in this clinical study. This information may be shared with regulatory agencies; however, Sponsor undertakes not to otherwise release the subject's personal and private information. 
 
 
11.[ADDRESS_504260] investigators qualified by  [CONTACT_3903], to participate in the study of the 
MitraClip XR device. Sites will be  selected based upon review of a recent site assessment, if applicable, 
and the qualifications of the Principal Investigator [INVESTIGATOR_400081] e. 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 19 of 36 
  
 
 
11.2 Protocol Amendments  
Approved Protocol amendments will be provided to the Investigators by [CONTACT_196578]. The Principal Investigator [INVESTIGATOR_400082] (administrative changes) or obtaining EC’s approval of the Protocol amendment 
(changes in subject care or safety), according to the instructions provided by [CONTACT_13099] r with the 
Protocol amendment.  
 
Acknowledgement/approval by [CONTACT_400156] i n writing prior 
to implementation of the Protocol amendment. Copi[INVESTIGATOR_400083].  
 
11.3 Training  
11.3.1  Site Training  
All study personnel are required to attend Sponsor training sessions, which may be conducted at an 
Inves tigator's meeting, a site initiation visit or other appropriate training sessions. Over -the-phone or self -
training may take place as required. Training of study personnel will include, but is not limited to, the Protocol requirements, device usage, electronic case report form completion and study personnel responsibilities. All study personnel that are trained must sign a training log (or an equivalent) upon 
completion of the training. Prior to signing the training log, Investigator/ study personnel must not  perform 
any study -related activities that are not considered standard of care at the site.  
 
11.3.2  T raining of Sponsor’s Monitors  
Sponsor and/or designated monitors will be trained to the Protocol, case report forms and device usage 
(as appropriate). Documentation of this training will be according to written procedures. 
 
11.4 Monitoring  
Sponsor and/or designee will monitor the study over its duration according to the pre -specified monitoring 
plan which will include the planned extent of source data verification.  
 
Prior to initiating any procedure, the Sponsor monitor (or delegate) will ensure that the following criteria 
are met:  
• The investigator understands and accepts the obligation to conduct the research study according to the Protocol and applicable regulations, and has signed the Investigator Agreement or the 
Clinical Study Agreement.  
• The Investigator and his/her staff have sufficient time and facilities to conduct the study and that they have access to an adequate number of appropriate subjects to conduct the study.  
• Source documentation (including original medical records) must be available to substantiate proper informed consent procedures, adherence to Protocol procedures, adequate reporting and follow- up of adverse events, accuracy of data collected on cas e report forms, and device 
information.  
• The Investigator/site will permit access to such recor ds. A monitoring visit sign- in log will be 
maintained at the site. The Investigator will agree to dedicate an adequate amount of time to the monitoring process.  The Investigator and/or research coordinator will be available for monitoring 
visits. It is exp ected that the Investigator will provide the study monitor with a suitable working 
environment for review of study -related documents.  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504261] KEEPI[INVESTIGATOR_1645]  
12.1 Data Management/Data Analysis  
Data Management will include documentation of the systems and procedures used in data collecti on for 
the duration of the study. All CRF data collection will be performed through a secure web portal and all 
authorized personnel with access to the Electronic Data Capture (EDC) system must use an electronic signature [CONTACT_196602], review or correct data. Passwords and electronic signatures will be 
strictly confidential.  
All CRF data will be downloaded from the EDC system and reformatted into a data structure acceptable 
to Abbott. The data will be subjected to consistency and validation checks within the EDC system and will be subject to supplemental validation following download. 
 
At the conclusion of the study, completed CRF images with the date -and-time stamped electronic audit 
trail indicating the user, the data entered, and any reason for  change (if applicable) will be archived for 
each study site and a backup copy archived with Abbott.  
 
For the clinical study duration, the Investigator will maintain complete and accurate documentation 
including, but not limited to, medical records, clinical study progress records, laboratory reports, 
electronic case report forms, signed ICFs, device accountability records, correspondence with the 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 21 of 36 
  
 
 
IRB/E C and clinical study monitor/Sponsor, adverse event reports, and information regarding subject 
discontinuation or completion of the clinical study.  
12.[ADDRESS_504262]’s original medical 
records that corroborates data collected on the case report forms. In order to comply w ith these regulatory 
requirements/GCP, the following information should be included in the subject record at a minimum and if applicable to the study:  
• Medical history/physical condition of the subject before involvement in the study sufficient to verify Protocol entry criteria  
• Dated and signed notes on the day of entry into the study referencing the Sponsor, Protocol number, subject ID number and a statement that informed consent was obtained 
• Dated and signed notes from each subject visit (for specific results of procedures and exams)  
• Adverse events reported and their resolution including supporting documents such as discharge summaries and lab results including documentation of site awareness of SAEs and of investigator device relationship assessment of SAEs. 
• Subject’s condition upon completion of or withdrawal from the study  
• Any other data required to substantiate data entered into the CRF  
 
12.3 Electronic Case Report Form Completion   
Primary data collection based on source -documented hospi[INVESTIGATOR_3491]/or clinic char t reviews will be 
performed clearly and accurately by [CONTACT_400157]. eCRF 
data will be collected for all patients in the study.  
 
12.[ADDRESS_504263] obtain permission from Sponsor in writing before 
destroying or transferring control of any clinical study records.  
 
 
13.0 ETHICAL CONSIDERATION   
13.1 Medical Ethics Committee Review   
Ethics Committee (EC) approval for the Protocol and ICF/other written information provided to the patient 
will be obt ained by [CONTACT_079] [INVESTIGATOR_400084]. 
The approval letter must  be received prior to the start of this clinical study and a copy must be provided 
to the Sponsor. No changes will be made to the Protocol or ICF or other written information provided to the patient without appropriate approvals, including EC, the Sponsor,  and/or the regulatory agencies as 
needed.  
 
Until the clinical study is completed, the Investigator will advise his/her EC of the progress of this clinical study, per EC requirements.  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 22 of 36 
  
 
 
14.0 RISK ANALYSIS  
14.1 Anticipated Clinical Benefits  
The MitraClip XTR was des igned for graspi[INVESTIGATOR_400071].  Based on testing, graspi[INVESTIGATOR_400085].   In design validation testing, differentiation of ease of graspi[INVESTIGATOR_400086] a model which simulated a mixed functional/degenerative etiology 
procedure with a tethered posterior leaflet and a flailing anterior leaflet. The end result of both gras pi[INVESTIGATOR_400087]. In other development tests prior to the design validation, both the NT and XTR devices were able to grasp leaflets equivalently. 
Subjects with such anatomies may therefore benefit from treatment with the Mi traClip XTR.   Data from 
this study may help to further identify the anatomical characteristics that can be treated with the MitraClip XTR device.   
 
14.[ADDRESS_504264] been identiﬁed as possible 
complications of the MitraClip procedure.  
Allergic reaction (anesthetic, contrast, Heparin, 
nickel alloy, latex)  
Aneurysm or pseudo- aneurysm 
Arrhythmias  
Atrial fibrillation  
Atrial septal defect requiring intervention  
Arterio -venous fistula  
Bleeding  
Cardiac arrest  
Cardiac perforation  
Cardiac tamponade / Pericardial Effusion  
Chordal entanglement/rupture 
Coagulopathy  
Conversion to standard valve surgery  
Death  
Deep venous thrombus (DVT)  
Dislodgement of previously implanted devices  
Dizziness  
Drug reaction to anti -platelet / anticoagulation 
agents / contrast media  
Dyskine sia 
Dyspnea  
Edema  
Emboli (air, thrombus, MitraClip Implant)  
Emergency cardiac surgery  
Endocarditis  
Esophageal irritation  
Esophageal perforati on or stricture 
Failure to deliver MitraClip to the intended site  
Failure to retrieve MitraClip System components  
Fever or hyperthermia  
Gastrointestinal bleeding or infarct  
Hematoma  
Hemolysis  Hemorrhage requiring transfusion  
Hypotension / hypertension  
Infection  
Lymphatic complications  
Mesenteric ischemia  
Mitral stenosis  
Mitral valve injury  
MitraClip Implan t erosion, migration or 
malposition  
MitraClip Implant thrombosis  
MitraClip System component(s) embolization  
Multi -system organ failure  
Myocardial infarct ion 
Nausea/vomiting  
Pain 
Peripheral ischemia  
Prolonged angina  
Prolonged ventilation  
Pulmonary congestion  
Pulmonary thrombo- embolism 
Renal insufficiency or failure 
Respi[INVESTIGATOR_1399] / atelectasis / pneumonia  
Septicemia  
Shock, Anaphylactic or Cardiogenic  
Single leaflet device attachment (SLDA)  
Skin injury or tissue changes due to exposure to ionizing radiation  
Stroke or transient ischemic attack (TIA)  
Urinary tract infection  
Vascular trauma, dissection or occlusion  
Vessel spasm  
Vessel perforation or lacerat ion 
Worsening heart failure  
Worsening mitral regurgitation  
Wound dehiscence  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504265] of care medications.  There are no protocol 
-required medications being used as part of this study. 
 14.6 Steps that will be Taken to Control or Mitigate the Risks  
Per the device IFU, the following contraindications, warnings and precautions will be provided with all 
devices to be used during this study.  
CONTRAINDICATIONS  
Patients with the following conditions should not be treated with the MitraClip System:   
Patients who cannot tolerate procedural anticoagulation or post procedural anti -platelet regimen  
Active endocarditis of the mitral valve  
Rheumatic mitral valve disease 
Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus   
 
WARNINGS  
The following anatomic considerations may result in suboptimal leaflet insertion and/or MitraClip implantation. 
Patients with these conditions who undergo the MitraClip procedure may have an increased risk of serious adverse events which may be minimized with proper device usage and echocardiographic assessment.  These events include the potential for increased procedure time, tissue injury, and/or worsening MR which may require 
additional MitraClip intervention or surgical treatment.  
• Severe leaflet calcification in the graspi[INVESTIGATOR_317727]  
• Severe calcification of the annulus and/or subvalvular apparatus, such as the chordae tendinae  
• Severely restricted posterior leaflet  
• Cleft or perforation in the graspi[INVESTIGATOR_317727]  
• Leaflet Flail gap ≥ 10 mm and/or Leaflet Flail width > 15 mm  
• Coaptation length < 2 mm  
• Intracardiac mass  
 The following anatomic considerations may result in serious adverse events, including tissue injury, worsening 
MR or in the case of the mitral valve area, mitral stenosis. If these events were to occur they can require additional percutaneous or surgical intervention for treatment. The occurrence of these events can be minimized with appropriate preoperative evaluation of the valve anatomy and regurgitant jet.  
• Mitral valve orifice area < 4 cm
2 
• Primary regurgitant jet outside of the A2- P2 area and/or presence of a clinic ally significant 2nd jet 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504266] an increased 
risk of having a serious adverse event which may be avoided with preoperative evaluation and proper device 
usage.  
• Previou s interatrial septal patch or prosthetic atrial septal defect (ASD) closure device which could 
result in significant difficulty in visualization or technical challenges during transseptal puncture and/or 
introducing the SGC into the left atrium.  
• Known or suspected unstable angina or myocardial infarction within the last 12 weeks could increase 
the procedural morbidity and mortality, due to increased hemodynamic stress secondary to general 
anesthesia.  
• Patients with active infection have an increased risk of developi[INVESTIGATOR_400088]/or 
postoperative infection, such as sepsis or soft tissue abscess.  
• Known or suspected left atrial myxoma could result in thromboembolism and tissue injury due to difficulty with device positioning.  
• Recent cerebrovascular event (CVA) may increase the procedural morbidity associated with a transcatheter intervention, such as recurrent stroke.  
 
The MitraClip Implant should be implanted with sterile techniques using fluoroscopy and echocardiography (e.g. 
transesophageal [TEE] and transthoracic [TTE]) in a facility w ith on- site cardiac surgery and immediate access 
to a cardiac operating room.  
 Read all instructions carefully.  Failure to follow these instructions, warnings and precautions may lead to device damage, user injury, or patient injury.  Use universal precautions for biohazards and sharps while handling the MitraClip System to avoid user injury.  
 Use of the MitraClip System should be restricted to those physicians trained to perform invasive endovascular 
and transseptal  procedures and those trained in the pr oper use of the system.  
 
For the Clip Delivery System and Steerable Guide Catheter only: this device is designed for single use only. Cleaning, re- sterilization and / or re- use may result in infections, malfunction of  the device and other serious injury 
or death.  
 
PRECAUTIONS  
NOTE the “Use by” date specified on the package.  
 
Inspect all product prior to use. Do not use if the package is open or damaged, or if product is  
damaged.  
 
14.[ADDRESS_504267] a small risk of loss of confidentiality as part of the data collection 
process.  This risk is mitigated to as low as possible with the use of data collection systems, methods and procedures that are used commonly in clinical research.  This  includes the use of only validat ed 
electronic systems, the training of study personnel and the use of de- ident ified data for all data entry.  
 
Based upon the established safety profile of the MitraClip device; the low risk of loss of confidentiality is 
adequately mitigated to justify use of the next generation MitraClip to treat patients for this study.    

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504268] Market Clinical Follow -Up 
SAE Serious Adverse Event  
SLDA  Single leaflet device attachment  
TEE Transcatheter Esophageal Echocardiogram  
TIA Transient Ischemic Attack  
TRAMI  Transcatheter Mitral V alve Interventions Study  
TTE Transcatheter Thorac ic Echocardiogram  
UADE  Unanticipated Adverse Device Event  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Event  
 
  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 26 of 36 
  
 
 
APPENDIX II - DEFINITIONS  
 ANTICIPATED ADVERSE EVENT  
Derived from ISO14155, MEDDEV 2.7.3: an effect which by [CONTACT_5942], incidence, severity or  outcome 
has been previously identified as “POTENTIAL COMPLICATIONS AND ADVERSE EVENTS”, as documented in the IFU or CIP ( Appendix IV ). 
 DEATH (All Cause)  
All deaths regardless of cause.   Death is further divided into 2 categories  
 
1.  CARDIOVASCULAR DEATH (VARC)  
Per the Valve Academic Research Consortium (VARC)
5 as any one of the following:  
• Any death due to proximate cardiac cause (e.g. MI, cardiac tamponade, worsening heart failure)  
• Unwitnessed death and death of unknown cause  
• All pr ocedure- related deaths, including those related to a complication of the procedure or 
treatment for a complication of the procedure  
• Death caused by [CONTACT_105]- coronary vascular conditions such as cerebrovascular disease, 
pulmonary embolism, ruptured aortic aneury sm, dissecting aneurys m, or other vascular disease  
 
2. NON- CARDIOVASCULAR DEATH 
Any death not covered by [CONTACT_361905], such as death caused 
by [CONTACT_80601], malignancy, sepsis, pulmonary causes, accident, suicide, or trauma.  
 
 
DEVICE EMBOLIZATION 
Detac hment of the deployed MitraClip from the leaflets as assessed by [CONTACT_3452].  
 
DEVICE THROMBOSIS  
Formation of an independently moving thrombus on any part of the MitraClip evidenced by 
[CONTACT_361906].  If the Mitra Clip is explanted or an autopsy is performed, this diagnosis 
should be confirmed.  
 
ENDOCARDITIS  
A diagnosis of endocarditis based on the following Duke criteria, from The ACC/AHA Guidelines for the 
Management of Patients with Valvular Heart Disease, JACC, Vol 32, No.5,November 1, 1998:pg1541, 
Table 21)  
 Endocarditis is based on the confirmation of either Pathological Criteria or Clinical Criteria.   
 
Diagnosis for Clinical Criteria of Endocarditis must at least meet 1 of the following combinations:  
• 2 major criteria or  
• 1 major plus 3 minor criteria or  
• 5 minor criteria  
 
Pathological Criteria  
 
Microorganisms : culture or histology in a vegetation, in a vegetation that has embolized, or 
in an intracardiac abscess, OR  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 27 of 36 
  
 
 
Pathological lesions:  vegetation or intracardiac abscess present, confirmed by [CONTACT_400158]:  
Typi[INVESTIGATOR_361839]: Streptococcus viridans, S bovis , “HACEK” group, 
community acquired Staphylococcus aureus  or enterococci, in the absence of a 
primary focus  
Persistent bacteremia:  
≥ 2 positive cultures separated by ≥12 hours or ≥ 3 positive cultures ≥ 1 h apart or 
70% blood culture samples positive if ≥ 4 are drawn 
Evidence of endocardial involvement 
Positiv e echocardiogram  
Oscillating vegetation  
Abscesses Valve perforation  
New partial dehiscence of prosthetic valve  
New valvular regurgitation 
 
Minor Criteria  
Predisposing heart condition: 
Mitral Valve Prolapse, bicuspid aortic valve, rheumatic or congenital he art disease, 
intravenous drug use  
Fever  
Vascular phenomena:  
Major arterial  emboli, septic pulmonary emboli, mycotic aneurysm, intracranial 
hemorrhage, Janeway lesions  
Immunologic phenomena 
Glomerulonephritis,  Osler's nodes, Roth spots , and rheumatoid factor  
Positive blood culture: not meeting major criteria  
Echocardiogram: p ositive but  not meeting major criteria  
 HOSPI[INVESTIGATOR_55108] (ALL -CAUSE)  
Defined as admission to inpatient unit or ward in the hospi[INVESTIGATOR_93971] 24 hours, including emergency department stay.  Excludes hospi[INVESTIGATOR_361840] -existing conditions, unless there is worsening 
in the baseline condition.  
 
HEART FAILURE HOSPI[INVESTIGATOR_361841]:  
 
A. Requires hospi[INVESTIGATOR_361842] 
24 hours, including emergency department stay,  
 
AND  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.[ADDRESS_504269] has clinical signs and/or symptoms of heart failure, including new or worsening 
dyspnea, orthopnea, paroxysmal nocturnal dyspnea, increasing fatigue, worsening functional 
capacity or activity intolerance, or signs and/or symptoms of volume overload,  
 
AND  
 C. Results in intravenous (e.g, diuretic or vasoactive therapy) or invasive (e.g., ultrafiltration, 
IABP, mechanical assistance) treatment for heart failure.  
 
For the purpose of this protocol, overnight stays at nursing home facilities, physical rehab or 
extended care facilities, including hospi[INVESTIGATOR_6125], do not meet the protocol definition of hospi[INVESTIGATOR_059].   
 OTHER CARDIOVASCULAR HOSPI[INVESTIGATOR_361843] 24 hours, including 
emergency department stay for conditions such  as coronary artery disease, acute myocardial 
infarction, hypertension, cardiac arrhythmias, cardiomegaly, pericardial effusion, atherosclerosis 
and peripheral vascular disease, not related to heart failure as defined.  
 NON- CARDIOVASCULAR HOSPI[INVESTIGATOR_400089], as defined 
above, will be categorized as non -cardiovascular hospi[INVESTIGATOR_602]. 
 
MAJOR ADVERSE EVENT (MAE)  
MAE is a CEC- adjudicated composite of all-cause death, stroke, myo cardial infarction, and non elective CV 
surgery for device related adverse events  
 
MAJOR BLEEDING  
Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research 
Consortium (BARC)
35 definition:  
• Type 3  
o Type 3a  
 Overt bleeding plus hemoglobin drop of 3 to <5 g/dL*  (provided  hemo globin 
drop is related to bleed)  
 Any transfusion with overt bleeding  
o Type 3b  
 Overt bleeding plus hemoglobin drop ≥5 g/dL * (provided hemoglobin drop is 
related to bleed)  
 Cardiac tamponade  
 Bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoid)  
 Bleeding requiring intravenous vasoactive agents  
o Type 3c  
 Intracranial hemorrhage (does not include microbleeds or hemorrhagic 
transformation, does include intraspi[INVESTIGATOR_1304])  
 Subcategories confirmed by [CONTACT_15745]  
 Intraocular bleed compromising vision  
• Type 4: CV Surgery -related bleeding  
 
 
35 Mehrana R, Rao SV, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report 
from the Bleeding Academic Research Consortium. Circulation 2011;123:2736- 2747.  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 29 of 36 
  
 
 
o Perioperative intracranial bleeding within 48 h  
o Reoperation after closure of sternotomy for the purpose of controlling bleeding  
o Transfusion of ≥5 U whole blood or packed red blood cel ls within a 48 -h period†  
o Chest tube output ≥2L within a 24- h period  
• Type 5: Fatal bleeding  
o Type 5a  
 Probable fatal bleeding; no autopsy or imaging confirmation but clinically 
suspi[INVESTIGATOR_15665]  
o Type 5b  
 Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation  
*Corrected for transfusion (1 U packed red blood cells or 1 U whole blood= 1 g/dL hemoglobin)  
†Cell saver products are not counted  
 
MAJOR VAS CULAR COMPLICATION 
Any major complication, relating to, or affecting, the circulatory system as a result of the MitraClip  
procedure, including new onset of any of the following:   
• Hematoma at access site >6 cm.; 
• Retroperitoneal hematoma;  
• Arterio -venous fis tula; 
• Symptomatic peripheral ischemia/ nerve injury with clinical signs or symptoms lasting >24 hours;  
• Vascular surgical repair at catheter access sites;  
• Pulmonary embolism;  
• Ipsilateral deep vein thrombus;  or 
• Access site -related infection requiring intravenous antibiotics and/or extended hospi[INVESTIGATOR_059].  
 MYOCARDIAL INFARCTION  
Myocardial infarction (MI) classification and criteria for diagnosis is defined as follows:  
 
Peri-procedural MI (≤ 72 hours after M itraClip  procedure)  
Mandatory: CK- MB (preferred) ≥10x ULN within [ADDRESS_504270] -MitraClip  procedure in patient with 
normal bas eline CK -MB  
 OR 
 
Mandatory: CK- MB ≥5x ULN within [ADDRESS_504271] - MitraClip  procedure in patient with normal 
baseline CK- MB plus new pathological Q -waves in ≥[ADDRESS_504272] -surgery  
Mandatory: CK -MB ≥10x ULN (preferred) within 24 hrs. of cardiothoracic surgery plus 1 of the 
following:  
 
• New pathological Q -waves in ≥2 contiguous leads or new persistent LBBB on ECG ≥30 
min. and ≤[ADDRESS_504273] -CABG cardiothoracic surgery, or  
 
• New substantial wall motion abnormalities by [CONTACT_361908][INVESTIGATOR_361845].  
 
Spontaneous MI (>72 hours after MitraClip  procedure)  
Any one of the following criteria:  
 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 30 of 36 
  
 
 
• Detection of rise and/or fall of cardiac biomarkers (CK -MB) with at least one value above 
the upper limits of normal (ULN), together with evidence of myocardial ischemia with at least one of the following:  
 
o ECG changes indicative of new ischemia [new ST- T changes or new left bundle 
branch block (LBBB)]  
o New pathological Q waves in at least two contiguous leads  
o Imaging evidence of new loss of viable myocardium or new wall motion 
abnormality  
 
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by [CONTACT_361909], or new LBBB, and/or evidence of fresh thrombus by [CONTACT_361910]/or at autopsy, but death occurring before blood samples could be obtained, or at a time before 
the appearance of cardiac biomarkers in the blood.  
 
• Pathological findings of an acute myocardial infarction.  
 
NEW YORK HE ART ASSOCIATION CLASSIFICATION (NYHA CLASS)  
 
Class I  Patients with cardiac disease but without resulting  limitations of physical 
activity.  
Class II  Patients with cardiac disease resulting in slight limitation of physical activity.  
Patients are comfortable at rest.  Ordinary physical activity results in fatigue, 
palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  
Class  III Patients with cardiac disease resulting in marked limitation of physical activity.  
Patients are comfortable at rest.  Less than ordinary physical activity causes 
fatigue, palpi[INVESTIGATOR_361846], or anginal pain.  
Class IV  Patients with cardiac disease r esulting in inability to carry on any physica l 
activity without discomfort.  Symptoms of cardiac insufficiency or of the anginal 
syndrome may be present even at rest.  If any physical activity is undertaken, 
discomfort is increased.  
 
 
NON- ELECTIVE (i.e., URGENT or EMERGENT) CARDIOVASCULAR SURGERY FOR PROCEDURE 
OR DEVICE RELATED EVENTS 
Cardiovascular surgical procedure performed for device related complication requiring surgery within 24 
hours of onset of adverse event, including events found during scheduled follow -up.  If non- urgent 
surgery was performed within 24 hours of the onset of the adverse event but was not required within this timeframe, it will not be considered “non -elective”.   Examples of Device Related Complications that may 
lead to non -elect ive cardiovascular surgery include, myocardial perforation, Single Leaflet Device 
Attachment (confirmed by [CONTACT_400159] e Lab), embolization of the MitraClip or MitraClip System 
components, iatrogenic atrial septal defect, or the need for valve replacement inst ead of repair due at 
least in part to the MitraClip  procedure or the presence of the Mitra Clip. 
 
SINGLE LEAFLET DEVICE ATTACHMENT (SLDA)  
Defined as unilateral MitraClip detachment from one leaflet as assessed by [CONTACT_400160].  Re asons for MitraClip Detachment include leaflet tearing, MitraClip  unlocking, MitraClip  fracture or 
inadequate MitraClip  placement.  Not included are any fractures or other failures of the MitraClip that do not 
result in MitraClip  detachment from one or both leaflets.   

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 31 of 36 
  
 
 
 
STROKE/CEREBROVASCULAR ACCIDENT  and TIA  
Cerebrovascular Accident (Stroke) is defined as an acute epi[INVESTIGATOR_256815], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of hemorrhage or infarc tion.  
Stroke m ay be classified as ischemic or hemorrhagic with appropriate sub-definitions or as undetermined 
if there is insufficient information to allow categorization as ischemic or hemorrhagic.  
 
An entity closely related to ischemic stroke is transient ischemic att ack (TIA).  TIA is defined as a transient 
epi[INVESTIGATOR_361849], spi[INVESTIGATOR_1831], or retinal ischemia, without acute 
infarction.  The difference between TIA and ischemic stroke is the presence of infarction.  In the absence 
of affirmative evidence confirming the presence or absence of infarction, a symptom duration of 24 hours will be used to distinguish TIA from ischemic stroke.  By [CONTACT_108], TIA does not produce lasting disability.  
 The assessment of disabi lity resulting from the stroke will be performed by [CONTACT_212150] 
(mRS).  Assessment of the mRS should occur at all scheduled visits through [ADDRESS_504274] of a given stroke.  A disabling stroke is one that results (at 90 days after stroke onset) in an 
mRS score of [ADDRESS_504275] one mRS category from the individual’s pre-stroke 
baseline.  A non -disabling stroke is one that results (at 90 days after stroke onset) in an mRS score of 
less than 2 or that does not result in an increase of at leas t one mRS category from an individual’s pre-
stroke baseline.  
 Although imaging (typi[INVESTIGATOR_897], MRI for acute and chronic ischemia and haemorrhage, and CT for acute and 
chronic haemorrhage and chronic ischemia) is often used to supplement the clinical diagnosis  of stroke, 
a diagnosis of stroke may be made on clinical grounds alone.   
 
Diagnostic criteria  
 
Acute epi[INVESTIGATOR_44715] a focal or global neurological deficit with at least one of the following: change in level 
of consciousness, hemiplegia, hemiparesis, numbness  or sensory loss affecting one side of the body, 
dysphasia or aphasia, hemianopia, amaurosis fuga x, or other neurological signs or symptoms 
consistent with stroke  
 
Stroke – Duration of a focal or global neurological deficit ≥24 h; OR <[ADDRESS_504276]; OR the neurological deficit results in death  
 
TIA – Duration of a focal or global neurological deficit <[ADDRESS_504277] 
 
No other readily identifiable non- stroke cause for the clinical presentation (e.g. brain tumor, trauma, 
infection, hypoglycemia, peripheral lesion, pharmacological influences), to be de termined by [CONTACT_400161]*  
 
Confirmation of the diagnosis by [CONTACT_37408]:  
– Neurologist or neurosurgical specialist  
– Neuroimaging procedure (C T scan or brain MRI), but stroke may be diagnosed on clinical 
groun ds alone  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 32 of 36 
  
 
 
Stroke classification  
 
Ischemic – An acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal dysfunction caused by [CONTACT_400162].  
 
Hemorrhagic – An acute epi[INVESTIGATOR_400090], intraventricular, or subarachnoid hemorrhage.  
 
Undetermined – An acute epi[INVESTIGATOR_400091].  
Stroke definitions†  
 
Disabling stroke –  a mRS score of [ADDRESS_504278] one mRS category 
from an individual’s pre- stroke baseline 
 
Non-disabling stroke – a mRS  score of less than [ADDRESS_504279] one mRS category from an individual’s pr e-stroke baseline  
*Patients with non -focal global encephalopathy will not be reported as a stroke without unequivocal 
evidence of cerebral infarction based upon neuroimaging studies (CT scan or Brain MRI).  
†Modified Rankin Scale assessments should be made by [CONTACT_400163] a 
certification process.  
  
Tricuspid Regurgitation Severity  
TR grading will be based on the 2017 ASE Guidelines (Zoghbi 2017)
36:  Rating will be:  none, mild, 
moderate, or severe .   
 
Unanticipated Adverse Device Effect  [UADE]  
UADEs or Unanticipated serious adverse device effect ([LOCATION_003]DE) refers to any (serious ) adverse effect 
on health or safety or any life- threatening problem or death caused by, or associated with, a device, if 
that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in 
the protocol  or application (including a supplementary plan or application), or any other unanticipated 
serious problem associated with a device that relates to the rights, safety, or welfare  of subjects.  Al l 
reported adverse events are reviewed by [CONTACT_400164]/[LOCATION_003]DEs are identified and addressed.   
 
VULNERABLE POPULATION (ISO14155 Definition)  
Defined as subject whose willingness to volunteer in a clinical investigation could be unduly influenced 
by [CONTACT_162161], whether justified or not, of benefits associated with participation or of retaliatory 
response from senior members of a hierarchy in case of refusal to participate.  Examples of populations which may contain vulnerable subjects include: Individuals with lack of or loss of autonomy due to 
immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and 
those incapable of giving informed consent. Other vulnerable subjects may include, for example, 
members of a group with a hierarchical structure such as university students, subordinate hospi[INVESTIGATOR_400092], employees of the sponsor, members of the armed forces, and persons kept in 
detention.    
 
 
36 Zoghbi WA, Adams D, Bonow RO, Enriquez -Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang 
RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for 
Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017 Apr;30(4):303- 371. 

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 33 of 36 
  
 
 
 
APPENDIX III  - Case Report Forms  
 
Data will be collected on electronic case report forms (eCRFs).  The eCRFs will be made available before 
the study starts enrollment.   
  
  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 34 of 36 
  
 
 
APPENDIX IV - Summa ry of Changes  
 
Amendment History  
 
Version #  Date of Release  Reason for Amendment  
1.[ADDRESS_504280] inconsistencies in protocol  
  
Details  of Change  
 
Section/pg#  Version 1.[ADDRESS_504281] from BSI  
to update endpoint 
analysis  
Summ ary, p5 
Section 1. 1, p6  
Introduction page 6,  
Section 3.1/3.2, p9   
and  
Section 5.0, p 10 & 12 Sample size =200  Sample size increased to 220  Required for 
success to 
Performance Goal  
Summary p5,  
Section 4.2 p11,  
Definitions p 30 &32  MAE definition 
was in advertently 
taken from a 
MitraClip tricuspid 
study  Updated MAE definition to make 
more consistent with other MitraClip 
MR studies  More appropriate 
to use definition 
from pervious MR 
studies  
Section/  
page# Version 1.0_7 February 2018  Version 2.0_ 26 June 20 18 Rationale  
Summary 
/p5 
 
5.3.1/p11  Inclusion Criteria #2:  
Subjects eligible to receive the 
MitraClip per the current approved 
indications for use  Inclusion Criteria #2:  
Subjects scheduled to receive the 
MitraClip per the current approved 
indications for  use  To clarify that the 
intention is for the 
treatment decision to 
be made before 
study enrollment  
Summary / 
page 5  
4.2 / page 
10 Device Related Adverse Events 
(including device embolization, 
single leaflet device attachment 
(SLDA), bleeding, perforation, etc)  
 Device Related Adverse Events 
(including mitral valve stenosis, device 
embolization, single leaflet device 
attachment (SLDA) , Iatrogenic atrial 
septal defect, myocardial perforation, or 
the need for mitral valve replacement 
instead of repair due at least in part to 
the MitraClip procedure or the presence 
of the MitraClip device ) Correct 
inconsistency of this 
definition to other  
MitraClip studies  
4.2 / p 10   Added: Clinical Endpoints will be 
assessed at each study time point, 
all data reported at the To clarify data to be 
included in clinical 
endpoints  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 35 of 36 
  
 
 
corresponding study visit will be 
included for the study time point.      
 Table 1/ 
page 14  Visits at:  
30 days (30 days +14 days)  
12 months (365 days ± 30 days)  
 
Phone call or visit at:  
6 months ( 180 days ± 90 days)  
 Visits at:  
30 days (30 days  -14 days /+60 days)  
12 months (365 days  -30 days / +90 
days )  
 
Phone call or visit at:  
6 months (180 days -30 days / +90 days ) 
 Windows in protocol 
inconsistent with 
standard of care. 
Increased time to 
permit  visits per 
standard of care 
without deviation.    
7.1.2/ 
page 14-
15 Serious Adverse Event definition 
includes:   
An important medical event that 
may not result in death, be l ife-
threatening, or require 
hospi[INVESTIGATOR_400093], based 
upon appropriate medical judgment, 
may jeopardize the subject and/or 
may require intervention to prevent 
one of the outcomes listed in this 
definition.  
Note 1 : This inclu des device 
deficiencies that might have led to a 
serious adverse event if a) sui table 
action had not been taken or b) 
intervention had not been made or 
c) if circumstances had been less 
fortunate. These are handled under 
the SAE reporting system.  
Note 2 : A planned hospi[INVESTIGATOR_400094]- existing condition, or a 
procedure required by [CONTACT_400165], without a serious 
deterioration in health, is not 
considered to be a serious adverse 
event.  Serious Adverse Event updated to only 
to remove this text, except for the one 
sentence:   
 
A planned hospi[INVESTIGATOR_5912]- existing 
conditi on, or a procedure required by [CONTACT_400166], without a serious 
deterioration in health, is not considered 
to be a serious adverse event.  
 Definition 
inconsistent with 
ISO14155, corrected 
to match ISO14155 
standard definition  
7.2.1/ 
page 15  Unanti cipated (Serious Adverse) 
Device Effect [U(S)ADE]  
Unanticipated serious adverse 
device effect ([LOCATION_003]DE) refers to any 
serious adverse effect on health or 
safety  or any life- threatening 
problem or death caused by, or 
associated with, a device, if that 
effect, problem, or death was not 
previously identified in nature, 
severity, or degree of incidence in 
the protocol or application (including 
a supplementary plan or  
application), or any other 
unanticipated serious problem 
associated with a device that relates 
to the rights, safety, or welfare of 
subjects.  This section has been removed  Remove 
inconsistency 
21CFR 812 and 
U(S)ADE/UADE 
definition do not 
apply to this protocol  

 
 MitraClip® XTR PMCF Study   
 
Protocol 17-518-1 : Version 2.0 26 June 2018  
      Page 36 of 36 
  
 
 
Table 1 / 
p1 4 
 and 
7.3.1./ p15   Added footnote to Table 1 and 
paragraph to section 7.3.1 as follows:  
Adverse Events to reported during this 
study include: cardiovascular events, 
device- related complications (as defined 
in section 4.2), and events classified as 
MAEs (as defined in section 4.2 ).  These 
AEs should be reported starting from the 
time that the MitraClip delivery system is 
introduced to the femoral vein through 
the [ADDRESS_504282]-
market study  
 
9.3 / p17  The sample size calculation was 
performed using PASS 11 (Hintze 
JL, 2002. PASS User’s Guide- II. 
NCSS).  The sample size calculation was 
performed using PASS 15 (Hintze J,  
2017, NCSS, LLC. Kaysville, Utah).  Software Update.  
The actual 
calculation was 
performed under 
PASS 11 and a 
duplicate output was 
confirmed under 
updated software 
(PASS 15 ) 
9.4.3 / p18   Added section on Handling of Multiplicity 
Issues  This section is 
added to clarify that 
the PMCF study i s 
not subject to 
multiplicity issues, 
since only one 
primary endpoint will 
be tested with 
hypothesis.  
Appendix 
II 
Definitions  
/ p33   Unanticipated Adverse Device Effect 
[UADE]  
UADEs or Unanticipated serious 
adverse device effect ([LOCATION_003]DE) refers to 
any (serious) adverse effect on health or 
safety or any life- threatening problem or 
death caused by, or associated with, a 
device, if that effect, problem, or death 
was not previously i dentified in nature, 
severity, or degree of incidence in the 
protocol or application (including a 
supplementary plan or application), or 
any other unanticipated serious problem 
associated with a device that relates to 
the rights, safety, or welfare of subj ects.  
All reported adverse events are 
reviewed by [CONTACT_400167]/[LOCATION_003]DEs are identified and 
addressed.   Added to specify 
that Sponsor review 
will take place to 
identify UADEs  
  
END OF MitraClip X TR PMCF Protocol  
  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 38 of 68 
  
 
 
 
 
APPENDIX II: ABBREVIATIONS AND ACRONYM         
 
 
A2-P2 Second location on anterior and posterior leaflets  
ACCESS  ACCESS -EU Study  
AE Adverse Event  
APS Acute Procedural Success  
ASD Atrial Septal D efect  
CDS  Clip Delivery System  
CE Conformité Européene  
CEC  Clinical Events Committee  
Co-PIs Co-Primary Investigators  
CRF Case Report Form  
CV Cardiovascular  
CVA Cardiovascular Accident  
DC Delivery Catheter  
DD Device Deficiency  
DM Device Malfunction  
DMR  Degenerative Mitral Regurgit ation  
DVT Deep venous thrombus  
EC Ethics Committee  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
EROA  Effective Regurgitant Orifice Area  
EU European Union  
Euroscore  European System for Cardiac Operative Risk Eva luation  
EVEREST II  The EVEREST II Study  
EXPAND  The MitraClip EXPAND Study  
FDA U.S. Food and Drug Administration  
FMR  Functional Mitral Regurgitation  
GCP  Good Clinical Practice  
GRASP  The GRASP Registry  
HIPAA  Health Insurance Portability and Accountabi lity Act  
HRR  High Risk Registry (part of EVEREST II)  
ICF Informed Consent Form  
IFU Instructions for Use  
IRB Institutional Review Board  
IVC Inferior Vena C ava 
KCCQ  Kansas City Cardiomyopathy Questionnaire  
LVOT  Left Ventricle Outflow Tract  
   

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 39 of 68 
  
 
 
 
MAE  Major Adverse Event  
MitraClip NT  MitraClip NT System   
MitraClip NTR  MitraClip N TR System  (new delivery system)  
MitraClip XTR  MitraClip XTR System  (new delivery system and longer clip arms)  
MOPs  Manual of Operations  
MR Mitral Regurgitation  
NYHA  New Yor k Heart Association  
PMCF  Post Market Clinical Follow -Up 
QOL  Quality of Life  
RCT Randomized Controlled Trial  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SAX Short Axis  
SGC  Steerable Guide Catheter  
SLDA  Single leaflet device attachment  
TEE Transcatheter Esophageal Echocardiogram  
TIA Transient Ischemic Attack  
TR Tricuspid Regurgitation  
TRAMI  Transcatheter Mitral Valve Interventions Study  
TTE Transcatheter Thoracic Echocardiogram  
TVT Transcat heter Val ve Treatment Registry  
UADE  Unantic ipated Adverse Device Event  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Event  
  
  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 40 of 68 
  
 
 
APPENDIX III: DEFINITIONS  
 DEATH (All Cause)  
All deaths regardless of cause.   Death is further divided into 2 categories  
 
1.  CARDIOVASCULAR DEATH (VARC)  
Per the Valve Academic Research Consortium (VARC)
5 as any one of the following:  
• Any death due to proximate cardiac cause (e.g. MI, cardiac tamponade, worsening heart 
failure)  
• Unwitnessed death and death of unknown cause  
• All procedure- related deaths, including those related to a complication of the procedure 
or treatment for a complication of the procedure  
• Death caused by [CONTACT_105]- coronary vascular conditions such as cerebrovascular disease, 
pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular diseas e 
 
3. NON- CARDIOVASCULAR DE ATH 
Any death not covered by [CONTACT_361905], such as death caused 
by [CONTACT_80601], malignancy, sepsis, pulmonary causes, accident, suicide, or trauma.  
  
DEVICE EMBOLIZATION Detachment of the deployed MitraClip from the leaflets a s assessed by [CONTACT_3452].  
 DEVICE THROMBOSIS  
Formation of an independently moving thrombus on any part of the MitraClip evidenced by [CONTACT_361906].  If the MitraClip is explanted or an autopsy is performed, this diagnosis 
should be confirmed.  
 
ENDOCARDITIS  
A diagnosis of endocarditis based on the following Duke criteria, from The ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease, JACC, Vol 32, No.5,November 1, 1998:pg1541, 
Table 21)  
 
Endocarditis is based on  the confirmation of either Pathological Criteria or Clinical Criteria.   
 
Diagnosis for Clinical Criteria of Endocarditis must at least meet 1 of the following combinations:  
• 2 major criteria or  
• 1 major plus 3 minor criteria or  
• 5 minor criteria  
 
Pathological Criteria  
 
Microorganisms: culture or histology in a vegetation, in a vegetation that has embolized, or in an intracardiac abscess, OR  
 
Pathological lesions:  vegetation or intracardiac abscess present, confirmed by [CONTACT_400168]® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 41 of 68 
  
 
 
 
Clinical Criteria  
 
Major Criteria  
Persistently positive blood cultures:  
Typi[INVESTIGATOR_361839]: Streptococcus viridans, S bovis , “HACEK” group, 
community acquired Staphylococcus aureus  or enterococci, in the absence of a 
primary focus  
Persistent bacteremia:  
≥ 2 positive cultures separated by ≥12 hours or ≥ 3 positive cultures ≥ 1 h apart or 
70% blood culture samples positive if ≥ 4 are drawn 
Evidence of endocardial involvement 
Positive echocardiogram  
Oscillating vegetation  
Abscesses Valve perforation  
New partial dehiscence of prosthetic valve  
New valvular regurgitation 
 
Minor Criteria  
Predisposing heart condition: 
Mitral Valve Prolapse, bicuspid aortic valve, rheumatic or congenita l heart disease, 
intravenous drug use  
Fever  
Vascular phenomena:  
Major arterial emboli, septic pulmonary emboli, mycotic aneurysm, intracranial 
hemorrhage, Janeway lesions  
Immunologic phenomena 
Glomerulonephritis,  Osler's nodes, Roth spots , and rheumatoid factor  
Positive blood culture: not meeting major criteria  
Echocardiogram: p ositive but  not meeting major criteria  
 HOSPI[INVESTIGATOR_55108] (ALL -CAUSE)  
Defined as admission to inpatient unit or ward in the hospi[INVESTIGATOR_93971] 24 hours, including emergency department stay.  Excludes hospi[INVESTIGATOR_361840] -existing conditions, unless there is worsening 
in the baseline condition.  
 
HEART FAILURE HOSPI[INVESTIGATOR_361841]:  
 D. Requires hospi[INVESTIGATOR_361842] 
[ADDRESS_504283] has clinical signs and/or symptoms of heart failure, including new or worsening 
dyspnea, orthopnea, paroxysmal nocturnal dyspnea, increasing fatigue, worsening functional capacity or activity intolerance, or signs and/or symptoms of volume overload,  
 AND  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 42 of 68 
  
 
 
 
F. Results in intravenous (e.g, diuretic or vasoactive therapy) or invasive (e.g., ultrafiltration, 
IABP, mechanical assistance) treatment for heart failure.  
 
For the purpose of this protocol, overnight stays at nursing home facilities, physical rehab or 
extended care facilities, including hospi[INVESTIGATOR_6125], do not meet the protocol definition of hospi[INVESTIGATOR_059].   
 OTHER CARDIOVASCULAR HOSPI[INVESTIGATOR_361843] 24 hours, including emergency department stay for conditions such as coronary artery disease, acute myocardial 
infarction, hypertension, cardiac arrhythmias, cardiomegaly, pericardial effusion, atherosclerosis 
and peripheral vascular disease, not related to heart failure as defined.  
 NON- CARDIOVASCULAR HOSPI[INVESTIGATOR_400089], as defined above, will be categorized as non -cardiovascular hospi[INVESTIGATOR_602]. 
 
MAJOR ADVERSE EVENT (MAE)  
MAE defined as a composite of all -cause Death, MI, Stroke, or non-elective CV surgery for device related 
complications (CEC adjudicat ed)  
 
MAJOR BLEEDING  
Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research 
Consortium (BARC)
37 definition:  
• Type 3  
o Type 3a  
 Overt bleeding plus hemoglobin drop of 3 to <5 g/dL*  (provided  hemoglobin 
drop is related to bleed)  
 Any transfusion with overt bleeding  
o Type 3b  
 Overt bleeding plus hemoglobin drop ≥5 g/dL * (provided hemoglobin drop is 
related to bleed)  
 Cardiac tamponade  
 Bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoid)  
 B leeding requiring intravenous vasoactive agents  
o Type 3c  
 Intracranial hemorrhage (does not include microbleeds or hemorrhagic 
transformation, does include intraspi[INVESTIGATOR_1304])  
 Subcategories confirmed by [CONTACT_15745]  
 Intraocular bleed compromising vision  
• Type 4: CV Surgery -related bleeding  
o Perioperative intracranial bleeding within 48 h  
o Reoperation after closure of sternotomy for the purpose of controlling bleeding  
o Transfusion of ≥5 U whole blood or packed red blood cells within a 48- h peri od† 
o Chest tube output ≥2L within a 24- h period  
• Type 5: Fatal bleeding  
o Type 5a  
 
 
37 Mehrana R, Rao SV, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report 
from the Bleeding Academic Research Consortium. Circulation 2011;123:2736- 2747.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 43 of 68 
  
 
 
 Probable fatal bleeding; no autopsy or imaging confirmation but clinically 
suspi[INVESTIGATOR_15665]  
o Type 5b  
 Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation  
*Corrected for transfusion (1 U packed red blood cells or 1 U whole blood= 1 g/dL hemoglobin)  
†Cell saver products are not counted  
 MAJOR VASCULAR COMPLICATION 
Any major complication, relating to, or affecting, the circulatory system as a result of the MitraClip  
procedure, including new onset of any of the following:   
• Hematoma at access site >6 cm.; 
• Retroperitoneal hematoma;  
• Arterio -venous fistula;  
• Symptomatic peripheral ischemia/ nerve injury with clinical signs or symptoms lasting >24 hours;  
• Vascular surgical repair at catheter access sites;  
• Pulmonary embolism;  
• Ipsilateral deep vein thrombus;  or 
• Access site -related infection requiring intravenous antibiotics and/or extended hospi[INVESTIGATOR_059].  
 MYOCARDIAL INFARCTION  
Myocardial infarction (MI) classification and criteria for diagnosis is defined as follows:  
 
Peri-procedural MI (≤ 72 hours after MitraClip  procedure)  
Mandatory: CK- MB (preferred) ≥10x ULN within [ADDRESS_504284] -MitraClip  procedure in patient with 
normal bas eline CK -MB  
 OR 
 
Mandatory: CK -MB ≥5x ULN within [ADDRESS_504285] -MitraClip  procedure in patient with normal 
baseline CK- MB plus new pathological Q -waves in ≥[ADDRESS_504286] -surgery  
Mandatory: CK -MB ≥10x ULN (preferred) within 24 hrs. of cardiothoracic surgery plus 1 of the 
following:  
 
• New pathological Q -waves in ≥2 contiguous leads or new persistent LBBB on ECG ≥30 
min. and ≤[ADDRESS_504287] -CABG cardiothoracic surgery, or  
 
• New substantial wall motion abnormalities by [CONTACT_361908][INVESTIGATOR_400095].  
 
Spontaneous MI (>72 hours after MitraClip  procedure)  
Any one of  the following criteria:  
 
• Detection of rise and/or fall of cardiac biomarkers (CK -MB) with at least one value above 
the upper limits of normal (ULN), together with evidence of myocardial ischemia with at least one of the following:  
 
o ECG changes indicative of new ischemia [new ST- T changes or new left bundle 
branch block (LBBB)]  
o New pathological Q waves in at least two contiguous leads  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 44 of 68 
  
 
 
o Imaging evidence of new loss of viable myocardium or new wall motion 
abnormality  
 
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by [CONTACT_361909], or new LBBB, and/or evidence of fresh thrombus by [CONTACT_361910]/or at autopsy, but death occurring before blood samples could be obtained, or at a time before 
the appearance of cardiac biomarkers in the blood.  
 
• Pathological findings of an acute myocardial infarction.  
 
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA CLASS)  
 
Class I  Patients with cardiac disease but without resu lting limitations of physical 
activity.  
Class II  Patients with cardiac disease resulting in slight limitation of physical activity.  
Patients are comfortable at rest.  Ordinary physical activity results in fatigue, 
palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  
Class III  Patients with cardiac disease resulting in marked limitation of physical activity.  
Patients are comfortable at rest.  Less than ordinary physical activity causes 
fatigue, palpi[INVESTIGATOR_361846], or anginal pain.  
Class IV  Patients with cardiac dise ase resulting in inability to carry on any physica l 
activity without discomfort.  Symptoms of cardiac insufficiency or of the anginal 
syndrome may be present even at rest.  If any physical activity is undertaken, 
discomfort is increased.  
 
 
NON- ELECTIVE (i .e., URGENT or EMERGENT) CARDIOVASCULAR SURGERY FOR PROCEDURE 
OR DEVICE RELATED EVENTS 
Cardiovascular surgical procedure performed for device related complication requiring surgery within 24 
hours of onset of adverse event, including events found during scheduled follow -up.  If non- urgent 
surgery was performed within 24 hours of the onset of the adverse event but was not required within this timeframe, it will not be considered “non -elective”.   Examples of Device Related Complications that may 
lead to non -elective cardiovascular surgery include, myocardial perforation, Single Leaflet Device 
Attachment (confirmed by [CONTACT_361911]), embolization of the MitraClip or MitraClip System 
components, iatrogenic atrial septal defect, or the need for valve replacement  instead of repair due at 
least in part to the MitraClip  procedure or the presence of the MitraClip.  
 
SINGLE LEAFLET DEVICE ATTACHMENT (SLDA)  
Defined as unilateral MitraClip  detachment from one leaflet as assessed by [CONTACT_400160] .  Reasons for MitraClip Detachment  include leafle t tearing, MitraClip unlocking,  MitraClip  fracture or 
inadequate MitraClip  placement.  Not included are any fractures or other failures of the MitraClip  that do not 
result in MitraClip  detachment from one or both leaflets.   
 
STROKE/CEREBROVASCULAR ACCIDENT  and TIA  
Cerebrovascular Accident (Stroke) is defined as an acute epi[INVESTIGATOR_36231], spi[INVESTIGATOR_1831], or retinal vascular injury as a result of hemorrhage or i nfarction.  
Stroke may be classified as ischemic or hemorrhagic with appropriate sub-definitions or as undetermined if there is insufficient information to allow categorization as ischemic or hemorrhagic.  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 45 of 68 
  
 
 
An entity closely related  to ischemic stroke is transient ischemic attack (TIA).  TIA is defined as a transient 
epi[INVESTIGATOR_361849], spi[INVESTIGATOR_1831], or retinal ischemia, without acute infarction.  The difference between TIA and ischemic stroke is  the presence of infarction.  In the absence 
of affirmative evidence confirming the presence or absence of infarction, a symptom duration of 24 hours 
will be used to distinguish TIA from ischemic stroke.  By [CONTACT_108], TIA does not produce lasting disabil ity. 
 The assessment of disability resulting from the stroke will be performed by [CONTACT_212150] 
(mRS).  Assessment of the mRS should occur at all scheduled visits through [ADDRESS_504288] of a given stroke.  A disabling stroke is one that results (at 90 days after stroke onset) in an 
mRS score  of [ADDRESS_504289] one mRS category from the individual’s pre- stroke 
baseline.  A non -disabling stroke is one that results (at 90 days after stroke onset) in an mRS score of 
less than [ADDRESS_504290] one mRS category from an individual’s pre-
stroke baseline.  
 Although imaging (typi[INVESTIGATOR_897], MRI for acute and chronic ischemia and haemorrhage, and CT for acute and 
chronic haemorrhage and chronic ischemia) is often used to supplement the clinical diagnosis of stroke, 
a diagnosis of stroke may be made on clinical grounds alone.   
 
Diagnostic criteria  
 
Acute epi[INVESTIGATOR_44715] a focal or global neurological deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss 
affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or 
other neurological signs or symptoms consistent with stroke  
 Stroke – Duration of a focal or global neurological deficit ≥24 h; OR <[ADDRESS_504291]; OR the neurological deficit results 
in death  
 TIA – Duration of a focal or global neurological deficit <[ADDRESS_504292] 
 
No other readily identifiable non- stroke cause for the clinical presentation (e.g. brain 
tumor, trauma, infection, hypoglycemia, peripheral lesion, pharmacological influences), to be determined by [CONTACT_361913]* 
 
Confirmation of the diagnosis by [CONTACT_37408]:  
– Neurologist or neurosurgical specialist  
– Neuroimaging procedure (CT scan or brain MRI), but stroke may be diagnosed on 
clinical groun ds alone  
Stroke classification  
 Ischemic – An acute epi[INVESTIGATOR_196545], spi[INVESTIGATOR_1304], or retinal dysfunction caused by 
[CONTACT_256904].  
 Hemorrhagic – An acute epi[INVESTIGATOR_361850], intraventricular, or subarachnoid hemorrhage.  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 46 of 68 
  
 
 
Undetermined – An acute epi[INVESTIGATOR_361851]. 
Stroke definitions†  
 
Disabling stroke –  a mRS score of [ADDRESS_504293] one 
mRS cate gory from an individual’s pre- stroke baseline  
 
Non-disabling stroke – a mRS  score of less than [ADDRESS_504294] one mRS category from an individual’s pr e-stroke baseline  
*Patients with non -focal global encephalopathy will not be reported as a stroke without 
unequivocal evidence of cerebral infarction based upon neuroimaging studies (CT scan or Brain MRI).  
†Modified Rankin Scale assessments should be made by [CONTACT_361914] a certification process.  
 Unanticipated Adverse Device Effect [UADE]  
UADEs or Unanticipated serious adverse device effect ([LOCATION_003]DE) refers to any (serious ) adverse effect 
on health or safety or any life- threatening problem or death caused by, or associated with, a device, if 
that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in 
the protocol  or application (including a supplementary plan or application), or any other unanticipated 
serious problem associated with a device that relates to the rights, safety, or welfare of subjects.  All 
reported adverse events are reviewed by [CONTACT_400164]/[LOCATION_003]DEs are identified and addressed.   
 VULNERABLE POPULATION (ISO14155 De finition)  
Defined as subject whose willingness to volunteer in a clinical investigation could be unduly influenced by [CONTACT_162161], whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate.  Examples of populations 
which may contain vulnerable subjects include: Individuals with lack of or loss of autonomy due to 
immaturity or through mental disability, persons in nursing homes, children, impoverished persons,  
subjects in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, and those incapable of giving informed consent. Other vulnerable subjects may include, for example, members of a group with a hierarchical structure such as university students, subordinate hospi[INVESTIGATOR_400092], employees of the sponsor, members of the armed forces, and persons kept in 
detention.   
   

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 47 of 68 
  
 
 
 
APPENDIX I V: LITERATURE REVIEW AND SUMMARY OF PRECLINICAL TRIALS  
 
 
CINICAL TRIALS  
In the [LOCATION_002], the MitraClip System has been studied under an Investigational Device Exemption 
(IDE G030064). The IDE consists of the following cohorts:  
1) Phase I Feasibility Study (EVEREST I)  
1) Phase II Safety / Effectiveness Study (EVEREST II)  
a) EVEREST II Roll-In 
b) EVEREST II Randomized Controlled Trial Arm  
c) EVEREST II High Risk Registry Arm  
2) Phase II Continued Access Study (REALISM)  
a) Non-High Risk Arm  
b) High Risk Arm  
c) Emergency Use/Compassionate Use cases  
 
1)  EVEREST I  
 EVEREST I
[ADDRESS_504295] 
prospective, multi -center, non -randomized trial to evaluate the preliminary safety and effectiveness of 
the percutaneous MitraClip System in patients with moderate -to-severe (3+) or severe (4+) MR in surgical 
candidates.  Percutaneously -treated patients were followed at discharge, 30 days, 6, 12, 18 and 24 
months and annually thereafter through 5 years. An independent Echocardiography Core Laboratory (ECL) assessed MR severity and other echocardiographic parameters at baseline and follow -up. The 
last patient has completed 5- year follow -up and the study is now closed.  
 The M itraClip device was implanted in 89% (49/55) of patients and the trial met its pre- specified safety 
acceptance criterion, demonstrating mechanistic feasibility of implant and safety of the MitraClip System and procedure. There were no intra -procedural deat hs.  Acute procedural success was achieved in 
70.9% of patients.  A majority of patients ( 83.3%)  implanted with a MitraClip deviced  experienced 
reduction in MR severity to 2+ or less at discharge.   No MitraClip device embolizations occurred in this 
cohort.  Ten percent (10%) of the initial cohort had single leaflet device attachment (SLDA).  A majority 
of SLDAs were detected early (within [ADDRESS_504296] -MitraClip procedure). Patients demonstrated 
improvement in NYHA Functional Class and left ventricular measurements that were sustained through 5 years. At 5 years, freedom from death was 86.4% and freedom from mitral valve surgery was 55. 1%. 
The results of the EVEREST I trial at 5 years provide evidence of the safety and long- term durability of 
the MitraClip device in the early cohort of patients treated in the [LOCATION_002].  
  
 
  
 
 
 
 
 
38 IDE G030064/ P100009/A017 EVEREST I Final Clinical Report Version 1.0 - 17/Nov/2011  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 48 of 68 
  
 
 
 
2) EVEREST II  
a. Randomized Clinical Trial (RCT)[ADDRESS_504297] II RCT40,41,42 is a prospective, multi -center, randomized controlled trial where patients 
with moderate- to-severe (3+) or severe (4+) MR were randomized in a 2:1 r atio between the Device 
group (MitraClip device) and the Control group (mitral valve surge ry). Patient follow -up occurs at 
discharge, 30 days, 6, 12, 18 and 24 months and yearly thereafter through 5 years. An independent 
Echocardiography Core Laboratory (ECL) assessed MR severity and other echocardiographic 
parameters at baseline and follow -up. The trial was intended to demonstrate superiority of safety 
balanced against reduced effectiveness of the MitraClip device when compared to mitral valve surgery. 
All patients have completed 5 years of follow -up and the study is now closed.  
 The trial enrolled 279 patients: 184 were randomized in the Device group and 95 were randomized in the 
Control group. Of these, 178 patients in the Device group underwent the MitraClip procedure and 80 
patients in the Control group underwent mitral valve surgery. The trial met both primary safety and 
effectiveness endpoints. There were no intra -procedural deaths.  Among patients who underwent the 
MitraClip procedure in the Device group (MitraClip patients), a device was implanted in 89% of patients. 
The procedure time averaged approximately 3 hours, patients were hemodynamically stable during the 
procedure, and the average length of hospi[INVESTIGATOR_208141] 2.6 days. In comparison, the average length of 
hospi[INVESTIGATOR_400096] (surgery patients) was 7.5 days. A 
large majority (94.9%) of MitraClip patients were discharged home without home healthcare. In comparison, only 71.3% of surgery patients were discharged home without home healthcare. Acute 
procedural success (APS) was achieved in 77% of patient treated in the Device Group.  A majority of 
patients implanted with the MitraClip device (784) experienced reduction in MR severity to 2+ or less at 
discharge, while 100% of patients undergoing mitral valve surgery in the Control group exper ienced 
reduction in MR severity to 2+ or less.  
 Patients who underwent the MitraClip procedure experienced a 30- day major adverse event rate 
(composite of death, myocardial infarction (MI), re- operation for failed surgical repair or replacement, 
non-elective cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, 
ventilation for greater than 48 hours, gastro -intestinal (GI) complication requiring surgery, new onset of 
permanent atrial fibrillation, septicemia and major bleeding complication) of 7.9% versus 50% in patients who underwent mitral valve surgery in the Control group. Excluding the most common event of major 
bleeding complication, MitraClip device patients still experienced a lower major adverse event rate (4.5%) 
than surgery patients (11.3%).  
 
 
 
[ADDRESS_504298] II Randomize d Controlled Trial (RCT) -0401 – Five Year F inal Report, Report Version 1.0 - 
03/Nov/[ADDRESS_504299] II Trial: Design and Rationale for a Randomized Study of the Evalve MitraClip System C ompared 
with Mitral Valve Surgery for Mitral Regurg itation.  Am Heart J .  2010; 160:23- 29. 
41 Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, 
Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, Investigators EI.  Percutaneous Repair  
or Surgery for Mitral Regurgitation.  N Engl J Med .  2011; 364:1395- 1406.  
42 Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, 
Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, 
Silvestry FE, Foster E, Wang A, Glower DD, Mauri L, Investigators EI.  Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5- Year Results of EVE REST II.  J Am Coll Cardiol .  2015; 66:2844-
2854.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 49 of 68 
  
 
 
Through 30 days, MitraClip patients experienced a lower site- reported adverse event rate than surgery 
patients in the following categories: cardiac rhythm disorders (atrial arrhythmias, bradyarrhythmia, ventricular arrhythmia), congestive heart failure, peripheral edema, anemia, infections, neurologic events 
and respi[INVESTIGATOR_29343].  At 30 days, MitraClip patients experienced a higher event rate than surgery 
patients in the following categories: atrial sept al defect, myocardial ischemia, residual or recurrent MR, 
single leaflet device attachment (SLDA), gastrointestinal bleed, and vascular complications such as hematoma, bleed or bruising.  
 Significant and meaningful clinical benefits were observed in both MitraClip and surgery patients, which were sustained through 5 years: 
MR reduction to 2+ or less at 5 years was in 82.1% of MitraClip patients and 97.6% of surgery patients  
Reduction in left ventricular end diastolic volume and dimension was observed in both MitraClip and surgery patients, which was sustained through 5 years  
Improvement in NYHA Functional Class was demonstrated in both groups, with 91.5% of MitraClip patients and 97.6% of surgery patients free from NYHA Functional Class III or IV symptoms a t [ADDRESS_504300] II High Risk Registry (HRR)
[ADDRESS_504301] II High Risk Registry44 is a single -arm prospective, multi -center, clinical trial designed to 
evaluate the safety and effectiveness of the MitraClip System in patients with moderate- to-severe (3+) 
or severe (4+) MR c onsidered to be at high risk of surgical mortality.  High risk was defined as predicted 
procedural mortality risk calculated using the STS surgical risk calculator of ≥12% or in the judgment of the surgeon investigator the patient was considered a high risk surgical candidate due to the presence of specific protocol -defined criteria.  
 The primary objective of the EVEREST II HRR was to assess procedural safety in high surgical risk 
patients.   Accordingly, the primary safety endpoint was procedural mortality at [ADDRESS_504302] II 
HRR was high with 96.2% of patients implanted with one (59.0%) or two (37.2%) MitraClip devices .  The 
mean post -procedure ICU/CCU/PACU stay was 2.[ADDRESS_504303] II High Risk Registry (HRR) – 0401 - Five Year Final Report, Report Version 1.0 – 03/Nov/[ADDRESS_504304], Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T, Herrmann HC, Lasala J,  
Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel RJ, Foster E, Glower D, Mauri L, Kar S, Investigators EI.  Acute 
and 12- Month Results with Catheter -Based Mitral Valve Leaflet Repair: The EVEREST II (Endovascular Valve 
Edge -to-Edge Repair) High Risk Study.   J Am Coll Cardiol .  2012; 59:130- 139. 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 50 of 68 
  
 
 
a median of 2 days.  Approximately 75% of patients were discharged home without the need for 
professional home healthcare.  An additional 10% were discharged home with home healthcare required, 
resulting in a total of almost 86% being discharged home after the MitraClip pr ocedure.  At discharge, 
MR was  reduced in a majority of patients (74.7%) to ≤2+ and in 40% of patients to ≤ 1+.   
 
The primary safety endpoint of procedural mortality (observed vs. predicted) was met.   The observed 
procedural mortality rate at 30 days was 7.7% (95.472% UCB= 14.8%) and compared favorably (p=0.006) 
to the average predicted surgical mortality of 18.2%.  The observed procedural mortality rate was also 
lower when compared to the average STS mortality risk (14.2%).   
 Among patients with paired data at baseline and 1 year, MR r eduction was sustained to ≤ 2+ in 77.8% of 
patients and to ≤ 1+ in 31.5% of patients.   Significant improvement in NYHA Class was observed at [ADDRESS_504305] II HRR.  Among patients with paired data at baseline and 1 year, the proportion of 
patients with NYHA Class III or IV reduced from 88.9% at baseline to 25.9% at 1 year .  Improvement in 
both physical and mental components of the SF- 36 quality of life by 4.0 and 3.2 points respectively were 
observed at 1 year.  A significant decrease in the rate of heart failure hospi[INVESTIGATOR_602] (0.65 to 0.36 per 
patient -year) was observed in the year following the MitraClip procedure compared to the year prior.  
 Adverse events occurred at rates as expected in the advanced age patient population w ith significant co -
morbidities .  The MAE rate at 30 days was 26.9%, with transfusions ≥2 units comprising the majority of 
events (17.9%).  There was no incidence of non -elective (urgent/emergent) cardiovascular surgery for 
adverse events or new onset of persistent atrial fibrillation in this cohort through [ADDRESS_504306] -procedure, site-reported adverse events (AE) occurred at a steady low rate 
as expected for this population.  The most commonly site-reported AEs through [ADDRESS_504307] commonly reported renal AE were renal 
insufficiency/failure and infection. The most commonly reported vascular AE was  hemodynamic 
instability.  These rates are as expected for a percutaneous procedure in elderly patients with multiple 
baseline co- morbidities.   
 
Device complications were rare; the rate of single leaflet device attachment (SLDA) was 1.3% in the first 
year with no new occurrences reported thereafter.  Only 2 patients had confirmed mitral stenosis thr ough 
5 years.  
 
Through 5 years, a total of 42 (53.8%) deaths occurred in the EVEREST II HRR.  This mortality rate is as expected due to the high risk nature of the patient population.  At 5 years , MR reduction was sustained 
to ≤2+ in 73.9% of  surviving patients  with paired data  and to ≤1+ in 47.8% of  surviving patients  with 
paired data.  Among patients with paired data at baseline and 5 years, the proportion of s urviving patients 
with NYHA Class III or IV reduced from 89.7% at baseline to 18.9%, 9.7%, and 16.7% at [ADDRESS_504308] a role for the MitraClip device in treating symptomatic 
patients with 3+ to 4+ MR who are at high risk of mortality with MV surgery.  MitraClip device placement 
in this selected high- risk group is feasible, effective in reducing symptoms and improving clinical status, 
and relatively safe in patients who otherwise have no safe option to reduce MR.  
  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 51 of 68 
  
 
 
3) REALISM Continued Access 
The EVEREST II REALISM study is a continued access registry designed for continued data collection on the use of the MitraClip System in “real world” conditions.  After the completion of enrollment in the 
pi[INVESTIGATOR_400097], co ntinued access to the technology was 
warranted to collect additional safety and effectiveness data on the MitraClip d evice.  There are two arms 
(High Risk and Non -High Risk) in the REALISM study.  Enrollment in the Non- High Risk arm of the study 
concluded on April 14, 2011, and enrollment in the High Risk arm concluded on December 19, 2013.  
Patients with serious or life -threatening conditions that did not meet REALISM High Risk or Non- High 
Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate 
Use (CU).    
 Each arm of the REALISM study was designed with inclusion/exclusion criteria and endpoints aligned to 
maintain consistency with the EVEREST II RCT and HRR studies.  Eligibility criteria in REALISM HR are 
identic al to EVEREST II HRR, with one exception: patients are excluded from REALISM HR if they had 
a concurrent medical condition resulting in a life expectancy of less than [ADDRESS_504309] been enrolled in the non- high risk arm of REALISM.  MitraClip implant rate 
was 95.2% .  Post -procedure, the average duration of hospi[INVESTIGATOR_40175] 2.8 days.  The mean duration 
of stay in the ICU/CCU/PACU post -procedure was 28.8 hours, and a majority of patients (91.5%) returned 
home  post procedure and required no home- health care.  Two patients (0.7%) died prior to discharge of 
non-cardiac causes.  
 At the 30- day and 12 -month time points, 11.4% and 27.3% of the participants  respectively experienced 
MAEs  as adjudicated by [CONTACT_15741].   A total of  27 deaths  were  reported during the 12- month follow -up 
window  (410 days).  Thirteen of the 27 deaths were CEC- adjudicated to cardiac causes.  Interim  Kaplan-
Meier analysis at 5 years demonstrated an event -free survival rate of 61.0%.  The incidence of SLDA 
after index procedure was reported in 11  (4.3%) of the [ADDRESS_504310] one MitraClip 
device in the Non- High Risk arm.  No cases of MitraClip procedure- related embolizations were reported. 
 Reduction to MR ≤2+ was achieved in 89% of patients at 30 days and in 84% of patients at 12 months.  
A similar trend was observed at subsequent follow- ups with a majority (>75%)  of patients with MR 
severity  remaining consistently mild to moderate .  A reduction was observed in LV dimensions and 
volumes m easured with echocardiography on analysis of matched data up to 60 months, which was 
consistent with the reduction in MR severity and indicative of LV remodeling.   
An overall improvement in cardiac status was observed, with more than 88.0% of the treated patients 
being categorized as NYHA Class I or II through follow -up visits  which indicated an improvement in the 
symptomatic status and was consistent with the results of MR severity improvement and LV remodeling.  
Statistically significant  improvements in SF-[ADDRESS_504311] II REALISM – Non- High Risk   2017 Annual Report , Protocol #0401- Clinical Investigation Report  Ver 
1.0  - 24/APR/201 7 
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.[ADDRESS_504312] been enrolled in the high risk arm of REALISM.  A majority of patien ts had 
multiple pre -existing co -morbidities at baseline  and were considered high risk for mitral valve surgery.  
The mean STS mortality risk score of this high- risk population was 11.1%, with 43.5% of patients having 
a mortality risk score ≥12% .   
 
In the high- risk cohort, the MitraClip implant rate was 96%, with 53% of the patients receiving a single 
MitraClip d evice and 43% of the patients receiving multiple devices.  Following the intervention, patients 
spent  a mean duration of 36.5 hours in the ICU/CCU/PACU during an average hospi[INVESTIGATOR_271477] 3.2 days.  
A majority (83.3%) of the patients returned home with no further need for assisted healthcare.  Twelve 
patients (1.9%) died before discharge.   
 
The CEC -adjudi cated major adverse event (MAE) rates including transfusions were 15.6% at 30 days 
and 35.4% at 12 months.  A total of 146 deaths were reported up to the 12- month follow -up window (410 
days) .  Of these  146 deaths, 97  (66.4%) were adjudicated as cardiac -related and 49  (33.6%) were  
adjudicated as  non-cardiac  related.  There were no reports of MitraClip device embolization during the 
study.  Of the [ADDRESS_504313] one MitraClip device implanted, 13 cases of single leaflet 
Device attachment (SLDA) were noted .   
 Reduction to MR ≤2+ was achieved in 90% of patients at discharge/30 days and in 85% of patients at 12 
months.   A similar trend was observed at subsequent follow- ups with a majority (>80%)  of patients with 
MR severity  remaining consistently mild to moderate.  A  steady reduction in LV volume and dimensions  
was observed through [ADDRESS_504314] (6MWT) at 12 months.  There were statistically significant 
improvements in the physical component score (PCS) and mental component score (MCS)  domains of 
the SF- 36 QoL scores at both 30 days and 12 months.  
 There was a reduction in the proportion of patients hospi[INVESTIGATOR_400098] -enrol lment time- point (36.6% and 402, respectively) to the 12- month  follow- up (17.8% 
and 174, respectively) . 
 Safety and Device efficacy data from the high -risk arm of the REALISM study show that the MitraClip is 
a viable option for treatment of degenerative and functional MR in high- risk individuals who carry a 30 -
day STS- calculated or surgeon- assessed mortality risk ≥12%.   Follow -up through [ADDRESS_504315] II REALISM– High Risk 201 7 Annual Report , Protocol #0401- Clinical Investigation Report Ver 1.0   
24/Apr/2017  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.[ADDRESS_504316] II exclusion criteria.  Of 51 consecutive patients treated with the MitraClip device at the Hamburg University Heart Centre between 
September 2008 and July 2009, 35 (69%) had LV characteristics and/or a mitral valve morphology that would have excluded them from enrolment in the EVEREST I and II trials.  The positive acute outcomes achieved in these patients paved the way for larger contemporary commercial registries, the most 
prominent of which are summarized below:  
 
ACCESS -EU Phase I  
ACCESS- EU
[ADDRESS_504317] to health economics and clinical care, and 
to provide further evidence of safety and effectiveness. Five hundred s ixty-seven (567) patients were 
treated with the MitraClip in Europe.  One -year clinical follow- up was available in 487 patients.  The study 
is now closed.   
 Patients in ACCESS -EU had a mean age of 73.7 years and were predominantly males (63.8%).  A 
majority (77.1%) had functional MR.  At baseline, 84.9% were in NYHA functional class III or IV, and the 
mean LVEF was 35%.  The mean logistic EuroScore was 23.0% with approximately half of patients 
having a logistic EuroScore of 20% or greater.  Despi[INVESTIGATOR_400099], 
the patients treated in the ACCESS -EU study were representative of the higher end of the surgical risk 
spectrum.  
 Patients enrolled in ACCESS -EU represent a population with significant, symptomatic MR, a high rate of 
multiple serious comorbidities.  Considering the high MitraClip device implant rate (99.6%, 565/567), the high rate of meaningful MR reduction (78.9%, 258/327 MR<2+), and the resulting improvements in 6-
minute walk (59.5 m difference, p<0.0001), Minnesota Living with Heart Failure Questionnaire qualit y of 
life score (13.5 point improvement, p<0.0001) and NYHA Functional Class (71.5% NYHA Class I or II, 
p<0.0001), at 1 year, it is concluded that the MitraClip device provides an important therapeutic option 
for patients with significant mitral regurgitation, and is an especially important option for patients who 
may be considered high surgical risk.  
 
Getting Reduction of Mitral Insufficiency by [CONTACT_400169] (GRASP)  
The GRASP registry is a single- center, prospective, observational study of consecutive high surgical risk 
patients with moderate -to-severe or severe MR undergoing percutaneous mitr al valve repair with the 
MitraClip System at Ferrarotto Hospi[INVESTIGATOR_307] (Catania, Italy).  The study does not have specific exclusion criteria; and the indication for MitraClip therapy is established by a multidisciplinary Heart Team.  The 
 
 
[ADDRESS_504318]-
Jackle A, Schluter M, Reichenspurner H, Meinertz T.  Acute Outcomes of MitraClip Therapy for Mitral Regurgitation 
in High- Surgical -Risk Patients: Emphasis on Adverse Valve Morphology and Severe Left Ventricular Dysfunction.  
Eur Heart J .  2010; 31:1373- 1381.  
48 Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder JD, 
Moccetti T, Schillinger W.  Percutaneous Mitral Valve Interventions in the Real World: Early and 1- Year Results 
from the ACCESS -EU, a Prospective, Multicenter, Nonrandomized Post -Approval Study of the MitraClip Therapy 
in Eur ope.  J Am Coll Cardiol .  2013; 62:1052- 1061.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.[ADDRESS_504319] 2008 and October 2012 as part of the ongoing GRASP registry
49.  Mean age was 72± 10 year s and 67% were male.  The 
mean logistic EuroSCORE was 12±14%, and a majority (76%) of patients had functional MR.  MR grade 3+ or 4+ was present in 98% of patients, and NYHA functional class symptoms in 80% of patients.  At 
baseline, 63% of patients met the EVEREST leaflet anatomic criteria (i.e., coaptation depth <11 mm, 
coaptation length >2 mm) . 
 Acute procedural success was achieved in all patients.  MR was reduced to 1+ and 2+ post- procedure 
in 63% and 37% of patients, respectively.   
 
The primary safety end point was the rate of major adverse events (MAEs) at 30 days, defined as the 
composite of  death, myocardial infarction, reoperation for failed mitral valve surgery, nonelective 
cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, mechanical 
ventilation for >48 hours, gastrointestinal complication requiring surgery, new -onset permanent atrial 
fibrillation, septice mia, and transfusion of ≥2 units of blood.  The primary efficacy end point was freedom 
from death, surgery for mitral valve dysfunction, or grade ≥3+ MR at 30 days and 1 year after clip 
implantation.  
 MAEs occurred in 4 patients  (4.3%)  at [ADDRESS_504320] -procedure.   
 Deterio ration to MR ≥3+ was recorded in 25% of patients with degenerative MR and 7% of  those with 
functional MR at [ADDRESS_504321] year after 
clip implantation.  No cases of clip detachment or embolization were observed.  Kaplan- Meier estimates 
of freedom  from the primary efficacy  endpoint was 96.4% at 30 days and 75.8% at 1 year.  No survival 
difference was noted based on MR etiology.   
 
Results from the GRASP registry support the safety and efficacy of the MitraClip device in a real -world 
setting.  
 
 
GRASP Registry:  EVEREST
ON versus EVEREST OFF Criteria  
Attizzani et al.[ADDRESS_504322] echocardiographic criteria were assigned to the 
investigational group (EVEREST OFF; N=93), whereas those meeting the EVEREST echocardiographic 
 
 
49 Grasso C, Capodanno D, Scandura S, Cannata S, Imme S, Mangiafico S, Pi[INVESTIGATOR_400057] A, Ministeri M, Barbanti M, 
Caggegi A, Chiaranda M, Dipasqua F, Giaquinta S, Occhipi[INVESTIGATOR_88757] M, Ussia G, Tamburino C.  One- and Twelve- Month 
Safety and Efficacy Outcomes of Patients Undergoing Edge- to-Edge Percutaneous Mit ral Valve Re pair (from the 
GRASP Registry).  Am J Cardiol .  2013; 111:1482- 1487.  
[ADDRESS_504323] 
(Endovascular Valve E dge-to-Edge Repair) Criteria: 30- Day and 12- Month Clinical and Echocardiographic 
Outcomes from the G RASP  (Getting Reduction of Mitral Insufficiency by [CONTACT_400169]) Registry.  
JACC Cardiovasc Interv .  2015; 8:74- 82. 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 55 of 68 
  
 
 
criteria were assigned to the control group (EVEREST ON; N=78).  Among the [ADDRESS_504324] OFF group,  35 patients had LVEF ≤25%, 28 patients had LV end systolic diameter >55 mm, 34 
patients had coaptation depth ≥11 mm, and 10 patients had the flail width ≥15 mm.  Otherwise, baseline 
characteristics were comparable between the two groups. 
 
High rates of acute procedural success  were achieved in both groups (97.8% and 100% for EVEREST OFF 
and EVEREST ON, respectively). At 30 -days, the rate of MAEs (i.e. primary safety endpoint) was 
comparable between groups (2.6% vs. 6.5%, respectively, p=0.204).  Freedom from  death, surgery for 
mitral valve dysfunction, or grade ≥3+ MR (i.e. primary effectiveness endpoint) was 90.1% and 93.5%, 
respectively (p=0.427).  Reduction in MR severity, symptomatic improvements, and re- hospi[INVESTIGATOR_400100].  
 At 1 year, Kaplan- Meier freedom from the primary efficacy endpoint was demonstrated in 71.4% and 
76.2%, respectively, in the EVEREST
OFF and EVEREST ON groups.  Approximately 90% of surviving 
patients in both groups had sustained MR reduction to ≤2+, and approximately 78% of patients fro m both 
groups had NYHA functional class I or II at [ADDRESS_504325] of different characteristics of 
enrollment based on 1) valve geometry, 2) ventricle function/geometry, and 3) a combination of the two.  Although the combined group revealed numerically lower efficacy (primary efficacy endpoi nt 76.2%, 75%, 
and 62.5%, respectively, p=0.521), higher rates of MR ≥3+ (14.5%, 12.5%, and 20.8%, p=0.710), as well 
as higher death rates (9.5%, 12.5%, and 25%, respectively, p=0.312), these differences did not reach statistical significance.   
 This analysis of the GRASP Registry suggests that MitraClip implantation in patients with expanded 
baseline echocardiographic features was associated with similar rates of safety and efficacy through 12-month follow -up when compared with patients meeting the EVEREST anatomical criteria.  
 The German Transcatheter Mitral Valve Interventions (TRAMI)  
The German transcatheter mitral valve interventions (TRAMI) registry was initiated in August [ADDRESS_504326] prospective cohort was 
described by [CONTACT_400170].53.  A total of 828 patients were prospectively enrolled at 21 German sites  between 
2010 and 2013.  One- year follow -up was available in 749 patients.   
 
 
51 Baldus S, Schillinger W, Franzen O, Bekeredjian R, Sievert H, Schofer J, Kuck KH, Konorza T, Mollmann H, 
Hehrlein C, Ouarrak T, Senges J, Meinertz T, investigators GTMVI.  MitraClip Therapy in Daily Clinical Practice: 
Initial Results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry.  Eur J Heart Fail .  2012; 
14:1050- 1055.  
52 Schillinger W, Hunlich M, Baldus S, Ouarrak T, Boekstegers P, Hink U, Butter C, Bekeredjian R, Plicht B, Sievert 
H, Schofer J, Senges J, Meinertz T, Hasenfuss G.  Acute Outcomes after MitraClip Therapy in Highly Aged Patients: 
Results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry.  EuroIntervention .  2013; 9:84-
90. 
53 Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert H, 
Nickenig G, Eggebrecht H, Senges J, Schillinger W.  One- Year Outcomes  and Predictors of Mortality after MitraClip 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 56 of 68 
  
 
 
 
Patients had an average age of 76 years and a majority (89%) were symptomatic with NYHA functional 
class III or IV.  Median STS mortality risk score was 6.0%.  Approximately 70% of patients underwent the MitraClip procedure for functional MR.  The MitraClip implant rate in this cohort was 97%, with an average 
of 1.4±0.6 clips  implanted per procedure.  Mean procedure time and fluoroscopy duration were 102.8 
±54.1 minutes and 28.8±57.9 minutes, respectively.  Mitral regurgitation was reduced from severe (94%) 
at baseline to none or mild in 85.2% of patients post procedure. 
 
One patient died intra- operatively and in- hospi[INVESTIGATOR_400075] 2.4% (n= 18).  No emergent cardiac 
surgery was required.  The rate of in- hospi[INVESTIGATOR_400076]  
(MAC CE) was 3.1% . Other in -hospi[INVESTIGATOR_400101] 12.8% of  patients  and were mainly 
associated with major bleeding complications.   Five (0.7%) cases of SLDA were reported in this cohort.  
The median length of hospi[INVESTIGATOR_208141] 9 days, and a majority of patients (89.3%) were discharged to 
their normal social envir onment . 
 Thirty -day and 1 -year mortality were 4.5% and 20.3%, respectively.  The rates of transient ischemic 
attack (TIA; 3.8%), stroke (2.1%), and myocardial infarction (0.9%) at 1- year were low.  A total of 8.5% 
of patients underwent a subsequent mitral valve surgery (2.3%) or second MitraClip device intervention (5.2%), respectively, to correct recurring MR.  A majority (63.3%) of patients were in NYHA functional 
class I or II at 1 -year and significant improvement in quality of life was observed using the EuroQuol 
visual analogue scale (EQ-5D). 
 Predictors of 1 -year mortality included NYHA class IV, anemia, previous aortic valve intervention, serum 
creatinine ≥1.5 mg/dL, peri pheral artery disease, LVEF 30%, severe tricuspid regurgitation, and 
procedural failure (defined as operator -reported failure, conversion to surgery, failure of clip placement, 
or residual post -procedural severe mitral regurgitation). 
 These results demonstrate that treatment of significant MR with the MitraClip device is efficacious and 
results in significant clinical improvements in a high proportion of TRAMI patients after [ADDRESS_504327] ratio for predicting 1- year 
mortality.  
 Transcatheter Valve Treatment Sentinel Pi[INVESTIGATOR_400102] 12 -month follow -up results of 628 
consecutive patients treated between January 2011 and December 2012 in 25 centers in 8 European 
countries.  
 Mean age of the patients entered in the registry was 74.2± 9.7 years, 63.1% were male, and 72.0% had 
functi onal MR.  A majority (85.5%) of patients were in NYHA functional class III or IV at baseline.  Mean 
logistic EuroSCORE was 2 0.4±16.7%, indicative of population of patients at high risk for surgical mortality.  
 Acute procedural success was high (95.4%)  with no difference between FMR and DMR patients.  Overall, 
in-hospi[INVESTIGATOR_400075] 2.9% .  MR reduction to ≤2+ was achieved in 98.2% of patients post -procedure 
with no difference between MR etiologies.  At 1 -year, MR was reduced to ≤2+ in 94.0% of patients and 
 
 
Therapy in Contemporary Clinical P ractice: Results from the German Transcatheter Mitral Valve Interventions 
Registry.  Eur Heart J .  2016; 37:703- 712. 
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 57 of 68 
  
 
 
58.6% had mild or no MR, with comparable results obtained for FMR and DMR.  A majority (74.2%) of 
patients were in NYHA functional class I or II at 1 -year.  
 At 1-year, mortality was 15.3%, without significant differences between groups (FMR 15.0% vs. DMR 
16.2%, p[log -rank]=0.650).  The estimated 1 -year rate of  heart failure re- hospi[INVESTIGATOR_40175] 22.8% and 
was significantly h igher in the FMR group compared to the DMR group (25.8% vs. 12%, p[log-
rank]=0.009).  Freedom from the composite endpoint of deat h or re-hospi[INVESTIGATOR_400103] 
69.0%, with no difference between FMR and DMR ( p[log rank] =0.103).  Multivariate analysis showed 
that EuroSCORE  and successful deployment of the MitraClip device were independently associated with 
the composite  endpoint at 1 year.  
 Re-intervention for recurring MR was infrequent with 2.9% of patients requiring a second MitraClip 
interv ention and 0.9% requiring mitral valve surgery.  
 
The results of the pi[INVESTIGATOR_400104] a high-risk cohort, without differences between FMR and DMR.   
These results confirm long- term benefits previously reported in other real -world registries.  
 
MitraClip Asia -Pacific Registry (MARS)  
MitraClip in the Asia -Pacific Registry (MARS)
54 is a multicenter retrospective registry that includes 
patients treated at 8 centers in Australia, China, Indonesia, Malaysia and Singapore.  The study did not mandate specific anatomic requirements beyond the technical feasibility of graspi[INVESTIGATOR_400105] A2/P2 segments were deemed 
eligible for enrollment.  
 A total of 145 patients underwent the MitraClip procedure between February 2011 to October 2013.  
Patients were predominantly male (64%) with a mean age was 71.4± 11.9 years.  At baseline, all patients  
had MR severity 3+ (19%) or 4+ (81%).  Functional MR etiology was present in 53.5%.  A majority (68.3%) of patients were symptomatic with NYHA functional class III or IV at baseline.  Mean STS score for the 
cohort was 7.4±8.1%.  
 
The MitraClip implant rate was 97.9% and the average procedure time was 130±98 minutes.  Acute 
procedural success was achieved in 93.7% (133/142).  One MitraClip device was implanted in 70 (49.3%) patients, whereas 72 (50.7%) patients received ≥2 devices.  There were no device embolization and 6 
(4.2%) patients experienced an SLDA.  The mean length of hospi[INVESTIGATOR_400106] -procedure was 6.0±7.8 
days.  
 
The 30-d ay mortality rate was 5.6% (n=8), while the 30- day MAE rate, defined as a composite of stroke, 
myocardial infarction, bleeding requiring transfusions >1 unit of blood, septicemia, reoperation for failed mitral valve procedure, non- elective cardiac surgery for adverse events, renal failure, gastrointestinal 
complications requiring surgery, ventilation for >48 hours, and new onset of  atrial fibrillation was 12.7% 
(18/142).    
 
At 30 days, 76.8% of patients had MR ≤2+, with no significant differences observed between the FMR 
and DMR sub -group s.  There was significant improvement in NYHA functional  class with 82.1% of 
patients in class I  or II at 30 days compared to 31.7% at baseline.  At 30 days, there was a significant 
 
 
54 Yeo KK, Yap J, Yamen E, Muda N, Tay E, Walters DL, Santoso T, Liu X, Jansz P, Yip J, Zambahari R, Passage 
J, Koh TH, Wang J, Scalia G, Kuntjoro I, Soesanto AM, Muller D.  Percutaneous Mitral Valve Repair with the 
MitraClip: Early Results from the MitraClip Asia- Pacific Registry (MARS).  EuroIntervention.  2014; 10:620- 625. 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 58 of 68 
  
 
 
reduction in LVEF, LVEDD, LVESD, LA indexed volume and calculated pulmonar y artery systolic 
pressure compared to baseline.  
 
In a separate analysis, Tay et al.55 described and compared the use of the MitraClip therapy in patients 
with FMR and DMR treated as part of the MARS registry.  The authors reported similar rates of acute 
procedural success for FMR (95.5%, n=84) and DMR (92%, n=69) (p=0.515).   
 The 30- day mortality rate for FMR and DMR was similar at 4.5% and 6.7% respectively (p=0.555). Thirty -
day MAE rate was 9.2% for FMR and 14.7% for DMR (p=0.281). Both FMR and DMR patients achieved 
significant improvements in MR severity and NYHA class after 30 days.  However, a significantly greater 
reduction in left ventricular end -diastolic diameter and end systolic diameter was observed in DMR 
compared to FMR.  
 
Overall, results from the MARS registry demonstrate that the MitraClip therapy  is effective in reducing 
mitral regurgitation and has favorable short- term safety outcomes in both FMR and DMR patients.  
 TVT Registry  
The Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry is a joint initiative of the STS and the  ACC.  The goals of the registry are to serve 
as a platform for: 1) device and procedural surveillance; 2) quality assurance and improvement initiatives; and 3) efficient conduct of studies that will speed [LOCATION_002] access to new devices and support the expansion of device labeling through evidence development.  
 Centers that participate in the TVT Registry  collect data on demographics, morbidities, functional status, 
quality of life, hemodynamic status, procedural details, and outcomes (post -operative, 30- day, and 1-
year).  The ACC National Cardiovascular Data Registry data warehouse and the Duke Clinical Research Institute Data Analysis Center both implement data quality checks, including feedback reports and checks 
on data range and consistency.  
 Initial Experience (Nov 2013 – Aug 2014)  
The initial experience with commercial transcatheter mitral valve repair in the [LOCATION_002] was first 
published by [CONTACT_400171].
56 in 2016.  A total of 564 patients were entered into the transcatheter mitral 
leaflet clip (TMC) module of the TVT registry between November [ADDRESS_504328] 2014.  Approximately 70% of patients were enrolled at centers with pre -commercial experience.  Median age of the patients 
was 83 years, 56% were male.  NYHA functional class was III or IV in 86.0%; 292 patients (60.5%) had been hospi[INVESTIGATOR_400107].  The median STS -PROM 
scores for MV repair and MV replacement were 7.9% (IQR: 4.7% to 12.2%) and 10.0% (IQR: 6.3% to 
14.5%), respectively.  
 Consistent with the commercial indication for the MitraClip System, the vast majority (85.5%) of patients 
had degenerative MR, 9.2% had functional MR, and 5.1% had mixed etiology.  However, contrary to the 
EVEREST studies, implanting physicians were given greater discretion in the treatment of mitral valve 
 
 
55 Tay E, Muda N, Yap J, Muller DW, Santoso T, Walters DL, Liu X, Yamen E, Jansz P, Yip J, Zambahari R, 
Passage J, Ding ZP, Wang J, Scalia G, Soesanto AM, Yeo KK.  The MitraClip Asia- Pacific Registry: Differences in 
Outcomes between Functional and Degenerative Mitral Regurgitation.  Catheter Cardiovasc Interv .  2016; 87:E275-
281. 
[ADDRESS_504329], Jr., Stebbins A, Kar S, Lim DS, Thourani V, McCarthy P, Kapadia 
S, Grayburn P, Pedersen WA, Ailawadi G.  Initial Experience with Commercial Transcatheter Mitral Valve Repair 
in the [LOCATION_002].  J Am  Coll Cardiol.  2016; 67:1129- 1140.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 59 of 68 
  
 
 
pathologies.  As such, an important proportion (37.8%) of patients had significant left ventricular dil ation 
(end- systolic dimension ≥40 mm), baseline mean mitral gradient ≥5 mm Hg (8.0%), and MV area was  <4 
cm2 (19.7%).  Moderate and severe tricuspid regurgitation was present in 35.1% and 15.1% of patients 
at baseline, respectively.  
 The MitraClip implant rate was 96.8% with most devices implanted in the A2- P2 region (78.4%).  MR 
reduction to ≤2+ was achieved in 93.0% of patients, while MR grade ≤1+ occurred in 63.7%.  Three 
patients (0.5%) required conversion to open cardiac surgery, and 13 (2.3%) in- hospi [INVESTIGATOR_400108].  The incidence of in- hospi[INVESTIGATOR_400109] 1.2%, while major bleeding (VARC -2 criteria) occurred 
in 3.9%.  Six (1.1%) patients had a single leaflet device attachment (SLDA), and 2 (0.4%) patients had a device embolization.  Overall, procedural success, defined as a reduction to moderate or less MR in the 
absence of cardiac surgery o r in-hospi[INVESTIGATOR_34380], occurred in 90.6% of patients.  The median length of 
hospi[INVESTIGATOR_400106] -procedure was 3 days and a majority (84%) of patients were discharged home.  
 
The 30- day mortality rate in the TVT Registry was 5.8%.  Stroke at 30 days occurred in a total of 8 
patients (1.8%). The 30- day incidence of life -threatening or disabling bleeding (VARC -2 criteria) was 
2.6%.  A total of 13 (3.1%) patient s were re -hospi[INVESTIGATOR_400110] [ADDRESS_504330] -procedure.   
 
Variables with univariate associat ion for  reduction in MR  ≤2+ were end -diastolic dimension, baseline MR 
severity, A2- P2 location of clip implantation, and institutional case volume.   MitraClip device implantation 
at A2 -P2 remained significant in multivariate models.  
 
Reduction to MR grade ≤2+ was similar at sites  with and without precommercial experience (93.8% vs. 
91.1%, p=0.26), though reduction to MR grade ≤1+ was more common at pre- commercial sites (66.5% 
vs. 57.4%, p=0.04).  
 
Preliminary outcomes from the TVT Registry show that the MitraClip devices is predominantly used in a 
population of patients at prohibitive surgical ris k with symptomatic severe MR due to degenerative 
disease.  Safety and efficacy outcomes of the MitraClip in a commercial setting in the [LOCATION_002] 
were comparable with pre- approval resea rch studies and other commercial registries.  
 
 
1-Year Outcomes (Nov 2013 – Sep 2015)  
In a subsequent report, Sorajja et al.
57 updated previously published data on acute procedural success 
and extended the evaluation of these patients to 1- year follow -up.  This expanded cohort includes all 
patients who underwent commercial therapy  with the MitraClip S ystem since initial U.S. Food and Drug 
Administration approval and who were enrolled in the TVT registry through September 1, 2015. 
 
Procedural and in -hospi[INVESTIGATOR_400111].  For clinical events 
after hospi[INVESTIGATOR_2345] (i.e.,30 -day and 1 -year outcomes), data from CMS administrative claims were 
used via linkage of the clinical records of the TVT registry to Medicare admini strative claims  data using 
direct patient identifiers . 
 Primary outcomes were death, re-hospi[INVESTIGATOR_19934], and the combined endpoint of death or 
heart failure re- hospi[INVESTIGATOR_21342] [ADDRESS_504331] Jr, Stebbins A, Kar S, Thourani V, Ailawadi G.  
Outcomes With Transcatheter Mitral Valve Repair in the [LOCATION_002]: An STS/ACC TVT Registry Report.  J Am 
Coll Ca rdiol. 2017;70(19):2315- 2327.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 60 of 68 
  
 
 
A total of 2,952 patients were enrolled between November 2013 and September 2015 at 145 clinical sites 
in the U.S.  Patients were elderly with a median age of 82 year; 56% were male.  At baseline, 85% were 
symptomatic with NYHA functional class III or IV.  Overall, the median (IQR) STS -predicted risks  of 
mortality for MV repair and MV replacement were 6.1% (3.7% to 9.9%) and 9.2% (6.0% to 14.1%), 
respectively.  
 Degenerative MR etiology was present in a majority (85.9%) of patients, whereas functional MR was 
noted in 17.5% (FMR only 8.6%; mixed etiology  8.9%).  Ninety -three percent (93%) of patients presented 
with 3+ or 4+  MR at baseline.  Significant left ventricular dilation (end- systolic dimension ≥40 mm) was 
present in 32.2%.  The median LVEF was 55% and 35.4% of the patients had an LVEF <50%.  Baseline mean mitral gradient was ≥5 mm Hg in 9.2%, and the MV area was <4 cm
2 in 20.5%.  Severe tricuspid 
regurgitation was present in 16.0% of the patient s. 
 
The MitraClip was predominantly implanted in the A2- P2 region (82.8% of cases).  MR reduction to ≤2+ 
was achieved in 93.0% of patients, while MR grade ≤1+ was achieved in 61.8%.  Single- leaflet device 
attachment occurred in 1.5% of treated patients.  There were 4 reported cases of device embolization (0.1%).  Major or life- threatening bleeding (VARC -2 criteria) occurred in 3.9%.  The rates of stroke (0.4%) 
and myocardial infarction (0.1%)  were both low.  Twenty patients (0.7%) had in- hospi[INVESTIGATOR_400112].  Overall in- hospi[INVESTIGATOR_400075] 2.7%.  The median length of hospi[INVESTIGATOR_208141] 2 
days and a majority (85.9%) of the treated patients were discharged directly home . 
 A total of 1,867 patients (63.2%) from [ADDRESS_504332] functional MR.  However;  the STS-predicted risk s of operative mortality  for MV repair and MV replacement were higher 
in patients with linked CMS claims data compared to those without linked CMS claims data. 
 
In this cohor t, 30-day mortality, including in- hospi[INVESTIGATOR_400113], was 5.2% and the rate of re- hospi[INVESTIGATOR_400114] 4.9%.  A majority (95.5%) of patients were discharged from hospi[INVESTIGATOR_400115] ≤2+, 
alive and free from MV surgery at 30 days.  
 
One- year mortality in patients with linked CMS claims data was 25.8% and the rat e of re -hospi[INVESTIGATOR_400116] 1 year was  20.2%.  The combined endpoint of death or heart failure re- hospi[INVESTIGATOR_400117] 1 year occurred in 37.9% of the patients.  These endpoints were lower for patients who had 
degenerative MR etiology (24.7%, 20.5%, and 35.7%, respectively) compared to those who had 
functional MR etiology (31.2%, 32.6%, and 49.0%, respectively ). 
 
The subgroup of patients with severe tricuspid regurgitation also had significantly worse outcomes, with 
1-year cumulative incidences of 38.5%, 31.5%, and 54.3% for death, heart failure re-hospi[INVESTIGATOR_059], and 
the combined endpoint of death and heart failure re- hospi[INVESTIGATOR_059], respectively.  
 
Similarly, a graded effect was noted when comparing cumulative incidence of death and the combined 
endpoint of death or heart failure re -hospi[INVESTIGATOR_400118] 1 year by [CONTACT_400172].  As expected, better 
outcomes were observed in patients discharged with MR ≤1+ (21.7% and 35.7%, respectively) compared 
to those discharged with MR 2+ (29.2% and 39.2%, respectively), and MR ≥3+ (48.9% and 54.4, 
respectivel y). 
 At 1 year, 6.2% of patients with linked CMS claims data  required a second MitraClip procedure.  The 
cumulative rate of stroke was 2.7%.  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.[ADDRESS_504333] 2 mm, a coaptation 
depth of no more than 11 mm, and for patients with leaflet flail,  a flail gap <10 mm and a flail width <15 
mm.  In addition, leaflet anatomy which may preclude device implantation, proper MitraClip device 
positioning on the leaflets or sufficient reduction in MR were excluded.  This may include:  
Evidence of calcification in the graspi[INVESTIGATOR_400119] A2 and/or P2 scallops  
Presence of a significant cleft of A2 or P2 scallops  
More than one anatomic criteria dimensionally near the exclusion limits  
Bileaflet flail or severe bileaflet prolapse  
Lack of both primary and secondary chordal support  
 In a real -world clinical setting, experienced implanters have started treating more complex mitral valve 
anatomies, often falling outside of the traditional EVEREST criteria.  In a recent publication, Lesevic et 
al.
[ADDRESS_504334] (N=59) or non- EVEREST 
(N=75) groups depending on whether they would have met the eligibility criteria for the EVEREST II trial.   
 In this study, key reasons for not meeting the EVEREST criteria included LVEF <25 % and/or LVESD 
>55 mm  in 24% of patients, coaptation length <2 mm  in 19%, main pathology in P1- and/or A1 -segment 
(prolapse +/ - flail) in 15%, main pathology in P3- and/or A3- segment (prolapse +/ - flail) in 12%, flail gap  
>10 mm in 8%, and flail width >15 mm in 4%.  
 Baseline characteristics were comparable between the two groups.  Functional MR etiology was present 
in 39% and 41% of EVEREST and non- EVEREST groups, respectively.  Both groups were high risk for 
surgery with STS mortality scores of 10.7% and 10.1% for EVEREST and non- EVEREST patients, 
respectively.  
 
 
 
[ADDRESS_504335] Inclusion Criteria.  Am J Cardiol .  2017; 119:1255- 1261.  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 62 of 68 
  
 
 
One hundred and thirty -four (134) patients were treated with the MitraClip device.  Acute procedural 
success was achieved in 95.5% of patients with no difference between EVEREST (97%) and non-EVEREST (95%) patients.  There was no statistical difference in the number of device implanted between 
the two groups.  A similar mean acute MR reduction was achieved in both groups ( -2.3±0.9 vs -2.2±1, 
respectively; p=0.497).   
 During a mean follow- up of 3.[ADDRESS_504336] patients 
(p=0.656).  Recurring MR ≥3+ was more frequent in non- EVEREST patients than in EVEREST patients 
(28% vs 45%; p=0.066).  Re -interventions for recurring MR were more frequently required in non-
EVEREST patients than in EVEREST patients, including second MitraClip device interventions  (2% vs 
13%; p=0.085) and mitral valve surgeries (9% vs 28%; p=0.047).  Of the 21 patients requiring re-
intervention in both groups, 17 (81%) had degenerative MR.  Flail width was found to be an independent 
predictor for re -intervention, whereas flail gap ≥10 mm displayed a strong trend (flail width: adjusted HR 
11.2, 95% CI 2.6 to 48.3; p=0.001; flail gap: adjusted HR 3.1, 95% CI 0.9 to 11.5; p=0.077).  When entering the variables into logistic regression analyses for identifying independent factors associ ated with 
MR ≥3+ at follow -up, only flail gap ≥10 mm displayed a trend (p=0.082).  
 At last available follow -up (median of 381 days), both groups achieved significant reduction in MR 
severity over baseline.  Similarly, NYHA functional class improved in both  EVEREST and non -EVEREST 
patients from  baseline to longest available follow -up (median of 652 days).  Finally, both groups 
experienced clinically and statistically significant improvements in 6- minute walk distance from baseline 
to the latest follow- up vis it, with no difference between EVEREST and non- EVEREST groups.  
 
This data show that significant reduction of MR severity can be achieved in patients who do not meet the 
EVEREST II trial criteria.  Nevertheless, non -EVEREST patients were significantly more likely to require 
re-intervention for recurring MR due in part to more complex mitral valve pathologies including flail width 
>15 mm  and flail gap ≥10mm.  These results also support the assumption of previous studies that 
selected patients, especially with secondary MR, can benefit  from percutaneous treatment with the 
MitraClip device.   In contemporary clinical practice, a small, but non- negligible proportion of patients with severe MR 
present complex mitral valve pathologies which would normally be excluded based on a strict appli cation 
of EVEREST II anatomical criteria.  Success achieved with the MitraClip device in these patients and 
physician interest in using the clip for treating complex valve anatomies  forms the rationale for the 
MitraClip® EXPAND St udy.   
 
 
  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 63 of 68 
  
 
 
 
APPENDIX V: MONITORING PLAN  
 
A copy of the Monitoring Plan can be obtained upon request from the Clinical Project Manager for the study.  
  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 64 of 68 
  
 
 
 
APPENDIX VI:  CONTACT [CONTACT_7533] 
 
A list of site contacts  can be obtained upon request from the Clinical  Project Manager for the study.  
 
  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 65 of 68 
  
 
 
APPENDIX VII:  FORESEEABLE ADVERSE EVENTS  
  
Please see device instructions for use regarding potential adverse events.   
 
  

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 66 of 68 
  
 
 
APPENDIX VII I: SUMMARY OF CHANGES  
 
Amendment History  
 
Version #  Date of Release  Reason for Amendm ent 
1.[ADDRESS_504337] inconsistencies in the protocol  
 
 
Details  of Change  
Section/  
page# Version 1.0 _14 February 2018  Version 2.0 _26 June 2018  Rationale  
Summary 
/p6 
 
5.3.1/p21  Inclusion Criteria #2:  
Subjects el igible to receive the 
MitraClip per the current approved 
indications for use  Inclusion Criteria #2:  
Subjects scheduled to receive the 
MitraClip per the current approved 
indications for use  To clarify that the 
intention is for the 
treatment decision 
to be  made before 
study enrollment  
3.1 / p 15  A procedure is considered attempted 
when the MitraClip deli very system is 
introduced.   A procedure is considered attempted 
when the MitraClip delivery system is 
introduced into the femoral vein.   To clarify at wh at 
point a procedure 
is considered 
attempted  
3.4 / p17  The Steering Committee makes a 
recommendation to stop or terminate 
the study (such as higher frequency of 
anticipated adverse device effects).  The Steering Committee makes a 
recommendation to stop or terminate the 
study  Clarification on 
the role of the 
steering 
committee  
4.1 / p17   Added sentence s as follows:   
The assessment of safety will include all 
occurrences through [ADDRESS_504338] 
procedure.  
The assessment of performance measures 
will include all data reported at 30- day 
visits for this study.   To clarify data to 
be included in 
analyses  
4.2 / p18  Device Related Adverse Events 
(including device embolization, single 
leaflet device attachment (S LDA), 
bleeding, perforation, etc)  
 Device Related Adver se Events (including 
mitral valve stenosis, device embolization, 
single leaflet device attachment (SLDA), 
Iatrogenic atrial septal defect, myocardial 
perforation, or the need for mitral valve 
replacement instead of repair due at least 
in part to the MitraC lip procedure or the 
presence of the MitraClip device ) Correct 
inconsistency with 
this definition to 
other MitraClip 
studies  
6.4 / p 24 
 
 Table 2/ 
p 25 Visits at:  
• 30 days (30 days +14 days)  
• 12 months (365 days ± 30 days)  
 
Phone call or visit at:  
• 6 months (180 days ± 90 days)  
 Visits at:  
• 30 days (30 days  -14 days /+60)  
• 12 months (365 days -30 days /+ 90 days )  
 
Phone call or visit at:  
• 6 months (180 days -30 days /+ 90 days ) 
 Windows in 
protocol 
inconsistent with 
standard of care. 
Increased time to 
permit vi sits per 
standard of care 
without deviation.    
Table 2/   
p 25 Foot note 1 reads:  
Adverse Events include:  all device-
related complications, device 
deficiencies, device malfunctions, 
concurrent procedures and all 
hospi[INVESTIGATOR_400120] 1 updated to read:  
Adverse Events to collected in this study  
include: cardiovascular events, device-
related complications (as defined in 
section 4.2), and events classified as 
MAEs (as de fined in section 4.1)  To clarify 
appropriate AE 
reporting for a 
post-market study  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 67 of 68 
  
 
 
Section/  
page# Version 1.0 _14 February 2018  Version 2.0 _26 June 2018  Rationale  
 
Table indicates that Treatment TTE 
and Treatment TEE are required  
  
Footnote 2 added to say that T TE / TEE 
during treatment should be submitted for 
the study only  if capturing TTE / TTE 
echoes is part of standard of care.  To be consistent 
with standard of 
care 
7.1.2/ 
page 26  Serious Adverse Event  definition 
includes:   
An important medical event that may 
not result in death, be life- threatening, 
or require hospi[INVESTIGATOR_400093], based upon 
appropriate medical ju dgment, may 
jeopardize the subject and/or may 
require intervention to prevent one of 
the outcomes listed in this definitio n. 
Note 1 : This includes device 
deficiencies that might have led to a 
serious adverse event if a) suitable 
action had not been taken o r b) 
intervention had not been made or c) if 
circumstances had been less 
fortunate. These are handled under 
the SAE reporting system.  
Note 2 : A planned hospi[INVESTIGATOR_31559]-existing condition, or a procedure 
required by [CONTACT_400136], 
without a serious deterioration in 
health, is not considered to be a 
serious adverse event.  Serious Adverse Event  updated to only  
to remove this text, except for the one 
sentence:   
 
A planned hospi[INVESTIGATOR_5912]- existing 
condition, or a procedure required by [CONTACT_400166], without a serious 
deterioration in health, is not considered to 
be a serious adverse event.  
 Definition 
inconsistent with 
ISO14155, 
corrected to 
match ISO14155 
standard definition  
7.2.1/ 
page  27 Unanticipated (Serious Adverse) 
Device Effect [U(S)ADE] 
Unanticipated serious adverse device 
effect ([LOCATION_003]DE) refers to any serious 
adverse effect on health or safety or 
any life- threatening problem or death 
caused by, or associated with, a 
device, if that effect, problem, or 
death was not previously identified in 
nature, severity, or degree of 
incidence in the protocol or 
application (including a 
supplementary plan or application), or 
any other unanticipated serious 
problem associated with a device that 
relates to the rights, safety, or welfare 
of subjects.  This section has been removed  Remove 
inconsistency 
21CFR 812 and 
U(S)ADE/UADE 
definition do not 
apply to this 
protocol  
7.3.1/ 
page 27   Added paragraph as follows:  
Adverse Events to be reported during this 
study include: all cardiovascular events, 
device- related complications (as defined in 
section 4.2), and events classified as 
MAEs (as defined in section 4.1 ).  These 
AEs should be reported starting from the To clarify 
appropriate AE 
reporting for a 
post-market study  
 

 
 MitraClip® EXPAND Study   
 
Protocol 17-518: Version 2.0 26 June 2018  
      Page 68 of 68 
  
 
 
Section/  
page# Version 1.[ADDRESS_504339] attempted procedure.    
7.3.2/ 
page [ADDRESS_504340] Reporting  
Abbott requires the Investigator to 
report any [LOCATION_003]DE to the sponsor 
within 3 calendar days of the 
investigator’s knowledge of the event, 
unless local requirements are more 
stringent, and to the IRB/EC per 
IRB/EC requirements .  This section has been removed  Remove 
inconsistenc y 
21CFR 812 and 
U(S)ADE/UADE 
definition do not 
apply to this 
protocol  
9.4.3/ p29  No hypothesis will be tested in this 
study,therefore, there is no adjustment 
for multiple testing.  Details will be defined in the Statistical 
Analysis Plan (SAP).   Statistical 
Analysis Plan is 
now in draft and 
addresses this  
15.6/ page 
[ADDRESS_504341] safety through 
enrollment.  Risks associated with the use of the 
device during this clinical study are 
minimized through device design, 
investigator selection and training,  pre-
specified patient eligibility requirements, 
study monitoring to ensure adherence to 
the protocol.    Remove 
inconsistency 
since the safety 
team has decided 
that a DSMB is 
not needed for 
this study  
Appendix 
II 
Definitions  
/ p46   Unanticipated Adverse Device Effect 
[UADE]  
UADEs or Unanticipated serious adverse 
device effect ([LOCATION_003]DE) refers to any 
(serious) adverse effect on health or safety 
or any life- threatening problem or death 
caused by, or associated with, a device, if 
that effect, problem, or death was not 
previously identified in nature, severity, or 
degree of incidence in the protocol or 
applicati on (including a supplementary 
plan or application), or any other 
unanticipated serious problem associated 
with a device that relates to the rights, 
safety, or welfare of subjects.  All reported 
adverse events are reviewed by [CONTACT_400173]/[LOCATION_003]DEs are identified and 
addressed.   Added to specify 
that Sponsor 
review will take 
place to identify 
UADEs  
 
